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ABSTRACT OF THE DISSERTATION 
The Role of Apolipoprotein E in Alzheimer disease: From Therapy to Mechanism 
by 
Tien-Phat Vuong Huynh 
Doctor of Philosophy in Biology and Biomedical Sciences 
Neurosciences 
Washington University in St. Louis, 2020 
Professor David M. Holtzman, Chair 
************* 
 
 Alzheimer’s disease (AD) is a neurodegenerative disorder associated with irreversible 
damage to the brain, which manifests in cognitive dysfunction, memory loss, and eventual death. 
The pathological hallmarks of AD are amyloid plaques, which are cerebral aggregates consisting 
of fibrils of the amyloid β-protein (Aβ), and filamentous lesions of the microtubule-associated 
protein tau known as neurofibrillary tangles. In the early 1990s, the apolipoprotein E (apoE) was 
found to co-localize with amyloid plaques. The ε4 allele of the APOE gene was sequentially 
identified as the strongest genetic risk factor for AD, increasing the risk by 4 – 12-fold, whereas 
the ε2 allele is protective relative to the prevalent ε3 allele. Since then, multiple lines of evidence 
suggest that the major mechanism by which apoE influences AD pathology is via its effects on Aβ 
metabolism, particularly aggregation and clearance. 
 An ongoing debate in the field is whether the ε4 allele impose a loss of protective function 
or a gain of toxic function. In support of the latter hypothesis, our colleagues previously 
demonstrated that APP/PS1-21 mice with only one copy of human apoE3 or apoE4 have 
significantly less amyloid plaque deposition and microglial activation compared to their 
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homozygous littermates. However, the effect of apoE reduction during the post-natal period or 
adulthood is unknown. To address this gap in knowledge, we utilized an apoE antisense 
oligonucleotide (ASO) to reduce apoE expression in the adult APP/PS1-21 mice homozygous for 
the human ε4 allele of APOE. Despite achieving reduction of apoE expression by more than 50% 
starting at the onset of amyloid deposition, no reduction of Aβ pathology was detected when mice 
were assessed at 4 months of age. Though there was not an overall reduction in amyloid deposition, 
there was a clear effect of reducing apoE4 on Aβ plaque morphology. Interestingly, ASO treatment 
starting after birth led to a strong and significant decrease in Aβ pathology when mice were 
assessed at 4 months of age. These results suggest that apoE levels can strongly affect the initiation 
of Aβ pathology in vivo but that once Aβ plaque pathology is present, reducing apoE does not 
have a strong effect on further amyloid deposition. This previously unknown age-dependent effect 
of apoE in the early stages of Aβ plaque formation suggest the important implication that 
decreasing brain apoE levels would be useful for primary prevention of amyloid deposition but 
not for decreasing or removing amyloid plaques once they have begun depositing. Strikingly, we 
observed a marked decrease in neuritic dystrophy around the plaques in APP/PS1-21/ε4 mice 
treated with ASO under either treatment paradigm, independent of plaque size or plaque load. This 
suggests a general role of apoE4 in modulating the brain’s response to neurotoxic insults (such as 
Aβ plaques), independent of its effects on Aβ metabolism. 
 The aggregation of Aβ into higher-order species follow nucleation-dependent kinetics in 
vitro. Our work suggested apoE affects the earliest stages of plaque formation (the nucleation 
phase), but it remains unclear whether apoE isoforms exert differential effects. We utilize an 
established in vivo seeding protocol to investigate the possibility that apoE can influence the 
formation and/or potency of the Aβ seeds in an isoform-dependent manner. We inoculated PBS-
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soluble brain extracts (containing Aβ seeds) isolated from aged APP/PS1-21 donor brains 
expressing different human APOE alleles (ε2/ε2, ε3/ε3, ε4/ε4) in the hippocampus of an APP-
expressing host. Following a defined incubation period, we analyzed the seeding patterns and 
found that brain extracts from APP/PS1 donors with different APOE backgrounds induce Aβ 
seeding patterns that are distinct from each other. Specifically, seeded Aβ species from ε2 donors 
have a diffuse pattern with minimal fibrillar content, while those from ε4 donors appear more 
punctate-like and are mostly fibrillar. Brain extracts from ε3 mice produced plaques with an 
intermediate phenotype. These results suggest that human APOE isoforms may differentially affect 
the properties of Aβ seeds, thus creating different strains of Aβ with distinct structural features and 
seeding capabilities. This isoform-dependent effect of apoE on Aβ may contribute to the overall 
AD risk associated with the different APOE isoforms. Further studies are needed to investigate the 
consequences of this isoform-specific difference in plaque morphology. 
 As apoE is produced both inside and outside of the central nervous system (astrocytes and 
microglia in the brain, and hepatocytes in the periphery), the specific contributions of different 
apoE pools to AD pathogenesis remain unknown. To address some aspects of this question, we 
generated new lines of APOE knock-in (APOE-KI) mice (ε2/ε2, ε3/ε3, and ε4/ε4) where the exons 
in the coding region of APOE are flanked by loxP sites, allowing for cell type-specific 
manipulation of gene expression.  We assessed these mice both alone as well as after crossing 
them with mice with and without amyloid deposition in the brain as well as after removing apoE 
expression from hepatocytes using biochemical and histological methods. Consistent with prior 
studies, our analyses demonstrated apoE protein was present predominantly in astrocytes in the 
brain under basal conditions and was also detected in reactive microglia surrounding amyloid 
plaques.  Primary cultured astrocytes and microglia from the APOE KI mice secreted apoE in 
xviii 
 
lipoprotein particles of distinct size distribution upon native gel analysis with microglia particles 
being substantially smaller than the HDL-like particles secreted by astrocytes.  Crossing of 
APP/PS1 transgenic mice to the different APOE-KI mice recapitulated the previously described 
isoform-specific effect (ε4 > ε3) on amyloid plaque and Aβ accumulation. Deletion of APOE in 
hepatocytes did not alter brain apoE levels but did lead to a marked decrease in plasma apoE levels 
and changes in plasma lipid profile.  Despite these changes in peripheral apoE and on plasma 
lipids, cerebral accumulation of amyloid plaques in APP/PS1 mice was not affected. Altogether, 
our new APOE knock-in strains offer a novel and dynamic tool to study the role of APOE in AD 


















1.1 Alzheimer disease 
 In 1907, the German psychiatrist Alois Alzheimer published a case report “On an unusual 
illness of the cerebral cortex,” in which he described what we now know as Alzheimer disease 
(AD)8. More than a century after this landmark discovery, AD is now recognized as the most 
common cause of late-life dementia. AD is rapidly becoming the most important malady affecting 
the adult population in the United States, with current prevalence of 5.7 million, rising ~123% 
between 2000 and 2015 7. AD pathology is characterized by the cerebral accumulation of amyloid 
plaques and neurofibrillary tangles, both of which consist predominantly of specific insoluble 
protein aggregates. 
1.2 The amyloid cascade hypothesis 
1.2.1 Efforts to purify the “β protein” 
From as early as the late 1800s, the presence of amyloid plaques (then described as ‘miliary 
foci’) was documented in the brain of elderly patients suffering from dementia. In 1906 (see Figure 
1), Alois Alzheimer reported the presence of a “peculiar substance” in the brain of the late Auguste 
Deter, but the identity of the substance was to remain a mystery for nearly eight decades.  
In the late 1960s, the pathological accumulation of proteinaceous deposits of β-sheet-
containing (amyloid) fibrils was described in the context of various clinical conditions, including 
systemic forms of amyloidosis (e.g., AL amyloid), Down syndrome (DS) and AD. Though 
researchers suspected some of these conditions might share certain pathologic entities, the 
limitations of biochemical techniques at the time, specifically those required to produce a 
homogeneous protein preparation, prevented the identification of the protein species involved. In 
1983, Allsop and colleagues described a method for isolating dense core neuritic plaques from 
post-mortem AD brains, and found the amino acid composition of the isolated species to be unique 
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compared to any previously described amyloid protein 5.  However, possible contaminants in the 
preparation (as noted by the authors) impeded a definitive identification of the amino acid 
composition, and in addition, no amino acid sequence was provided. Long-time researchers in the 
field of amyloidosis, George Glenner and Caine Wong applied a slightly different approach. By 
focusing on cerebrovascular amyloidosis, they made the observation that the latter was “seen only 
in Alzheimer’s disease [and] adult Down’s syndrome individuals.” Thus, the authors hypothesized 
that the isolation and identification of “the cerebrovascular amyloid fibril protein in Alzheimer’s 
disease” would lead to the discovery of a unique fibril precursor protein in the serum of these 
patients, which in turn could lead to a specific diagnostic serum test for AD. While their suspicion 
on the serum origin of the precursor protein turned out to be incorrect, Glenner and Wong were 
successful in their quest to identify the precursor protein (Aβ), sequencing its first N-terminal 24 
amino acids, as reported in their seminal 1984 paper in Biochemical and Biophysical Research 
Communications 68. 
1.2.2 The breakthrough  
Convinced of the vascular nature of the so-called amyloid precursor, the authors decided 
to enrich for amyloid-bearing meningeal vessels by dissecting out the meninges of autopsy-
confirmed AD brains (6) and those from age-matched controls (3). The AD brains were selected 
for their extensive cerebrovascular amyloidosis based on histological staining for amyloid. 
Following sequential homogenization steps in sodium chloride and Tris-hydrochloride (0.05 M), 
the amyloid-enriched material (monitored by polarization microscopy after Congo red staining) 
was further purified through treatment with collagenase, which removed a primary contaminant. 
Subsequent solubilization in the chaotropic salt guanidine hydrochloride (6M), followed by 
chromatographic enrichment for the amyloid subunit, yielded a 4.2 kDa band on SDS-urea PAGE 
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gels. Interestingly, HPLC analysis identified two peaks, which were found to have identical amino 
acid sequence up to residue 24 (most likely corresponding to Aβ1-40 and Aβ1-42) based on amino-
terminal sequencing. Of note, their report of a glutamine (instead of a glutamate) at position 11 
was later corrected in their subsequent sequencing of amyloid isolated from DS 
meningiovasculature (see below). Upon confirming the uniqueness of the peptide, Glenner et al. 
concluded that the novel protein “appears to be a biologic marker for the cerebrovascular amyloid 
fibril component of Alzheimer’s disease”. This latter prediction held true, for the most part, as low 
levels of Aβ1-42 levels in the cerebrospinal fluid (CSF), reflective of sequestration into amyloid 
fibrils in the brain, now serve as a biomarker for the presence of amyloid plaque presence in the 
brain. 
1.2.3 Additional insights from Down syndrome 
In the context of this discussion, it is important to mention another paper from Glenner and 
Wong that was published in the same journal just three months after their initial report of the “β 
protein” from AD blood vessels 67. Pathologic similarities between adult DS and AD brains had 
been observed as early as the 1920s, and George Glenner discussed his suspicion for a “chemical 
connection” as early as 1979 in an article in Medical Hypotheses 66. However, establishing such 
connections was not possible until the key pathologic entity was defined. Using a similar approach 
to their prior work, Glenner et al. successfully isolated another “β protein”, this time from the 
meningiovasculature of two adult DS patients. Strikingly, the identical amino acid sequence 
between this peptide and those isolated from AD patients confirmed Glenner’s prior suspicion 
about a connection between these two seemingly distinct entities. These results were confirmed 
and extended just a year later by Masters, Beyreuther, and colleagues who employed a variety of 
different techniques to isolate dense core plaques from the brain of AD and DS patients 144. 
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Importantly, upon these findings, Glenner made several predictions, many of which have since 
proved remarkably prescient. Glenner and Wong noted, for instance: 
 ‘It suggests that Down’s syndrome may be a predictable model for Alzheimer’s disease. 
Assuming the beta protein is a human gene product, it also suggests that the genetic defect in 
Alzheimer’s disease is localized on chromosome 21’ 67.  
 Among their many ramifications, the findings and predictions by Glenner and colleagues 
have been considered by many as foundational in leading eventually to the amyloid cascade 
hypothesis. 
1.2.4 The amyloid cascade hypothesis, circa 1992 
In the ensuing race to clone the gene encoding the Aβ sequence, Aβ was found to be, in 
fact, the cleavage product of a much larger precursor protein (β-amyloid precursor protein – APP), 
which was, indeed, localized to chromosome 21 110,193. Genetic mutations in the APP locus (near 
the Aβ sequence) were subsequently found in some families with an autosomal-dominant pattern 
of AD incidence 69. The accumulating evidence (Figure 1) led to the formal proposal of the amyloid 
cascade hypothesis (or the amyloid hypothesis) by John Hardy and Gerald Higgins in 1992, who 
postulated: “[The] deposition of amyloid β protein (AβP), the main component of the plaques, is 
the causative agent of Alzheimer’s pathology and that the neurofibrillary tangles, cell loss, vascular 
damage, and dementia follow as a direct result of this deposition” 78. Around the same time, it 
became apparent to researchers that APP mutations were not found in all families, suggesting a 
genetically heterogeneous nature of dominantly inherited AD 185 and by extension, pointing at 
possible heterogeneity in the underlying causes.  Apart from the APP mutations, some AD-linked 
mutations were identified in genes outside chromosome 21, for instance those in the PSEN1 and 
PSEN2 loci on chromosome 14, which on the surface may seem to question the idea of an Aβ-
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centric component of the disease. But in fact, the PSEN1 and PSEN2 loci are components of the 
proteolytic complex that cleaves APP, and mutations in them were later shown to alter APP 
processing and enhance the production of Aβ42, so altogether, these mutations do seem to provide 
further support for (or at least be consistent with) an Aβ-centric cause of AD 181.  
1.2.5 The amyloid cascade hypothesis, circa 2018 
As noted by Hardy later on, the amyloid hypothesis “was intended to generate ideas and 
act as a framework for a research agenda, not to be a definitive statement”76. In line with this idea, 
the amyloid hypothesis had been at the forefront of AD research efforts for the past 26 years, where 
parts of it were validated, and others revised or supplemented 152. While most in the field believe 
that Aβ appears necessary but not sufficient for the ultimate development of dementia due to AD, 
some researchers have also expressed more basic reservations on the causative role of Aβ in the 
disease’s pathology, or on whether the amyloid cascade hypothesis provides a useful overarching 
conceptualization of the pathophysiology. Doubts around the overall validity of the hypothesis 
have been argued by some to be validated by the initial failure of some therapeutic compounds 
that target APP metabolism or Aβ itself in clinical trials in dementia due to AD. While the details 
of pathways driving the disease are still being worked on, the failure of some of the clinical trials 
targeting Aβ/APP– does not necessarily conflict with a causal component of Aβ accumulation. 
One crucial aspect to consider is the timing of treatment and the progression profile of the disease. 
In fact, Aβ accumulation in the brains of AD patients often precedes clinical symptoms by several 
decades, during a period known as “preclinical” AD 100. By the time people are diagnosed with 
dementia due to AD, Aβ accumulation in the brain has already been evolving for an extended 
period, often around 20 years or so, and the tau phase of the disease is already taking over. With 
that in mind, it is conceivable that Aβ accumulation is indeed the initiator (or one of the initiators) 
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of AD pathogenesis, but by the time an AD patient becomes symptomatic, some irreversible 
neuronal loss has already occurred, rendering amyloid-targeting therapies less likely to be effective 
when given at the symptomatic stage of disease. Would targeting amyloid during the preclinical 
phase prevent or mitigate AD? An ongoing international study (Dominantly Inherited Alzheimer 
Network – DIAN) is designed to answer this question, at least in some contexts, by following 
families that carry known mutations that cause AD 17. In addition to collecting longitudinal data 
on key biomarkers (i.e., Aβ, tau), the patients are also treated with amyloid-targeting compounds 
in hope of delaying (or preventing) the development of AD. This study is not only critical in 
assessing the validity of the amyloid hypothesis, but will also provide invaluable information on 
the temporal progression of the disease, which regardless of the specific outcome, will help 
constrain models of the disease’s progression and advance clarifying the underlying causes. 
Ultimately, this progress in understanding the disease will hopefully provide concrete guidance 
for future interventions or preventative measures. 
1.3 Apolipoprotein E: physiologic functions and risk factor 
for Alzheimer disease 
1.3.1 Physiologic functions of apolipoprotein E (apoE) 
Like other apolipoproteins, apoE primarily functions to maintain the structure of specific 
lipoprotein particles, as well as to direct lipoproteins to specific cell surface receptors. apoE is 
found in a class of high-density lipoprotein (HDL)-like lipoprotein in the cerebral spinal fluid 
(CSF) and interstitial fluid (ISF) of the brain123,199. In the periphery, apoE is associated with many 
different classes of lipoproteins, including very low-density lipoproteins (VLDLs), intermediate 
density lipoproteins, chylomicron remnants, and a subclass of HDL136. Mice220 and humans138 
lacking apoE suffer from marked peripheral hypercholesterolemia. In the CNS, in vitro 
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experiments have suggested that apoE supports synaptogenesis147 and the maintenance of synaptic 
connections164, by virtue of the cholesterol species it carries. However, there is not strong evidence 
it has this function in vivo. Furthermore, both in vitro87,156 and in vivo143,166 evidence support a 
role of apoE in neuronal sprouting after injury. Perhaps unexpectedly, in the absence of injury, 
brain function appears to be grossly normal in the absence of apoE, as observed in both murine9,55 
and human138. 
1.3.2 Apolipoprotein E as a risk factor for Alzheimer disease 
The majority of AD cases are sporadic and have a relatively late onset, predominantly after 
the age of 65. This form of AD is known as late-onset AD (LOAD), in contrast to early-onset AD 
(EOAD), which has a strong genetic component, is often autosomal dominant, and accounts for 
less than 1% of AD cases16. While most genetic risk factors for LOAD identified in the past two 
decades have a relatively small impact on AD risk, extensive epidemiological, clinical, and 
pathological studies have established the Apolipoprotein E (APOE) gene on chromosome 19 as 
the most important genetic risk factor for developing LOAD42,43,187. This locus encodes a 299-
amino acid glycoprotein (apoE) that is expressed in several cell types, with highest expression 
levels found in the liver and the brain, where it is expressed predominantly by astrocytes136, and 
microglia to a lesser extent165 72. The human APOE gene contains several single-nucleotide 
polymorphisms (SNPs) that result in changes to the coding region of the apoE protein. The three 
most common variants of apoE are apoE2 (cys112, cys158), apoE3 (cys112, arg158), and apoE4 
(arg112, arg158). Although the three most common isoforms differ by only one or two amino 
acids, they have distinct structure and function, which may explain the differential effects they 
exert on AD risks. Relative to the prevalent ε3/ε3 genotype, carriers with one copy of the ε4 allele 
have an ~ 3.7-fold increase, while those with two copies have a 12-fold increase in risks for 
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developing AD. The ε2 allele appears to be protective (odds ratio = 0.4) relative to the ε3/ε3 
genotype6,57,173.  
It remains unclear whether the increased risk of ε4 is due to a loss of protective function or 
a gain of toxic function. However, numerous studies have suggested that one major mechanism by 
which apoE affects AD pathology is through its influence on the accumulation of amyloid plaques 
in the brain and cerebrovasculature.  
1.4 The Interaction between APOE and the β-amyloid 
protein (Aβ) 
Amyloid plaques are one of the pathological hallmarks of AD and consist mostly of 
aggregated fibrils of Aβ. Aβ peptides are 38 – 43 amino acids in length, although the most common 
species found in AD brains by far are Aβ1-40 (Aβ40) and Aβ1-42 (Aβ42). Aβ is generated by 
sequential cleavage of the β-amyloid precursor protein (APP) by β- and γ-secretases. The precise 
location and the number of cleavages determine the ultimate length of peptide. Autosomal 
dominantly-inherited missense mutations in APP or components of the human γ-secretase complex 
such as presenilin-1 (PS1) or presenilin-2 (PS2)77 appear to cause EOAD by increasing Aβ 
production or by increasing the ratio of Aβ42 relative to Aβ40191. In vitro kinetic studies indicate 
that Aβ42 is more prone to aggregation, and that specifically Aβ peptides ending at amino acid 42 
(e.g. Aβ1-42 or Aβ3-42) play a critical role in determining the rate of amyloid formation103.  
The link between apoE and AD, and apoE and Aβ particularly, was first suggested in the 
early 1990s, when apoE was found to co-localize with amyloid plaques154,210. Subsequently, the 
ε4 allele of apoE was identified as a strong genetic risk factor for AD26,179,187. Histopathologic 
examination of post-mortem brains from AD patients found a positive correlation between senile 
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plaque density and dosage of the APOE-ε4 allele169,179. While some studies did not reproduce the 
aforementioned findings24,81, a more recent study that examined a large (n = 296) cohort of 
autopsied AD brains found a significant correlation between the APOE-ε4 allele and neuritic 
plaques196. Remarkably, the isoform-dependent effect of APOE isoforms on the accumulation of 
Aβ plaques can also be found in cognitively normal individuals, with age as an independent (and 
significant) risk factor 102. The development116 and clinical utilization115 of Pittsburgh Compound-
B (PiB) as a Positron Emission Topography (PET) tracer for amyloid deposits revolutionized how 
AD is diagnosed and monitored. A ThT derivative, radioisotope-labeled PiB readily crosses the 
BBB145 and provides a quantitative in vivo detection of amyloid plaques. Early clinical studies 
utilizing PiB in cognitively normal middle-aged and older people found APOE-ε4 gene dosage to 
be associated with fibrillar Aβ burden150,170, along with low CSF Aβ42150,190. Consistent with prior 
epidemiological observations, APOE-ε2 carriers rarely develop fibrillar Aβ that is detected by 
PiB150. Altogether, data from human studies make a strong case for apoE genotype as a strong 
susceptibility factor for cerebral amyloid plaque accumulation and eventual development of AD. 
Aside from clinical investigations, a significant amount of basic research effort in the field 
has focused on understanding the effects of apoE on the accumulation of amyloid plaques and 
cerebral amyloid angiopathy (CAA) in the brain. Deposition of Aβ into insoluble plaques depend 
on several factors, including the rate of production, clearance from the brain ISF (where amyloid 
plaques are found), and the rate of fibrillization, all of which may be influenced by apoE. We 
discuss the current state of knowledge on each aspect of the process below. 
1.4.1 APOE and Aβ production 
Among the multitude of factors that have been hypothesized to affect Aβ deposition, 
studies on apoE’s role in Aβ production are probably the most controversial. In vitro studies from 
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one group using rat neuroblastoma B103 cells that express human APP suggested that lipid-poor 
apoE4 enhanced Aβ production compared to lipid-poor apoE3, and that this effect was mediated 
through the LRP pathway215. A very recent study shows that recombinant and HEK cell derived 
apoE can increase Aβ synthesis in human embryonic stem cell-derived neurons in vitro in an 
isoform-dependent fashion (apoE4 > apoE3 > apoE2)93. The observed phenomenon was driven by 
differences in the isoforms’ ability to bind and activate surface apoE receptors, which ultimately 
activate cFos-containing AP-1 transcription factors and increase APP transcription. Of note, APP 
transcription was maximally activated when human neurons were co-cultured with glial cells 
(which secrete several glial derived factors), and the isoform-specific effects were abolished under 
such conditions. However, other in vitro and in vivo studies found no apparent apoE isoform effect 
on APP processing and Aβ production29,36,95. In agreement with the latter findings, in vivo data 
from APP transgenic (Tg) mice found no changes in amyloidogenic processing of APP nor Aβ 
synthesis rates according to human apoE isoforms35. These conflicting findings might be explained 
by their different experimental conditions such as: the lipidation state of apoE and the experimental 
model system used to generate Aβ. Harmonizing the disparate in vitro and in vivo findings on the 
role of APOE on Aβ production will require additional studies. Future work assessing Aβ synthesis 
in the presence of different apoE isoforms in vivo in animal models that have the endogenous APP 
promoter as well as in humans provide insight into this important question. 
1.4.2 Direct APOE-Aβ interaction 
Early studies that focused on the direct interaction between apoE and Aβ yielded 
contradictory findings. ApoE was first proposed to be an Aβ binding partner in 1992210. Various 
studies showed that synthetic Aβ avidly forms a complex with apoE purified either from human 
CSF187, plasma188, or from conditioned media of apoE-expressing HEK cells122. However, the 
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affinity of different apoE isoforms for Aβ appears to be highly dependent on the preparation 
condition of apoE, the species of Aβ involved (soluble versus fibrillar), as well as pH level. Allan 
Roses’ group found apoE4 to bind synthetic Aβ more rapidly than apoE3178,188, while Ladu and 
colleagues found lipidated apoE3 to be a much more efficient binding partner of Aβ (20 fold) than 
apoE4122. These differences might be explained by the lipidation state of the apoE species being 
used, as several other groups confirmed that the efficiency of complex formation between lipidated 
apoE and Aβ follows the order of apoE2 > apoE3 >> apoE43,197,214. However, one study noted that 
the observed apoE-Aβ complex represents only a small proportion of the incubated apoE, despite 
a large molar excess of Aβ122. In support of this notion, a previous study from our group provided 
both in vitro and in vivo evidence that more than 95% of soluble Aβ (sAβ) detected is not associated 
with apoE-containing lipoproteins202. sAβ is defined as any Aβ species that is soluble in phosphate-
buffered saline, including monomeric and oligomeric Aβ. Using various techniques including 
density-gradient centrifugation, size-exclusion chromatography (SEC), and fluorescence 
correlation spectroscopy (FCS), the aforementioned study provided multiple lines of evidence that 
sAβ is a very poor binding partner of apoE-containing lipoproteins. The metastable nature of Aβ 
oligomers had made it difficult to study in the past, but it is important for future studies to further 
dissect out the potentially different role of monomeric versus oligomeric Aβ in the context of apoE 
interactions. Indeed, a study using an ELISA assay specific for Aβ oligomers found the latter 
species to be rapidly sequestered away from the ISF and CSF in J20 hAPP tg mice89. From these 
results, if oligomeric Aβ is present in the ISF, it could be the predominant species that interacts 
with apoE in the ISF prior to binding to other cell surface molecules such as receptors, thus leaving 
monomeric Aβ to be the predominant species to be detected in the fluid phase. A recently 
developed method for isolating and characterizing the different oligomeric Aβ species may 
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facilitate more rigorous studies on the relative contribution of monomeric and oligomeric Aβ to 
the APOE-mediated effects on amyloid pathology progression52. This is an important question to 
address, considering the substantial body of literature supporting the role of Aβ oligomers in 
facilitating neurotoxicity23. 
Upon examining functional consequences of the apoE/Aβ interaction, Tamamizu-Kato et 
al. found that Aβ binding to apoE compromises its lipid-binding function in vitro192. Thus, it is 
possible that apoE interacts with Aβ directly through the carboxy terminal domain that also 
overlaps with the lipid-binding region. Furthermore, some studies suggest that Aβ peptides 
modulate the binding of apoE isoforms differently to apoE receptors18,88. These in vitro data 
suggests that Aβ peptides can modulate or interfere with the normal function of apoE.  
1.4.3 APOE and Aβ aggregation 
The aggregation of Aβ into higher-order species follows a nucleation-dependent kinetics 
with a typical 3-phase sigmoidal curve when assessed in vitro. While the initial “lag phase” is slow 
and requires random collision of Aβ monomers103,174. It has been suggested that, upon formation 
of a sufficient amount of nucleating higher-order species of Aβ (termed “nuclei” or “seeds”), 
perhaps consisting mostly of Aβ oligomers, the incorporation of additional monomers (growth 
phase) occurs at a much faster rate. The rate of fibril growth slows down (plateau phase) when it 
is outcompeted by newly formed nuclei or, possibly, depletion of the local pool of monomer. Thus, 
apoE could potentially exert pro-amyloidogenic effects by influencing either the formation of Aβ 
“seeds” or the subsequent elongation of fibrils.  
All three isoforms of apoE have been previously shown to promote the fibrillization of Aβ 
in vitro, and the potency follows the order of apoE4 > apoE3> apoE2135,178,209. On the contrary, 
14 
 
other studies suggest that apoE isoforms can also inhibit Aβ aggregation, with apoE4 being least 
effective20,53,65,212. These seemingly contradicting findings may be explained by the variable 
experimental conditions such as the species and source of Aβ used112 (Aβ40 versus Aβ42, 
recombinant versus synthetic), and especially the preparation and the (resulting) lipidation state of 
apoE. Some studies utilized poorly lipidated apoE, while the most abundant and biologically active 
species of apoE found in vivo are lipidated. Indeed, in vivo studies had shown that alteration of 
apoE lipidation state in the brain can exert a profound impact on Aβ fibrillization. Nascent apoE 
peptides in the brain are normally lipidated by the ATP-binding cassette transporter A1 (ABCA1). 
Interestingly, APP Tg mice crossed onto an Abca1-/- background exhibit a marked increase in 
amyloid deposition, along with a decrease in apoE lipidation82,83,118,203,204. Conversely, 
overexpression of ABCA1 in the brain leads to an increase in apoE lipidation and a corresponding 
decrease in amyloid deposition204.   
To initially assess the effects of human apoE isoforms on Aβ in mouse models, transgenic 
mice expressing human apoE isoforms under the control of the astrocyte-specific GFAP promoter 
(in the absence of endogenous murine apoE) were crossed with APP Tg mice that develop Aβ 
plaques. These studies showed that, relative to mouse apoE, human apoE delayed Aβ deposition 
but that the order and amount of Aβ deposition was apoE4 > apoE3 > apoE2, as is seen in 
humans56,84. Early in vivo studies on the role of apoE on AD-related pathology utilized PDAPP 
mice, a model of Aβ amyloidosis that harbors the human APP transgene with the Indiana mutation 
(V717F)63,172. Introduction of the human apoE leads to delayed Aβ deposition in comparison to 
PDAPP mice expressing murine apoE or even those lacking apoE56,85 as was seen in previous 
studies. In 1997, Patrick Sullivan and colleagues generated the first mouse strains carrying various 
isoforms of human apoE through targeted replacement189. These lines allow for better 
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characterization of the isoform-dependent effects on Aβ aggregation propensity in that the apoE 
gene is regulated by the endogenous factors that control its expression. When these mice were 
crossed with different APP Tg mice, there is also a strong human apoE isoform specific effect on 
Aβ deposition in the order of apoE4 > apoE3 > apoE212,35. These results are consistent with studies 
in humans and confirm the relevance of genetically engineered mouse models that mimic at least 
some aspects of the Aβ aggregation component of the disease.  Using these human apoE knock-in 
mouse models, the allele-dependent effects of apoE on Aβ accumulation have been studied 
extensively.  
In addition to isoform effects of APOE, the expression level of apoE also appears to 
influence Aβ pathology. Deletion of the endogenous murine Apoe locus in PDAPP mice, as well 
as in the Tg2576 or APPswe model leads to significantly less Aβ deposition and virtually abolishes 
fibrillar Aβ deposits in the brain parenchyma as well as CAA and CAA-associated 
microhemorrhage13,14,48,86. These results suggest that apoE is a critical factor that facilitates Aβ 
aggregation in vivo into a fibrillar form, though the aforementioned studies did not offer insight 
into the mechanism for such process. To examine the effects of human APOE gene dosage, human 
APOE knock-in mouse lines were crossed to APP Tg (APP/PS1-21) mice. Interestingly, APP Tg 
mice expressing only one copy of human apoE have significantly less Aβ plaque deposition 
compared to mice expressing two copies of the same apoE isoform (either APOE-ε3 or APOE-
ε4)114. Very similar findings were also found by another group28, and have potentially important 
therapeutic implications, since there has been a long debate about whether increasing or decreasing 
apoE is beneficial for Aβ pathology. The caveat of these findings are that the animals carried the 
APOE gene and gene dosage differences since birth, and there could be developmental 
compensation in the genetic APOE haploinsufficiency model which could account for the 
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protective effect against Aβ deposition. Whether reducing APOE levels in adult mice would 
similarly affect Aβ burden is unknown. Additionally, reduction of APOE expression could 
influence both the aggregation and clearance of Aβ, the latter being another major effect of apoE 
on Aβ metabolism that is well-described, as discussed in the following section 
1.4.4 APOE and Aβ clearance 
Substantial evidence exists to support the role of apoE isoforms on monomeric Aβ 
clearance. Specifically, apoE has been proposed to influence Aβ clearance through several 
mechanisms: enzymatic degradation106,153, transport across the blood brain barrier38, ISF-CSF bulk 
flow, and cellular uptake/subsequent degradation60,195.  
Role of APOE in Aβ transport and clearance  
A large number of studies support the hypothesis that apoE influences Aβ transport and 
clearance from the ISF. The level of sAβ in the ISF can be measured continuously in live, freely 
moving animals through utilization of an in vivo microdialysis technique39. Clearance of Aβ from 
the ISF was found to be faster in apoE-KO mice48, suggesting an important role for apoE in 
regulating Aβ levels in the brain. ApoE isoforms differentially impact the level of ISF Aβ and rate 
of Aβ clearance in vivo35. ApoE4-expressing mice exhibited higher ISF levels of Aβ and a slower 
rate of Aβ clearance from the ISF than apoE3-expressing mice. Conversely, apoE2-expressing 
mice exhibited a lower level of ISF Aβ and a faster Aβ clearance rate relative to apoE3. The 
isoform-dependent effect of apoE was observed in aged mice but also at young ages well before 
plaque accumulation occurs. These findings suggest that the difference in Aβ accumulation 
between isoforms is likely due in part to their differential effects on Aβ clearance from the ISF, 
which can occur through a number of mechanisms. 
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One potential mechanism subject to apoE-dependent modulation is the transport of Aβ 
across the blood-brain barrier (BBB) to the systemic circulation. The BBB is a highly selective 
permeability barrier that separates the blood from brain ISF. It is formed by continuous capillary 
endothelial cells containing tight junctions, which are surrounded by basal lamina, astrocytic 
perivascular end-feet, and pericytes. Through specific transporters, the BBB and pericytes work 
together to control entry of substances from the blood and promote clearance from brain of various 
potentially neurotoxic and vasculotoxic macromolecules182. Similar to CAA, AD is associated with 
microvascular dysfunction and a locally defective BBB45,140,221, both of which could be influenced 
by Aβ. Intriguingly, carriers of the APOE-ε4 allele are predisposed to CAA33,71,157,163. In Tg2576 
mice, apoE4 promotes a shift of Aβ deposition from the brain parenchyma to arterioles in the form 
of CAA, relative to apoE3 or murine apoE59. Consistent with these findings, a recent study using 
5x-FAD mice (APP transgenic mice expressing these specific mutations in APP - APP 
KM670/671NL and V717I) harboring both human apoE4 and murine apoE found a higher degree 
of co-localization between murine apoE and parenchymal plaques, while plaques in the vasculature 
contained more apoE4130. Mechanistic studies linking apoE to Aβ transport from the ISF have 
identified a number of involved transporters including P-glycoprotein38, LRP1 (Low-density 
lipoprotein receptor-related protein 1)182, and LDLR (Low-density lipoprotein receptor) 34. 
LRP1 was found in amyloid plaques168 and can bind Aβ directly47, or indirectly via its 
ligands, including apoE32,112 and others109,155. Additionally, LRP1 participates in a lipid transport 
pathway that involves binding to heparan sulfate proteoglycans (HSPG)41,137. Intriguingly, HSPG 
was found in senile plaques as well as CAA44,200,201, and had been shown to directly interact with 
Aβ219, accelerating its oligomerization and aggregation31,37,207. A recent study found that ablation 
of HSPG in postnatal forebrain neurons of APP/PS1 mice led to a reduction in both Aβ 
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oligomerization and the deposition of amyloid plaques133. These reductions were driven by an 
accelerated rate of Aβ clearance from the ISF. Moreover, the authors also found a significantly 
increased level of various HSPG species in postmortem brain tissues from AD patients relative to 
controls. Deletion134 or overexpression218 of LRP1 causes increases or decreases of brain apoE 
levels, respectively. Whereas Aβ40 is cleared across the BBB at a much more rapid rate than via 
the ISF flow, binding to apoE-ε3 reduces Aβ40 efflux rate from the ISF by 5-7-fold21. Another 
study found that Aβ binding to apoE4 redirects its clearance from LRP1 to VLDLR (Very-low-
density lipoprotein receptor), which internalizes Aβ-apoE4 complexes at the BBB more slowly 
than LRP146. In contrast, Aβ-apoE2 and Aβ-apoE3 complexes are cleared through the BBB via 
both VLDLR and LRP1 at an accelerated rate compared to that of Aβ-apoE4 complexes. 
In support of LDLR’s role in APOE transport across the BBB, deletion of the LDLR gene 
in the mouse brain leads to higher apoE levels in the brain and CSF58, while overexpression of 
LDLR in the brain decreases brain apoE113. Furthermore, deletion of LDLR caused a decrease in 
Aβ uptake, whereas increasing LDLR levels significantly enhanced both the uptake and clearance 
of Aβ by primary astrocytes in culture, even in the absence of apoE15. Taken together, these data 
suggest that the influence of apoE on sAβ metabolism may not require direct binding of apoE with 
sAβ in solution, and that Aβ binding to apoE may lead to reduced clearance. This raises the 
possibility that APOE isoforms can significantly inhibit the uptake of sAβ by competing for the 
same pathway, facilitated through either LRP1 or LDLR. More rigorous in vivo studies are needed 
to provide direct evidence that the aforementioned mechanism is responsible for the increase in 
Aβ clearance in mice with reduced apoE level. 
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Independent from its effects on Aβ clearance, there are also isoform-specific effects of 
apoE on the BBB, as expression of APOE-ε4 and lack of murine apoE, but not APOE-ε2 and 
APOE-ε3, was found to lead to BBB breakdown in young mice22. The increase in vascular 
permeability in these mice were linked to a decrease in apoE dependent pericyte-expressed LRP1 
activation and a concomitant increase in CypA-MMP9 activity. In support of these findings, a 
human study using post-mortem brain samples from control and AD subjects found accelerated 
pericyte degeneration in AD APOE-ε4 carriers compared to AD APOE-ε3 carriers and non-AD 
controls75. Intriguingly, a significant increase in CypA and MMP-9 was also detected in pericytes 
and endothelial cells of APOE-ε4 subjects relative to APOE-ε3 subjects. However, in situ brain 
perfusion of the vascular marker [14C]-sucrose found no differences in cerebral vascular volume 
among mice carrying any of the APOE isoforms, despite an observed reduction in cerebral 
vascularization and basement membrane thickness in 12-month-old APOE-ε4 mice compared to 
APOE-ε2 and APOE-ε3 mice2. Additionally, a relatively recently study reported no apparent 
differences in the level of brain IgG and radiotracer uptake in apoE4 or apoE-/- mice when assessed 
at 2-3 months of age27. Though the latter results might not be expected, they suggest that the global 
homeostatic capacity of the BBB might be intact in APOE-ε4 mice, despite highly localized 
disruption in BBB integrity. 
APOE and cellular metabolism of Aβ 
Various cell types in the CNS have been shown to possess the ability to internalize Aβ, 
including astrocytes117, neurons175, and microglia139,161,162, albeit with different capabilities. 
Primary hippocampal neurons are more efficient at internalizing Aβ in the presence of apoE3 
compared to apoE419. Nevertheless, neurons appear to lack the ability to effectively degrade Aβ, 
resulting in formation of high molecular weight (HMW) Aβ species in endosomal vesicles90,218. 
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The rest of this section will focus on astrocytes and microglia, which probably account for a 
significant amount of cellular Aβ metabolism. 
Immunohistological studies on human AD brains using antibodies against various Aβ 
epitopes identified N-terminal-truncated fragments of Aβ40/42 that are found inside lipofuscin-
like granules within astrocytes60,195. In agreement with human studies, in vitro studies using 
primary astrocytes showed that astrocytes can internalize and degrade both soluble158,180 and 
insoluble213 Aβ. Interestingly, the ability of astrocytes to engulf and degrade Aβ is compromised 
in apoE knock-out astrocytes, or in WT astrocytes upon the addition of either an antibody against 
Aβ, apoE, or an LDLR family antagonist117. These results suggest an essential role of apoE in a 
receptor-mediated Aβ uptake mechanism by astrocytes. However, more recent studies provided 
evidence that such processes can occur in the absence of apoE15, and apoE can actually compete 
with Aβ for binding/uptake by LDLR receptors despite minimal interaction with sAβ202. 
Microglia are the resident macrophages and primary immune effectors in the brain, whose 
roles in AD are increasingly getting more attention, both in the context of disease pathogenesis as 
well as therapeutic opportunities. Microglia have the ability to clear sAβ as well as insoluble Aβ 
in vitro, followed by rapid degradation through the late endocytic/lysosomal pathway 40,139. ApoE 
has been shown to be essential for efficient Aβ degradation via microglia by neprilysin or in the 
extracellular milieu by insulin degrading enzymes (IDE)106. More importantly, this process is 
dependent on the lipidation status of APOE, suggesting that apoE exerts its effects via 
manipulation of cellular cholesterol levels106,125. More recently, the newly discovered AD risk gene 
that encodes the Triggering receptor expressed on myeloid cells 2 (TREM2)73,107 protein was found 
to have apoE as one of its ligands10,11. Accordingly, TREM2-deficient microglia or microglia with 
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an AD risk variant (R47H) lose the ability to effectively bind lipoproteins (including apoE), which 
decreases their phagocytic capabilities216. Furthermore, the lipid-sensing component of TREM2 
allows it to sustain the microglial response that is necessary to cluster and potentially play a role 
in more efficient plaque phagocytosis, a phenomenon that is attenuated in TREM2 deficient 
microglia206 as well as R47H mutants217. Intriguingly, APOE-ε4-expressing microglia exhibited 
more pronounced down-regulation of TREM2 than those that express APOE-ε3 in response to 
TLR (toll-like receptor) activation126. In the future, generation of murine models with human 
TREM2 and mutant variants should allow for more rigorous in vivo studies that will fill in the gaps 
in knowledge about TREM2’s role in AD pathogenesis and its potential link with apoE.  
1.5 APOE and other amyloidogenic proteins 
 The pro-amyloidogenic nature of APOE has prompted investigation of its role in other 
neurodegenerative diseases, many of which share the common features of pathogenic protein 
aggregation. Specifically, APOE had been linked to Parkinson disease 64,127 (PD), chronic 
traumatic encephalopathy148, Huntington disease111,160, frontotemporal dementia1, and certain 
subsets of Amyotrophic Lateral Sclerosis (ALS)121,128,167, though the latter findings conflicted with 
some other studies49,70,151. Here, we discuss the current state of knowledge on the specific 
interaction between APOE and the aggregation-prone proteins associated with some of these 
diseases. 
1.5.1 APOE and tau 
 The strong correlation between APOE genotypes and AD, and the presence of 
immunoreactive apoE in neurons containing neurofibrillary tangles154,210 led to numerous clinical 
and epidemiological studies on the potential interaction between APOE and Tau, both in the 
context of AD as well as other tauopathies, including Frontotemporal dementia (FTD). The 
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majority of clinical studies found an over-representation of the APOE-ε4 allele in both AD and 
FTD25,54,74,105, while histopathologic examinations revealed a significant positive correlation 
between APOE genotype and stage of neurofibrillary pathology159 according to Braak staging62. 
In support of these findings, the presence of the APOE-ε4 allele significantly correlates with brain 
atrophy in disease-specific brains regions in both AD and FTD1. However, studies have not 
demonstrated a consistent effect of APOE genotype on cognition in tauopathies1,51. It should be 
mentioned that a few studies found either no association between APOE status and FTD171, or that 
the association was only applicable to male cohorts184. The disagreement of these findings might 
be explained by the population being studied and/or difference in statistical power of the studies. 
More sufficiently powered longitudinal studies are necessary to investigate whether APOE status 
has any effect on cognitive status as well as other aspects of neuropathology in patients with non-
AD tauopathies. 
 Early studies by Allen Roses, Warren Strittmatter and colleagues found apoE3, but not 
apoE4, to interact with Tau in an in vitro binding assay186. This interaction is facilitated through 
the microtubule-binding domain of Tau and the LDLR binding domain on apoE3, which is distinct 
from its binding site for Aβ. Interestingly, expression of full length human apoE4 specifically in 
neurons alone is sufficient to induce NFT-like inclusions and hyperphosphorylation of Tau in WT 
mice92,194. Along with these findings, a C-terminal-truncated fragment of apoE ( 272-299) 80,92 
was found to accumulate in the brains of AD patients and mice with neuronal expression of 
APOE30. The same group also linked the increase in pTau to changes in the Zinc-induced Erk 
activation pathway79. Considering the availability of mice that develop Tau pathology4 and APOE 
knock-in189 mouse models, future in vivo studies on APOE/Tau interaction are feasible and warrant 
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new insights on the relationship between one of AD’s signature hallmarks and its biggest risk 
factor. 
1.5.2 APOE and alpha-synuclein (α-syn) 
 α-syn is a 140-amino-acid protein which is normally localized to pre-synaptic terminals. 
Aggregates of α-syn form the main constituent of Lewy bodies and Lewy neurites99,101,211, the 
pathological hallmarks of a class of neurodegenerative diseases termed “synucleinopathies” which 
includes Parkinson disease (PD) and the related disorders Parkinson disease dementia (PDD) and 
dementia with Lewy bodies (DLB) (Reviewed extensively in 124 and 97). Interestingly, up to 50% 
of patients with synucleinopathy and dementia also have Aβ plaques, while a smaller subset also 
has concomitant neurofibrillary tangles)94,96,104,120,146,149,176. Historically, this overlap presented a 
challenge with regards to disease nomenclature. The overlapping features between PD and AD 
have been demonstrated by clinical141,208, pathologic119,132, and genetic data129,142. Intriguingly, 
some of the findings in this area suggest a possible connection between apoE and α-syn.  
 Initial epidemiological studies found contradictory results as to whether APOE genotype 
influences the risk of PD. A meta-analysis of 22 clinical studies found the APOE-ε2 allele to 
positively associated with risk for developing sporadic PD (OR = 1.20), whereas no association 
was found for APOE-ε3 or APOE-ε491. On the contrary, an independent study by Li et al. 
genotyped 658 PD affected families for APOE functional polymorphisms found the APOE-ε4 
allele to increase the risk and decrease age at onset for PD, while APOE-ε3 allele had the opposite 
effects127. Recent efforts to combine data across multiple genetic association studies have 
demonstrated that compared to APOE-ε3, the APOE-ε2 allele modestly increases risk of PD (OR 
= 1.11 [95% CI 1.02, 1.21]) while APOE-ε4 has no effect on overall PD risk (OR = 1.00 [95% CI 
0.91, 1.10])131. In addition to the genetic diversity in study populations and differences in statistical 
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power, the disparity in results may also be attributed to the heterogeneity in both clinical and 
pathologic entities within the PD spectrum: that is, many patients with a diagnosis of PD also have 
cognitive impairment, and a large but not necessarily overlapping proportion have Aβ plaque 
pathology. Numerous studies support the association of APOE-ε4 with increased Aβ and, to some 
extent, tau pathology in individuals with PD as well as other neurodegenerative disorders98,108. The 
effect of APOE-ε4 on cognitive impairment in PD may be mediated at least in part through Aβ, as 
illustrated by a prospective cohort study of 45 patients with PD with at least one yearly follow-up 
visit in which any observed correlation between APOE-ε4 status and cognitive impairment was 
abolished after adjusting for CSF levels of Aβ42. However, this phenomenon does not account for 
the effect of APOE genotype on dementia in PD patients who do not have concomitant Aβ plaque 
pathology183. Several studies have found the presence of one or more APOE-ε4 alleles not only 
increases the Aβ plaque load, but also the α-syn pathology burden in PD cases146,177,205. 
Interestingly, when a relatively large group of PD cases was stratified pathologically and cases 
with concomitant Aβ pathology were excluded (leaving a cohort with pure α-syn pathology), 
APOE-ε4 was still strongly associated with dementia and even more strongly associated with early 
development of dementia198. Taken together, these findings suggest that the impact of APOE 
genotype on synucleinopathy and dementia is likely multifactorial and that apoE may directly 
influence α-syn pathology. 
 Basic research on the role of APOE on α-syn has lagged behind clinical and 
epidemiological studies, but several important findings have emerged. A study in Tg mice 
expressing mutations in the SNCA gene which codes for α-syn found that aged, symptomatic mice 
had elevated levels of endogenous murine Aβ40 and Aβ42, as well as apoE, relative to 
asymptomatic littermates61. Interestingly, deletion of the murine Apoe gene prolonged survival and 
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decreased levels of insoluble Aβ40, Aβ42, and α-syn in addition to decreasing levels of 
ubiquitinated proteins. These data suggest that apoE may directly influence proteostasis 
mechanisms that regulated α-syn and Aβ. More recently, an in vitro study found that apoE, and 
especially the apoE4 isoform, appeared to have a stimulatory effect on α-syn aggregation at low 
concentrations (low nM); however, this effect was attenuated at higher concentrations50. One 
caveat to this study is that the apoE particles used were lipid-poor, while most physiologically 
active apoE species found in vivo are lipid-rich. It’s also not yet clear how apoE, a predominantly 
secreted molecule found in the extracellular space, interacts with α-syn, which localizes to the 
intracellular space in both monomeric and aggregated forms. Further research is clearly needed to 
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Figure 1.1 In Search of an 
Identity for Amyloid Plaques 
A timeline of key discoveries in the 
quest to identify the primary component 
of amyloid plaques and its genetic links 
to early-onset Alzheimer disease. The 
numbers in the brackets refer to the 





Figure 1.2 Pathways by which apoE and Aβ interact in the brain  
Solid black arrows indicate normal secretion and lipidation of apoE by astrocytes. Solid blue 
arrows indicate the aggregation cascade and potential clearance route for Aβ. Solid red arrows 
indicate pathways or processes that apoE had been shown to influence. Dashed blue arrow 
indicate a small pool of Aβ-apoE complexes. Dashed red arrow indicate apoE’s proposed effect 








Chapter 2  
Age-dependent effects of apoE reduction 
using antisense oligonucleotides in a model of 
β-amyloidosis 
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 The apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset 
Alzheimer disease. Previous studies suggest reduction of apoE levels through genetic manipulation 
can reduce Aβ pathology. However, it is not clear how reduction of apoE levels after birth would 
affect amyloid deposition. We utilize an antisense oligonucleotide (ASO) to reduce apoE 
expression in the brains of APP/PS1-21 mice homozygous for human APOE-ε4 or APOE-ε3 allele. 
ASO treatment starting after birth led to a significant decrease in Aβ pathology when assessed at 
4 months of age. Interestingly, ASO treatment starting at the onset of amyloid deposition led to an 
increase in Aβ plaque size and a reduction in plaque-associated neuritic dystrophy, despite no 
change in overall plaque load. These results suggest that manipulation of apoE levels can strongly 
affect the initiation of Aβ pathology in vivo, while modulating plaque size and toxicity during the 















Alzheimer disease (AD) is a neurodegenerative disorder which clinically manifests as 
memory loss, cognitive dysfunction, and eventual death.  Two main proteins accumulate in the 
brain in aggregated forms in AD, amyloid-β (Aβ) and tau.  A significant amount of evidence 
suggests that Aβ aggregation initiates and is necessary but not sufficient for AD.  Tau accumulation 
strongly correlates with clinical decline and neurodegeneration 8.  Aβ accumulation in extracellular 
amyloid plaques consists mostly of aggregated forms of Aβ. In the early 1990s, apolipoprotein E 
(apoE) was found to co-localize with amyloid plaques 42,61, and the APOE gene was subsequently 
identified as the strongest genetic risk factor for late-onset AD 6,51,52.  The human APOE gene 
contains two single-nucleotide polymorphisms (SNPs) that result in three most common variants: 
ε2 (cys112, cys158), ε3 (cys112, arg158), and ε4 (arg112, arg158). Individuals with one copy of 
the ε4 allele have a 3.7-fold increased risk, and those with two copies of ε4 have a 12-fold increased 
risk of developing AD relative to the ε3/ε3 genotype 6,17,48. Multiple lines of evidence suggest that 
one way by which apoE strongly influences AD pathology is via its effects on Aβ metabolism, 
particularly aggregation and clearance. ApoE influences Aβ aggregation directly 38,50,60 as well as 
impairing its clearance from the brain interstitial fluid in an isoform-dependent fashion 10,13. 
Consistent with these in vitro and in vivo findings, studies in APP transgenic mice that are 
hemizygous for either human APOE4 or APOE3 (APOE+/-) have significantly less fibrillar plaques 
compared to homozygous littermates 7,31. These results show that genetically engineered, germ-
line reduction of apoE levels decreases Aβ pathology.  For both mechanistic and therapeutic 
implications, we were interested in knowing whether lowering apoE before and after the onset of 
Aβ pathology would have beneficial effects on Aβ deposition.  To this end, we utilized an anti-
sense oligonucleotide (ASO) that specifically and effectively lowers apoE expression by more than 
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50% in the brains of APP/PS1-21 mice that are homozygous for either the human ε4 or ε3 allele 
starting after birth. When ASO treatment was started just after birth, we observed a significant 
reduction in Aβ plaque pathology at 16 weeks of age for mice carrying either apoE isotypes. 
Interestingly, while significant changes in plaque size were detected when the treatment was 
initiated at 6 weeks of age and assessed at 16 weeks, there was no significant effect on overall Aβ 
levels in the brain of either cohort. Together, our data suggest that apoE level plays a critical role 
in the early stages of plaque formation but the effects are much more limited in the presence of Aβ 
pathology. 
2.3 Results 
Treatment with ASO effectively reduces APOE expression in vivo. 
To assess the efficacy of the anti-apoE ASO (hereon referred to as ‘ASO’), and determine 
the optimal dose for in vivo studies, APOE3/3 and APOE4/4-knock-in (KI) mice were subjected 
to a number of different treatment strategies (with varying doses and treatment durations) to ensure 
sufficient efficacy (Figure 2.1A). To control for any potential toxicity of the ASO, additional 
cohorts of mice were treated with PBS. To test for ASO efficacy in post-natal pups, APOE4/4 
mice were treated with ASO or PBS at P0 through unilateral ICV injections. We first tested ASO 
efficacy in adult animals, where 3-month-old APOE3/3 and APOE4/4-KI mice were treated with 
either ASO, PBS, or control ASO (cASO), which has the same length and chemical modifications 
as the anti-apoE ASO, but is not specific for any known sequence in mouse. To test for efficacy 
and determine the optimal dose, 10l of ASO dissolved in PBS was injected unilaterally into the 
right lateral ventricle of adult animals at a concentration of either 35 or 50 µg/µl (for a total bolus 
of 350 g or 500 g, respectively). Following a 2-week treatment period, apoE mRNA and protein 
expression in the hippocampus and cortex were assessed. In the ipsilateral cortex of ASO-treated 
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brains, apoE mRNA and protein levels were reduced by at least 50% relative to either the PBS- or 
cASO-treated brains when assessed through qPCR (Figure 2.1C) and ELISA (Figure 2.1D) 
analyses. The reduction of apoE levels was also evident by Western blot analysis of the brain 
lysates (Figure 2.1E). Similar knock-down of apoE was also seen in the contralateral hippocampus 
(Figure 2.5D and 2.5E) and cortex (data not shown). Since the ASO can target both apoE4 and 
apoE3, its efficacy was also tested in APOE3/3 knock-in mice and showed similar results (Figure 
2.5F-H). 
To test for ASO efficacy in newborn pups, the optimal dosage used in the adult mice (350 
µg) was adjusted for post-natal day 0 (P0) pups relative to weight (mg/kg). A total of 4 µl of either 
PBS or ASO dissolved in PBS was injected unilaterally intracerebroventricularly (ICV) into P0 
pups at a concentration of 8 µg/µl (total bolus of 32 µg). cASO was not included in the P0-treated 
cohort due to lack of any noticeable toxicity or modulation of apoE levels in the adult cohort. 
Following treatment, apoE levels in PBS-soluble brain lysates from the ipsilateral cortex were 
analyzed at 1 month (Figure 2.5B) and 2 months (Figure 2.1B) and were found to be significantly 
reduced. A significant reduction of PBS-soluble apoE was also observed in the contralateral cortex 
at 2 months (Figure 2.5C) following a single injection at P0. In all measures, we observed a ~40-
50% reduction of apoE in the ASO-treated group relative to the control (PBS-treated) group.  
To create a mouse model that allows us to assess the effect of lowering apoE on 
amyloidosis, we crossed APP/PS1-21 mice with either APOE4/4 or APOE3/3-KI mice to obtain 
APP transgenic mice on an APOE4/4 or APOE3/3 background (APP/PS1-21/ε4 and APP/PS1-
21/ε3 mice, respectively). Previous studies found this strain to have visible neocortical plaque 
deposits beginning around 2 months of age 31,46. To investigate whether the timing of apoE 
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reduction affected the outcome, the ASO treatment was initiated at two distinct developmental 
time points: post-natal day (P) 0 and 6 weeks of age, which is about the time of detectable onset 
of plaques in the neocortex. To maintain sufficient knockdown of apoE levels during the treatment 
period, a booster dose was given at the half-way point of the treatment duration for both cohorts 
(Figure 2.1F).  
For the 6-week cohort, based on efficacy and tolerability results from ASO treatment of 
adult animals, 10l of ASO dissolved in PBS was injected unilaterally into the right lateral 
ventricle of adult animals at a concentration of 35 µg/µl for a total bolus of 350 g. For controls, 
independent cohorts of mice were injected with PBS and cASO. ELISA analysis of PBS-soluble 
brain lysates from the contralateral cortex of APP/PS1-21/ε4 mice showed the ASO-treated group 
to have a significant reduction (at least 50%) relative to either control groups when assessed at the 
end of the treatment period (16 weeks of age) (Figure 2.1I). ASO treatment of APP/PS1-21/ε3 
mice starting at 6 weeks of age yielded similar levels of reduction of apoE in PBS-soluble fraction 
of brain lysates when assessed at 4 months of age (Figure 2.5K).  
For the P0 cohort, a 32 µg bolus of ASO (dissolved in PBS at 8 µg/µl) or PBS (at equivalent 
volume) was injected ICV into the right hemisphere of APP/PS1-21/ε4 or APP/PS1-21/ε3 pups at 
P0. Since a control ASO did not modulate apoE levels in the 6-week animals, we did not include 
a cASO group in this cohort. A booster dose of 35 µg ASO or PBS was given at 8 weeks of age 
(Figure 2.1F). At the end of the treatment period (4 months of age), significant reduction of PBS-
soluble apoE was observed in the contralateral cortex in both APP/PS1-21/ε4 (Figure 2.1G) and 
APP/PS1-21/ε3 mice (Figure 2.5I).  
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From these results, ASO treatment effectively reduced apoE protein levels by ~40 – 50% 
for the entirety of the treatment duration for both P0 and 6-week cohorts. There were no significant 
changes in apoE level in the guanidine-soluble brain lysates of 4-month-old APP/PS1-21/ε4 mice 
that were treated at P0 (Figure 2.1H) or 6 weeks of age (Figure 2.1J). In 4-month-old APP/PS1-
21/ε3 mice, a small reduction of guanidine-soluble apoE was detected in the brain lysates of mice 
that are treated with ASO starting at P0 (Figure 2.5J), but no significant change of guanidine-
soluble apoE was detected when treatment was started at 6 weeks of age (Figure 2.5L). 
Although the majority of apoE in the brain is secreted by astrocytes, microglia also secrete 
apoE 20,45. The observed reduction in apoE levels upon ASO treatment were likely to be driven by 
astrocytic uptake of the ASOs, which has been described previously 34. However, microglial 
uptake of ASOs is not as well-characterized. Thus, we set out to qualitatively examine whether 
ASO uptake occurs in microglia and astrocytes. To accomplish this, we co-stained brain sections 
from APP/PS1-21/ε4 mice that had been treated with either PBS or ASO with antibodies that target 
the ASO backbone, apoE, as well as with microglial (IBA1) and astrocytic (GFAP) markers. 
Representative co-stained sections suggest that ASOs are taken up by both microglia and 
astrocytes (Figure 2.1K). Similarly, analyses on APP/PS1-21/ε3 brain sections also reveal both 
microglial and astrocytic uptake of the ASOs (data not shown). 
ASO treatment at P0 significantly reduces Aβ plaque pathology 
We first examined the nature of the Aβ deposition in the P0-treated APP/PS1-21/ε4 mice 
(Figure 2.2A) by performing histological staining with the X-34 dye and Aβ immunostaining. The 
ASO-treated mice had a clear reduction in Aβ staining (Figure 2.2B). Quantitative analysis of the 
% area covered by Aβ immunostaining in the cortex showed a significant reduction of ~50% in 
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the ASO-treated compared to the PBS-treated group (Figure 2.2C). We next quantified the area 
covered by X-34 staining, which detects fibrillar plaques (Figure 2.2D), and found a significant 
reduction of ~50% in the ASO-treated group compared to the PBS-treated group (Figure 2.2E). In 
APP/PS1-21/ε3 mice that underwent similar experimental conditions (Figures 2.6B and 2.6D), a 
significant reduction of X-34-positive plaques was detected in mice treated with ASO relative to 
those treated with PBS (Figure 2.6E). Interestingly, no significant difference was observed when 
Aβ-immunoreactive plaques were analyzed (Figure 2.6C).  
To further assess the total amount of Aβ accumulation, we measured the amount of PBS-
soluble and PBS-insoluble (guanidine fraction) Aβ40 and Aβ42 in the cortex of P0-treated 
APP/PS1-21/ε4 mice. In the PBS-soluble fraction, significant reductions of both Aβ40 and Aβ42 
were observed in the ASO-treated group compared to the PBS-treated group (Figure 2.2F and 
2.2H). To determine if there was any change in oligomeric Aβ levels, we subjected the same PBS-
soluble brain lysates to a well-described ELISA for Aβ oligomers 16. No significant difference was 
detected between the two treatment groups in the APP/PS1-21/ε4 (Figure 2.2J) or the APP/PS1-
21/ε3 cohort (Figure 2.6J). We detected a significant decrease in insoluble Aβ40 in the ASO-treated 
group relative to the PBS-treated group (Figure 2.2G). While not statistically significant, there was 
a similarly strong trend towards a reduction of insoluble Aβ42 (Figure 2.2I). We performed similar 
biochemical analyses with brain lysates from the contralateral cortex of P0-treated APP/PS1-21/ε3 
mice. There were significant reductions of guanidine-soluble Aβ40 (Figure 2.6G) and Aβ42 (Figure 
2.6I) in mice treated with ASO relative to those treated with PBS. No significant differences of 
either Aβ40 (Figure 2.6F) or Aβ42 (Figure 2.6H) were detected in the PBS fraction. 
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We next investigated whether the ASO treatment at P0 alter the degree of neuritic 
dystrophy on a per-plaque basis by co-staining brain sections from P0-treated APP/PS1-21/ε4 mice 
with X-34 and LAMP1, a well-described marker of dystrophic neurites (Figure 2.2K) 19,29. The 
volume of LAMP1-positive area within 15 µm of an X-34-positive plaque was quantified, and was 
normalized to the volume of X-34 to adjust for any differences in plaque size. We found ASO-
treated mice had a significant reduction of dystrophic neurites/plaque compared to PBS-treated 
mice, independent of plaque size or plaque load (Figure 2.2L). 
To investigate the possibility that the reduction in Aβ pathology was due to altered 
metabolism of APP or Aβ, we performed western blot analyses for APP and C99 (a C-terminal 
fragment of APP that is generated upon cleavage of APP by β-secretase to generate Aβ). Using 
antibodies 6E10 and 82E1 to detect APP and C99, respectively, we did not detect a difference in 
the levels of these proteins in RIPA-soluble brain lysates from APP/PS1-21/ε4 mice treated with 
PBS or ASO at P0 (Figure 2.6L). Similarly, ASO treatment at P0 did not result in altered APP or 
C99 levels in RIPA-soluble brain lysates from APP/PS1-21/ε3 mice (Figure 2.6K). Thus, the 
reduction in Aβ pathology upon ASO treatment likely results from alterations in other Aβ 
metabolism such as clearance or aggregation that are directly or indirectly affected by apoE.  
Reduction of apoE expression starting at 6 weeks of age did not significantly alter total Aβ 
levels. 
To assess the effect of decreasing apoE expression on Aβ accumulation in the cohort of 
APP/PS1-21/ε4 mice that were treated with ASO starting at 6 weeks of age (Figure 2.3A), brain 
sections from 4-month-old APP/PS1-21/ε4 mice were assessed for Aβ immunostaining (Figure 
2.3B). Quantitative analyses of the area covered by Aβ staining showed a significant increase in 
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the ASO treatment group relative to both the cASO- and PBS-treated groups (Figure 2.3D). To 
further characterize the nature of the deposited Aβ plaques, brain sections were stained with X-34 
(Figure 2.3C). Interestingly, quantitative analyses of the area stained by X-34 showed no 
statistically significant difference among the treatment groups (Figure 2.3E). In histological 
analyses of brain sections from the cohort of APP/PS1-21/ε4 mice that were treated with ASO 
starting at 6 weeks of age, there were also no significant differences between any treatment group 
in the percentage of area stained with either an anti-Aβ antibody (Figure 2.7B and 2.7D) or X-34 
dye (Figure 2.7C and 2.7E). 
Next, we analyzed total Aβ levels biochemically in the ASO-treated mice and controls. 
The cortices of 4-month-old APP/PS1-21/ε4 mice were subsequently homogenized in PBS and 
5M guanidine and the amounts of Aβ40 and Aβ42 were measured in each fraction via ELISA. In 
the guanidine-soluble fraction, there was a small (~20%) reduction in the Aβ40 level in the ASO-
treated mice compared to the PBS treated mice (Figure 2.3G). However, there was no significant 
difference in Aβ42 levels between any treatment groups (Figure 2.3I). No dramatic differences in 
Aβ40 or Aβ42 among any treatment groups were detected in the PBS fraction, although there was a 
slight, albeit statistically significant increase in Aβ42 levels in ASO compared to PBS-treated 
groups. (Figure 2.3F and 2.3H). Together, these results suggest that, while ASO treatment starting 
at 6 weeks of age did not significantly lower the amount of total Aβ deposition, there are some 
subtle changes within the different Aβ pools as well as in types of plaques. Similar biochemical 
analyses of brain lysates from the cohort of APP/PS1-21/ε3 mice in which ASO treatment started 
at 6 weeks of age revealed a significant reduction of guanidine-soluble Aβ40, but not Aβ42, in the 
ASO-treated group compared to either control groups (Figure 2.7G and 2.7I, respectively). No 
changes in Aβ40 (Figure 2.7F) or Aβ42 (Figure 2.7H) were observed in the PBS fraction. 
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To determine whether the ASO treatment altered the degree of neuritic dystrophy on a per-
plaque basis, we performed co-staining of brain sections from the 6-week-treated cohort of 
APP/PS1-21/ε4 mice with X-34 and LAMP1 (Figure 2.3J). When the volume of LAMP1-positive 
area within 15 µm of an X-34-positive plaque was quantified, and was normalized to the volume 
of X-34, we found that the ASO-treated mice had a significant reduction of dystrophic neurites 
compared to PBS-treated mice, despite a lack of overall effect on plaque load. (Figure 2.3K).  
Most of the biologically active apoE exists in the brain in lipidated HDL-like particles and 
alterations in the lipidation state of apoE have been shown to drastically affect Aβ accumulation 
in some models of amyloidosis 22,23,33,58,59. Thus, we investigated whether ASO treatment altered 
the lipidation state of apoE. To accomplish this, we collected CSF samples from APP/PS1-21/ε4 
and APP/PS1-21/ε3 mice treated with either cASO, PBS, or ASO and performed a native gel 
analysis for apoE lipidated particles, as described previously 55. Western blotting analysis of CSF 
samples from APP/PS1-21/ε4 (Figure 2.7K) or APP/PS1-21/ε3 (Figure 2.7J) mice did not show a 
significant shift in the size or distribution of the apoE particles among mice treated with ASO 
versus either control groups. 
ASO treatment alters plaque size distribution 
To investigate the increase in Aβ deposition in the cohort of ASO-treated APP/PS1-21/ε4 
mice in which treatment started at 6 weeks of age, we analyzed the size of the plaques and 
compared this measure across the treatment cohorts (Figure 2.4A). This was accomplished by 
grouping the individual plaques based on size in bins of 326 µm2 per increment, and the total area 
covered by each “size-group” was plotted on the same graph to obtain an overall size distribution. 
Three brain sections, 300 µm apart, from each animal are included in the analysis. We first 
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performed an analysis on the plaque size data obtained from anti-Aβ staining (Figure 2.4B and 
2.4C).  Statistical analysis using the Kolmogorov–Smirnov test detected a significant shift in the 
size distribution of the plaques between the ASO-treated and control groups. Specifically, analysis 
of the frequency of each size-group revealed an increase in the number of the larger (> 694 µm2) 
plaques in the ASO-treated group relative to the control groups (Figure 2.4C, bottom panel). 
Correspondingly, the total area covered by the larger plaques was also increased in the ASO-
treated group (Figure 2.4C, top panel). This increase in the amount of larger plaques was 
accompanied by an increase in both plaque density and average plaque size in the ASO-treated 
group compared to either control groups (Figure 2.4F and 2.4G, respectively). To investigate 
whether this increase in plaque size is antibody-dependent, we performed immunohistological 
studies on tissue sections from the same cohort with another anti-Aβ antibody, 82E1 (Figure 2.8B). 
Quantification of histological sections found an increase in percent area coverage of Aβ-stained 
plaques (Figure 2.8D), as well as the number of plaques that are larger than 694 µm2 (Figure 2.8C). 
Further analysis of individual plaques suggested this shift to be driven by both an increase in plaque 
density (Figure 2.8E) and average plaque size (Figure 2.8F). 
Next, we performed similar analyses on the X-34-stained dataset from APP/PS1-21/ε4 
brain sections (Figure 2.4D and 2.4E). Interestingly, while the Kolmogorov-Smirnov test did not 
indicate a significant shift in cumulative distribution of plaque size in the X-34 staining, we 
detected a significant decrease in plaque density in the ASO-treated groups relative to either the 
control groups (Figure 2.4H), and no change in average plaque size was detected (Figure 2.4I). A 
frequency analysis of each size-group for the X-34-positive plaques suggests the significant 
decrease in plaque density might be due to a decrease in smaller (< 1020 µm2) plaques (Figure 
2.4E, bottom panel). Interestingly, plaque size analysis on Aβ-immunostained sections from 
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APP/PS1-21/ε3 mice also yielded very similar findings. Specifically, a two-sample Kolmogorov-
Smirnov test was used to compare the frequency of cumulative distribution of HJ3.4-stained 
plaque sizes between the treatment groups, and significant differences were found between the 
cASO and ASO groups, as well as between the PBS and ASO groups, but not between the cASO 
and PBS groups (Figure 2.8H). Further analysis suggested that this shift in plaque size distribution 
was primarily driven by an increase in average plaque size (Figure 2.8K), but not plaque density 
(Figure 2.8J). Similar two-sample Kolmogorov-Smirnov analyses performed on the X-34-stained 
brain sections from the same cohort of APP/PS1-21/ε3 mice found a significant shift in plaque size 
distribution between the ASO and PBS groups, but not between the ASO and cASO, or between 
the cASO and PBS groups (Figure 2.8I). No changes in plaque density (Figure 2.8L) or average 
plaque size (Figure 2.8M) were detected. 
Altered microglial responses have been shown to be associated with changes in plaque load 
31 or plaque properties 62. To probe for any changes in the microglial response as a result of apoE 
reduction and/or the changes in plaque size in the 6-week cohort, we performed a series of 
histological staining for well-established microglial markers. We first stained brain sections from 
these mice with an anti-CD45 antibody, a marker of activated microglia. Plaque-associated 
microglial activation was evident around Aβ deposits in APP/PS1-21/ε4 mice of all treatment 
groups (Figure 2.4J). Quantitative analysis of the area positive for CD45 did not detect any 
significant differences between treatment groups (Figure 2.4K). Similarly, no changes in CD45-




Aβ accumulation in aggregated forms is amongst the earliest detectable pathologies in AD 
and identifying methods to reduce the formation of Aβ aggregates has been the goal of extensive 
preclinical and clinical studies. APOE isoforms differentially affect the formation of amyloid 
pathology and germ-line deletion of Apoe expression strongly reduces the formation of amyloid 
plaques in mouse models of Aβ pathology, suggesting that modulating apoE expression could be 
a potential therapeutic target in AD. ApoE has been implicated in regulating Aβ clearance from 
the ISF, Aβ generation, and Aβ aggregation. However, the mechanistic basis by which apoE 
expression level influences amyloid formation remains poorly characterized. In this study, we 
investigated whether reducing apoE levels in post-natal animals onward would similarly affect Aβ 
burden in APP transgenic mice using an anti-apoE ASO. Using APP/PS1-21/ε4 and APP/PS1-
21/ε3 mice, which are aggressive models of β-amyloidosis, we observed that ASO treatment 
starting after birth led to a significant reduction in Aβ accumulation when assessed through 
biochemical and histological means, regardless of apoE isoform. However, when ASO treatment 
was initiated at 6 weeks of age, when Aβ aggregation is just beginning in the brain, no major 
change in amyloid plaque burden was detected. These results suggest that both apoE4 and apoE3 
promote the initial nucleation of Aβ into plaques, but following initial nucleation, apoE does not 
exert a strong effect on the subsequent growth of amyloid plaques. Consistent with previous 
publications in mice 1,7,18,24, it is likely that apoE4 is more potent as a pro-amyloidogenic agent as 
our data showed the total levels of Aβ accumulation in APP/PS1-21/ε4 brains to be consistently 
higher than that of APP/PS1-21/ε3 brains in any comparable treatment groups. Strikingly, we 
observed a marked decrease in neuritic dystrophy around the plaques in APP/PS1-21/ε4 mice 
treated with ASO under either treatment paradigm, independent of plaque size or plaque load. This 
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suggests a general role of apoE4 in modulating the brain’s response to neurotoxic insults (such as 
Aβ plaques), independent of its effects on Aβ metabolism. 
In addition to the well-established isoform-dependent effect of APOE on AD risk 1,24,41,47, 
an important question in the field is whether the ε4 allele represents a loss of protective function 
or a gain of toxic function relative to the other isoforms in regard to the different effects it has on 
AD pathology and other functions. Mouse models of Aβ deposition expressing only one copy of 
human apoE have significantly less Aβ plaque deposition compared to mice expressing two copies 
of the same apoE isoform (either APOE-ε3 or APOE-ε4) 7,31. These results suggest that both 
APOE-ε3 and APOE-ε4 promote Aβ plaque deposition, but the latter allele is much more potent, 
and reduction of apoE3 and apoE4 throughout life can reduce Aβ pathology. The caveat of these 
findings is that the animals carried the APOE gene and gene dosage differences since conception.  
Thus, there could be developmental compensation in the genetic APOE haploinsufficiency model.  
Additionally, it remained unknown when reduction of apoE during development and adult life can 
affect Aβ deposition. In this study, our experimental approach includes initiation of treatment at 
two distinct developmental timepoints, thus allowing us to assess whether the timing of treatment 
significantly affects the outcome. From a therapeutic perspective, this latter point is especially 
important to address in lieu of recent clinical observations that AD pathology occurs and 
progresses decades prior to symptom onset 2,26,44.  
The different outcomes between the P0 and 6-week treatment cohorts likely result from the 
6-week delay in the initiation of treatment. This developmental window in these mice likely 
corresponds to the period just prior to the “lag phase” in the in vitro Aβ aggregation model, where 
monomers aggregate to form oligomers 27. Traditionally, the metastable nature of these putative 
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oligomeric species had made them very difficult to be detected and studied reliably 16. Aβ 
oligomers have been proposed to act as nuclei (or seeds) that facilitate rapid fibrillization in the 
exponential “growth phase” 49. It should be noted that, while no Aβ deposits can be detected in 
these mice until ~2 months of age, it is likely that oligomeric Aβ has already formed in sufficient 
amount to initiate fibril elongation by 6 weeks of age in this model 32. While our oligomeric Aβ 
ELISA assays did not detect a significant difference upon P0 treatment of ASO versus PBS, our 
measurements were made once there was substantial plaque burden.  It is possible that oligomeric 
Aβ levels were lowered prior to plaque deposition. Additional time course studies are needed to 
conclusively determine whether early apoE reduction affects Aβ oligomer accumulation. We also 
point out while all APP/PS1-21 mice treated with ASO or control were assessed at 16 weeks of 
age, treatment started at some cohorts at P0 and some at 6 weeks of age.  It is possible that 6 weeks 
less exposure to ASO-treatment in the group treated later is in part responsible for the decreased 
effect on Aβ.  This seems unlikely given that the effects seen in the group treated later are clearly 
present but they are affecting fibrillar vs. non-fibrillar plaque distribution as opposed to Aβ levels.  
Longer treatment studies will be needed to definitively address this issue.    
There are many potential mechanisms though which apoE can alter the early stages of 
plaque growth. A substantial body of evidence supports a role for apoE in soluble Aβ clearance 
10,13,28, potentially through competition for the LDLR family of receptors 56. These effects could 
account in part for reduced Aβ deposition occurring with lower apoE levels in the ASO treated 
mice starting at P0.  However, lowering apoE by ASO treatment after 6 weeks of age, once Aβ 
seeds/nuclei have formed, did not have a significant effect.  This suggests that once Aβ seeding 
and nucleation take place, further growth of plaques is primarily driven by other factors and not 
greatly influenced by the effect of human apoE on ISF Aβ concentration.  This is consistent with 
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previous work showing the reduction of Aβ levels by reducing Aβ production is effective prior to 
Aβ seeding but has little effect once seeding has taken place 12. Concurrently, apoE might be 
directly affecting the aggregation propensity of Aβ. This hypothesis is supported by previous 
studies showing that all three isoforms of apoE can promote the fibrillization of Aβ in vitro 9,38,50,60. 
The pro-amyloidogenic effects of apoE on Aβ aggregation were also seen in vivo, where 
exogenous gene transfer of different human apoE isoforms using adeno-associated virus (AAV) 
can potentiate and differentially affect the trajectory of plaque accumulation 25,63. However, it 
remained unclear whether apoE exerts its effects in the nucleation phase or the growth phase of 
plaque growth, or both. Our results suggest a critical role of apoE4 in the early stages of plaque 
formation. Findings from Liu et al. (submitted) utilizing an inducible APOE-overexpression 
system supports this latter hypothesis. Specifically, induction of APOE4 expression in the 
background of APPSWE/PSE9 amyloidosis mice at birth, but not at 6 months of age, accelerates 
the plaque deposition. Altogether, data from our study and those from Liu et al. suggest that apoE 
plays a critical role in the initial formation of Aβ seeds in vivo, and possibly to a much less extent 
during the growth period of amyloid plaques.  
In addition to its effects on the early stages of plaque formation, our results from the 6-
week treatment cohort also suggest an effect of apoE on Aβ fibrillar plaques. The discordance 
between the significant increase in area coved by Aβ immunostaining following ASO treatment of 
APP/PS1-21/ε4 mice and the lack of change in total Aβ assessed biochemically prompted us to 
look closer at the plaques. When stratified according to size per immunostained plaque, the ASO-
treated group had significantly more of the larger Aβ-immunostained but not the fibrillar X-34 
stained plaques compared to either control groups. Interestingly, we also detected a significant 
shift in plaque size distribution when analyzing Aβ-immunostained sections from APP/PS1-21/ε3 
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brains, despite observing no change in the overall area covered by plaques. Together, our two data 
sets from two different APOE backgrounds further support findings in the apoE hemizygous 
models, and reinforce the notion that both apoE3 and apoE4 promote the accumulation of Aβ 
plaques, albeit with different potencies 7,31. However, there are noticeable differences between the 
APP/PS1-21/ε4 and APP/PS1-21/ε3 cohorts. First, there is an increase in plaque density in the 
ASO-treated 6-week APP/PS1-21/ε4 mice, but not in APP/PS1-21/ε3 undergoing the same 
treatment. This suggests that apoE4 is somehow able to facilitate more seeding events (despite the 
decreased level) relative to apoE3. It is also worth noting that we detect a reduction in X-34 
positive plaques, but not Aβ-immunoreactive plaques in P0-treated APP/PS1-21/ε3 mice. This 
notion correlates with our biochemical analyses where a reduction of Aβ was detected in the 
guanidine fraction, but not the PBS fraction. This distinction from the results described in APOE 
hemizygous mice might be explained by some unknown developmental compensation that occurs 
prior to P0, or lack of ASO uptake by a cell population that plays a role in plaque metabolism. 
Alternatively, this could result from an off-target effect of the ASO. Nevertheless, it is critical for 
future experiments to fully dissect out the differences in characteristics and behaviors (if any) of 
apoE3 versus apoE4, especially in how they modulate plaque formation. 
We next examined whether the microglial response is altered in response to this change in 
plaque morphology, since the innate immune system is believed to play a critical role in the brain’s 
response to amyloid plaques 21. We found no overall change in the microgliosis marker CD45 in 
either APP/PS1-21/ε4 or APP/PS1-21/ε3 mice treated at 6 weeks. While these results suggest that 
the ASO treatment in the 6-week cohort did not change the microglial response to the plaques at a 
global level, there could be an altered microglial response at the local level. Intriguingly, we 
observed a decrease in neuritic dystrophy immediately around the plaques in both the P0 and 6-
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week-treated cohorts, independent of plaque size and plaque load. These phenotypes raise the 
possibility that reduction of apoE4 levels may somehow alter the innate immune response (i.e. 
microgliosis) at the local level, resulting in decreased toxicity and subsequently decrease 
dystrophic neurites. This hypothesis is backed by a growing body of literature suggesting that 
apoE4 can modulate the innate immune response in the brain 30,35,36,39, and that apoE4-KI mice 
have a greater pro-inflammatory phenotype relative to other isoforms 57.  
In summary, we report an in vivo study on the effects of apoE-lowering ASO treatment in 
APP/PS1-21/ε4 mice, an aggressive model of β-amyloidosis. Our results show that lowering apoE 
starting at P0, but not 6 weeks of age, can significantly decrease Aβ deposition when assessed at 
4 months of age. Decreasing apoE at later times did not affect the total Aβ load, but did increases 
the size of the deposited Aβ species. More importantly, reduction of apoE4 at either time point led 
to a significant reduction in dystrophic neurites, which could reflect a role of apoE in modulating 
the brain’s response to plaques. These findings carry important implications for APOE-targeted 
therapy, suggesting that treatment would need to start very early, prior to significant amyloidosis 
in order to achieve a meaningful effect on plaque load and decrease at least this aspect of AD 
pathology. Alternatively, future studies on the role of apoE in modulating neurotoxicity and the 
immune system might open up therapeutic options bypassing the need to reduce plaque pathology. 
In addition, our findings also open up possibilities for future studies to examine in more details the 
effects of apoE on the early stages of plaque development and possibly identify new targets for 
therapeutic intervention. 
2.5 Experimental Procedures 
Experimental Model and Subject Details 
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Generation of human APOE isoform mice with APPswe/PS1(L166P) mutant transgenes. 
To determine the effect of human apoE3 and apoE4 levels on amyloid deposition, we used knock-
in mouse models in which the endogenous murine Apoe gene is replaced with either the APOE3 
or APOE4 gene 54. APPPS1-21 mice overexpress a human APP cDNA with a Swedish mutation 
(KM670/671NL) and mutant PS1 with the L166P mutation. Breeding pairs were obtained from 
Dr. Mathias Jucker, University of Tübingen, Tübingen, Germany 46. To replace the murine Apoe 
gene with human APOE isoforms, APPPS1-21 mice were bred with either APOE3/E3 or APOE4/4 
knock-in mice. APPPS1-21/APOE4/Apoe mice and APOE4/Apoe mice from the first generation 
were bred with each other to generate APPPS1-21/APOE4/4 and APOE4/4 mice. APPPS1-
21/APOE4/4 and APOE4/4 mice were then bred to generate more APPPS1-21/APOE4/4 mice. 
Similar breeding schemes were followed to generate APPPS1-21/APOE3/3 mice All mice used in 
this study were maintained on a C57BL/6J background. Mice were subjected to experiments at 
either P0, 1.5 months, or 3 months of age, per the various experimental designs. Mice were 
individually housed in AAALAC accredited facilities with temperature and humidity controls, and 
were under a 12-hours light/dark cycle (lights on at 6:00 AM) cycle with free access to food and 
water ad libitum throughout all phases of the experiments. All animal procedures were approved 
by the Institutional Animal Care and Use Committee (IACUC) at Washington University, and 
were in agreement with the Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC, WUSM). 
Method Details 
ASOs. The ASOs were designed and synthesized by Ionis Pharmaceuticals as described previously 
11,40 and had the following modifications: 5 nucleotides on the 5′- and 3′-termini containing 2′-O-
methoxyethyl modifications and 10 unmodified central oligodeoxynucleotides 14 to support 
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RNaseH activity. To improve nuclease resistance and promote cellular uptake, the ASOs had a 
phosphorothioate backbone 3. ASOs were solubilized in sterile DPBS immediately before 
injections. ASO sequences were as follow: anti-apoE ASO: GGTGAATCTTTATTAAAC; 
Control ASO:  CCTATAGGACTATCCAGGAA.  
Surgical procedures and tissue collection. Bolus injections of ASO into adult mice were 
performed as previously described 15.  Specifically, for the 6-week cohort, 10 µl of ASO dissolved 
in DPBS at 35 µg/µl was injected into the right lateral ventricle using a Hamilton syringe (model 
#1701, Hamilton Company). The injection was done at a rate of 1 µl/second and the needle was 
held in place for 5 minutes following completion of injection. The mice were allowed to 
completely recover on a warming blanket and then returned to the home cage. The following 
coordinates were used, relative to bregma: 0.3 mm rostral, 1 mm lateral (right), 2.5 mm ventral. 
P0 injections were performed under a protocol adapted from Passini et al. 43. Briefly, cryo-
anesthetized pups were injected using a 1701N Neuros syringe (Hamilton Company) with 4 µl of 
DPBS-dissolved ASO at 8 µg/µl or DPBS into the right lateral ventricle at a 90o angle. The 
injection was done at a rate of 1 µl/second and the needle was held in place for 10 seconds 
following completion of injection. The pups were allowed to completely recover on a warming 
blanket and then returned to the home cage. The following coordinates were used, relative to 
lambda: 1 mm rostral, 1 mm Lateral (right), 2 mm ventral. Upon perfusion with PBS containing 
0.3% heparin, the right hemisphere was fixed overnight at 4oC in 4% paraformaldehyde, followed 
by immersion into 30% sucrose solution for at least 24 hours.  The left hemisphere was snap-frozen 
with dry ice and stored at -80oC. 
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Histology. Following immersion in sucrose for at least 24 hours, serial coronal sections (50 
μm thickness) were collected from frontal cortex to caudal hippocampus (right hemisphere) using 
a freezing sliding microtome (ThermoFisher). Three hippocampal-containing sections (separated 
by 300 μm) from the right hemisphere of each brain were stained with biotinylated HJ3.4 (anti-
Aβ1–13, mouse monoclonal antibody generated in-house) and 82E1 (IBL America # 10323) to 
visualize Aβ immunopositive plaques, as described previously 4. Activated microglia were 
immunostained using rat anti-CD45 (Bio-Rad / AbD Serotec # MCA138), followed by biotinylated 
goat anti-rat IgG secondary antibody (Thermo Fisher Scientific PA1-84402). Quantitative analysis 
of immunopositive staining was performed as described previously 5. Briefly, images of 
immunostained sections were exported with NDP viewer (Hamamatsu Photonics). Using ImageJ 
software, images were converted to 8-bit grayscale, thresholded to highlight Aβ-specific staining 
and analyzed. For analyses of immunofluorescent staining (including LAMP1, GFAP, IBA1, 
ASO, APOE, X-34, and Aβ), 20X images were acquired on Nikon A1Rsi Confocal Microscope. 
Random windows containing clusters of plaques are captured, spanning approximately 30 µm of 
tissue in the z-plane.  The images were obtained with steps of 1.5 µm and were analyzed using 
Imaris software (Bitplane). Briefly, surfaces were created separately for each of the fluorescent 
channels, and the volume of the corresponding markers were quantified under the same threshold. 
Each data point represents the average value from three separate tissue sections (300 µm apart) 
from one single animal. All analyses were done blinded to treatment and genotype. Please see Key 
Resources Table for specific antibody references. 
Real-time qPCR analysis. RNA was extracted from frozen cortical tissue using Trizol (Life 
Technologies # 15596026) and purified using the RNeasy mine kit (Qiagen # 71404). Reverse 
transcription was performed using a High-Capacity cDNA Reverse Transcription Kit (Life 
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Technologies). Real-time qPCR was conducted with TaqMan primers (Life Technologies) and the 
TaqMan Universal PCR Master Mix (Thermo Fisher Scientific # 4304437) using the StepOnePlus 
machine (Applied Biosystems). Relative gene expression levels in ASO- and control-treated mice 
were compared using the ΔΔCt method with Taqman probe for human apoE (Hs00171168_m1). 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA level was used as a reference 
(Mm99999915_g1 Gapdh)  
Sandwich ELISA. Brain cortices or hippocampi were sequentially homogenized with cold 
PBS and then the PBS insoluble material with 5M guanidine buffer in the presence of 1X protease 
inhibitor mixture (Roche). The levels of Aβx-40 and apoE were measured by sandwich ELISA. For 
apoE ELISA, HJ15.6 and HJ15.4b 37 were used as capture and detection antibodies, respectively. 
For Aβx-40 ELISA, HJ2 (anti-Aβ35–40) was used as a capture antibody and for Aβx-42 ELISA, HJ7.4 
(anti-Aβ37–42) was used as a capture antibody. HJ5.1-biotin (anti-Aβ13–18) 
5,37 was used as the 
detecting antibody for both Aβ ELISAs. ELISA assays for oligomeric Aβ were performed on fresh 
PBS-soluble brain homogenates as described previously 16. 
Western blot analysis. PBS-soluble brain lysates from the sequential homogenization step 
were analyzed for total protein concentration with a micro BCA kit (Thermo Scientific). 30 µg of 
proteins from each sample were loaded onto a NU-PAGE 4-12% Bis-Tris 15 well gel (Thermo 
Fisher Scientific # NP0336BOX) and the gel was run at 150 V for 1.5 hours. The proteins were 
subsequently dry-transferred onto a PVDF membrane using the ibot2 system (Life Technologies) 
and blocked with 5% milk in TBS-T. The membrane was incubated with anti-apoE antibody 
HJ15.7 37 and anti-β-tubulin antibodies to probe for apoE and a loading control, respectively. 
Donkey Anti-mouse IgG-HRP was used as secondary antibody (Santa Cruz Biotechnology # sc-
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2096). For assessment of APP and C99 levels, brains were homogenized in detergent-containing 
buffer (RIPA) and the lysates were analyzed through SDS-PAGE and Western blotting using 6E10 
and 82E1 antibodies, respectively. All blots were developed for ~10 seconds using an enhanced 
chemiluminescence (ECL) Ultra kit (Lumigen TMA-6) and imaged on the SynGene Imager 
(BioRad) at the appropriate exposure. Assessment of APOE particles in the CSF were performed 
as described previously 55. Briefly, 2 µl of CSF were loaded onto a Novex WedgeWell 4 – 20% 
Tris-Glycine gel (Life Technologies # XP04205BOX) and was run at 100 V for 24 hours at 4oC. 
The proteins were subsequently transferred onto a nitrocellulose membrane using the Mini Gel 
Tank and Mini Blot Module (ThermoFisher). The blot was blocked with 5% milk in TBS-T and 
probed with the anti-apoE antibody HJ15.7. 
Quantification and Statistical Analysis 
Statistics. All values are reported as mean ± SEM. A Mann-Whitney U test was used to 
assess significance between two groups. A one-way ANOVA was used to assess significance 
between more than two groups, and Bonferroni’s post-hoc test was used to test for differences 
between each of the groups. A two-sample Kolmogorov-Smirnov test was used to compare the 
cumulative distribution of plaque sizes. All statistical analyses were performed using Prism 
software (Graphpad). p < 0.05 is considered significant for all tests. No statistical analysis was 
used to determine sample size a priori. The sample sizes chosen are based on those used in previous 
studies from our laboratory. The number of samples indicates biological replicates as indicated in 
each of the figure legends. 
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Figure 2.1 ASO Treatment reduces apoE mRNA and protein levels in 
APP/PS1-21/ε4 mice  
A, Timeline of various experimental approaches to test for efficacy and optimal dosing of the 
ASO. B, APOE4/4 mice were treated with a single bolus of ASO or PBS at P0, and the PBS-
soluble apoE levels in the ipsilateral cortex were assessed at 8 weeks of age (n = 7 – 8 per group, 
p = 0.0003). C, APOE4/4 mice were treated with cASO, PBS or ASOs at 3 – 4 months of age (n 
= 5 per group) and apoE mRNA level was analyzed 2 weeks later. ASO treatment effectively 
lowered apoE mRNA level by more than 50% in the ipsilateral posterior cortex (p = 0.0002, F = 
18.56). D, PBS-soluble apoE levels were measured in brain lysates from the same cohort of mice 
(p < 0.0001, F = 22.38). E, Western blot for apoE from the same cohort of mice using anti-apoE 
antibody HJ15.7. F, Experimental timeline: separate cohorts of APP/PS1-21/ε4 and APP/PS1-
21/ε3 mice were given a bolus of ASO ICV into the right hemisphere starting at P0 or into the 
right lateral ventricle starting 6 weeks of age, and the brains were harvested for analysis at 16 
weeks of age. A booster dose was given at either 8 weeks (P0 cohort) or 11 weeks (6-week 
cohort). G, APP/PS1-21/ε4 mice were unilaterally injected with a bolus of either ASO or PBS at 
P0, a booster bolus at 2 months of age, and the PBS-soluble apoE levels in the contralateral 
cortex were assessed at 4 months of age (n = 9 – 12 per group, p = 0.0129). H, Guanidine-
soluble apoE levels in the contralateral cortex were assessed from the same cohort of mice. (n = 
11 – 12 per group, p = 0.2844). I, Following a 10-week treatment with either ASO or controls 
starting at 6 weeks of age, the apoE protein levels in the contralateral cortex from 4-month old 
APP/PS1-21/ε4 mice were measured via ELISA (n = 20 – 25 per group, p < 0.0001, F = 35.64). 
J, ApoE protein levels were measured in the guanidine fraction from the same set of brain 
homogenates (n = 20 – 25 per group, p = 0.4316, F = 0.8524). K, Immunofluorescent staining of 
ASO- and PBS-treated brains from APP/PS1-21/ε4 mice. ASOs (Green) are taken up by both 
astrocyte (blue) and microglia (red), as indicated by co-localization with GFAP and Iba1, 
respectively. Scale bars = 500 µm, unless otherwise noted. *p < 0.05, **p < 0.01, ***p < 0.001, 















Figure 2.2 ASO treatment at P0 significantly reduces Aβ plaque pathology in 
APP/PS1-21/ε4 mice 
A, Experimental timeline for P0 cohort. B, Brain sections from 4-month-old APP/PS1-21/ε4 
mice unilaterally injected with PBS or ASO starting at P0 were immunostained for Aβ with anti-
Aβ antibody and the extent of Aβ deposition was quantified from the ipsilateral cortex (C) (Scale 
bar = 1mm). D, Brain sections from the same cohort of mice were stained with X-34 dye that 
recognizes only fibrillar plaques and the fibrillar plaque load was quantified from the cortex (E) 
(Scale bar = 1 mm). PBS-soluble Aβ40 (F) and Aβ42 levels (H) were measured from the 
contralateral posterior cortex of 4-month-old APP/PS1-21/ε4 mice following treatment with 
ASO or controls starting at P0 and a booster dose at 2 months of age (p = 0.0373 and 0.0129, 
respectively). Guanidine-soluble Aβ40 (G) and Aβ42 levels (I) were measured from the same 
cohort of mice (n = 9 – 10 per group, p = 0.0188 and 0.0903, respectively). J, PBS-soluble 
oligomeric Aβ levels were measured from the same brain lysates. K, Representative images of 
brain sections from P0-treated APP/PS1-21/ε4 mice co-stained with X-34 and LAMP1. Scale 
bars = 100 µm. Inset: 60X magnification view of two plaques of similar sizes (one from each 
treatment group). Scale bars = 25 µm. L, The volume of LAMP1 staining within 15 µm of an X-
34 positive plaque was quantified (n = 10 – 13 per group, p = 0.0196,). *p < 0.05. All values are 




















Figure 2.3 Reduction of apoE expression starting at 6 weeks of age did not 
significantly alter total Aβ levels in APP/PS1-21/ε4 mice 
A, Experimental timeline for 6-week cohort of APP/PS1-21/ε4 mice. B, Brain sections from 
APP/PS1-21/ε4 mice were immunostained with an anti-Aβ antibody and the extent of Aβ 
deposition was quantified from the ipsilateral cortex (D) (p = 0.0002, F = 10.21). C. Brain 
sections from the same cohort of mice were stained with X-34 dye that recognizes only fibrillar 
plaques and the fibrillar plaque load was quantified from the ipsilateral cortex (E) (p = 0.2095, F 
= 1.604). Scale bars = 1 mm. PBS-soluble Aβ40 (F) and Aβ42 levels (H) were measured in the 
contralateral posterior cortex from 4-month-old APP/PS1-21/ε4 mice following 10-weeks 
treatment (started at 6 weeks of age) with ASO or controls (p = 0.4673, F = 0.7711 and p = 
0.0171, F = 4.379, respectively). Guanidine-soluble Aβ40 (G) and Aβ42 levels (I) in the 
contralateral posterior cortex were measured from the same cohort of mice (p = 0.0326, F = 
3.635 and p = 0.2568, F = 1.391, respectively). N = 20 – 25 per group. J, Representative images 
of brain sections from P0-treated APP/PS1-21/ε4 mice co-stained with X-34 and LAMP1. Scale 
bars = 100 µm. Inset: 60X magnification view of two plaques of similar sizes (one from each 
treatment group). K, The volume of LAMP1 staining within 15 µm of an X-34 positive plaque 
was quantified (n = 13 per group, p = 0.0019,). *p < 0.05, ****p < 0.0001. Scale bars = 100 µm. 









Figure 2.4 ASO treatment alters plaque size distribution in APP/PS1-21/ε4 
mice 
A, Experimental timeline for 6-week cohort. B, Brain sections from APP/PS1-21/ε4 mice treated 
with either ASO or cASO stained with anti-Aβ antibody HJ3.4 are shown (Scale bars = 500 µm). 
Due to space constraints, only the representative images of cASO and ASO were shown. There 
was no statistical significance between the PBS and cASO treatment groups. C, Analysis of the 
plaque distribution was done by stratifying total plaque coverage based on size, and either the 
total area covered by plaques of each group (top panel) or the frequency of occurrence (bottom 
panel) was plotted on the Y-axis. Three brain sections, 300 µm apart, from each mouse are 
included in the analysis, and only plaques larger than 694 µm2 are shown in bottom panel for 
clarity. A two-sample Kolmogorov-Smirnov test was used to compare the cumulative 
distribution of plaque sizes between the groups, and significant differences were found between 
cASO and ASO groups (p = 1.39888E-14), as well as between PBS and ASO groups (p = 
3.08816E-07). D, Brain sections from the same cohort stained with X-34 were shown (Scale bars 
= 500 µm). E, Analysis of the plaque size distribution based on X-34 staining was done using a 
similar approach as in (C), and the total area covered by plaques of each group (top panel) or the 
frequency of occurrence (bottom panel) was plotted on the Y-axis. No significant differences in 
the cumulative distribution of plaques were detected between the groups by the Kolmogorov-
Smirnov test. The density of Aβ antibody-stained plaques (F) and average plaque size (G) was 
analyzed in the same cohort of mice (n = 20 – 25 per group, p = 0.0144, F = 4.563 and p < 
0.0001, F = 19.80, respectively). The density of X-34-stained plaques (H) and average plaque 
size (I) was analyzed in the same cohort of mice (n = 20 – 25 per group, p = 0.0173, F = 4.351 
and p = 0.5839, F = 0.5429, respectively). J, Brain sections from 4-month-old APP/PS1-21/ε4 
mice were immunostained with an antibody against activated microglial CD45 (Scale bars = 1 
mm). K, The percentage of area covered by CD45 staining was quantified from the cortex of 
APP/PS1-21/ε4 mice (n = 20 – 25 per group, p = 0.1764, F = 1.793). All values are reported as 





Figure 2.5 Related to Figure 2.1. ASO Treatment effectively reduces 
expression of apoE3 and apoE4 in mice  
A, Timeline of various experimental approaches to test for efficacy and optimal dosing of the ASO. 
B, APOE4/4 mice were given a single bolus of ASO or PBS at P0 through ICV injection ICV into 
the right hemisphere, and the PBS-soluble apoE levels in the ipsilateral cortex were assessed at 
one month of age. (n = 6 – 8 per group, p = 0.0004). C, A separate cohort of APOE4/4 mice were 
unilaterally injected with a single bolus of either ASO or PBS at P0, and the apoE levels in the 
contralateral cortex were assessed at 2 months of age through an ELISA. (n = 10 per group, p = 
0.0354). D, PBS, cASO, or ASOs were injected into the right lateral ventricle of ε4/ε4 mice mice 
at 3 – 4 months of age (n = 5 per group) and PBS-soluble apoE levels were measured in brain 
lysates from the contralateral hippocampus 2 weeks later. (p = 0.0049, F = 8.963). E, Western blot 
analysis of apoE from the same cohort of mice. F, 10 µl of PBS or ASOs at two different 
concentrations (15 or 50 µg/µl) were injected into the right lateral ventricle of APOE3/3 mice at 3 
– 4 months of age (n = 5 per group) and apoE mRNA level in the ipsilateral posterior cortex was 
analyzed 2 weeks later. ASO treatment effectively lowered apoE mRNA level in the PBS fraction 
by more than 50% in the ipsilateral posterior cortex (n = 5 per group, p = 0.0159). G, PBS-soluble 
ApoE levels were measured using brain lysates from the same region (p = 0.0079). H, Western 
blot analysis of apoE in the PBS fraction from the ipsilateral posterior cortex brain lysates using 
anti-apoE antibody HJ15.7. I, A cohort of APP/PS1-21/ε3 mice were unilaterally injected with a 
bolus of either ASO or PBS at P0, a booster bolus at 2 months of age, and the apoE levels in the 
ipsilateral cortex were assessed at 4 months of age (n = 7 – 17 per group, p < 0.0001). J, ApoE 
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levels in the guanidine fraction was measured from the same cohort (p = 0.0004). K, A separate 
cohort of APP/PS1-21/ε3 mice were unilaterally injected with a bolus of either cASO, PBS, or 
ASO starting at 6 weeks of age, a booster bolus at 11 weeks of age, and the apoE levels in the PBS 
fraction from the contralateral cortex brain lysates were assessed at 4 months of age (n = 20 – 25 
per group, p < 0.0001, F = 52.43). L, ApoE levels in the guanidine fraction were measured from 
the same cohort (p = 0.2099, F = 0.600). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. All 








Figure 2.6 Related to Figure 2.2. ASO treatment at P0 significantly reduces 
insoluble Aβ in APP/PS1-21/ε3 mice  
A, Experimental timeline for P0 cohort of APP/PS1-21/ε3 mice. B, Brain sections from 4-month-
old APP/PS1-21/ε3 mice unilaterally injected with PBS or ASO starting at P0 were immunostained 
for Aβ with anti-Aβ antibody and the extent of Aβ deposition was quantified from the ipsilateral 
cortex (C) (Scale bar = 1mm). D, Brain sections from the same cohort of mice were stained with 
X-34 dye that recognizes only fibrillar plaques and the fibrillar plaque load was quantified from 
the cortex (E) (Scale bar = 1 mm). PBS-soluble Aβ40 (F) and Aβ42 levels (H) from the 
contralateral posterior cortex were measured from the brains of 4- month-old APP/PS1-21/ε3 mice 
following unilateral treatment with ASO or controls starting at P0 and a booster dose at 2 months 
of age (p = 0.4722 and 0.3191, respectively). Guanidine-soluble Aβ40 (G) and Aβ42 levels (I) 
were measured from the same cohort of mice (p = 0.0195 and 0.0106, respectively). n = 9 – 10 per 
group. J, PBS-soluble oligomeric Aβ levels were measured from the same brain lysates. K, 
Western blot analysis of APP, C99, and apoE from PBS-soluble brain homogenates of P0-treated 
APP/PS1-21/ε3 mice, α-actin was used as a loading control. L, Similar analyses were done on 










Figure 2.7 Related to Figure 2.3. Reduction of apoE expression starting at 6 
weeks of age did not significantly alter total Aβ levels in APP/PS1-21/ε3 mice 
A, Experimental timeline for 6-week cohort of APP/PS1-21/ε3 mice. PBS, cASO, or ASOs were 
injected into the right lateral ventricle of APP/PS1-21/ε3 mice starting at 6 weeks of age, and the 
brains were harvested at 4 months of age. Brain sections were immunostained with an anti-Aβ 
antibody (B), and the extent of Aβ deposition was quantified from the ipsilateral cortex (D) (p = 
0.7417, F = 0.3003). C. Brain sections from the same cohort of mice were stained with X-34 dye 
that recognizes only fibrillar plaques and the fibrillar plaque load was quantified from the cortex 
(E) (p = 0.4559, F = 0.7955). PBS-soluble Aβ40 (F) and Aβ42 levels (H) were measured from the 
contralateral posterior cortex of the same cohort of mice (p = 0.0531, F = 3.070 and p = 0.1289, F 
= 2.114, respectively). Guanidine-soluble Aβ40 (G) and Aβ42 levels (I) were measured from the 
same cohort of mice (p = 0.0074, F = 5.297 and p = 0.2918, F = 1.255, respectively), n = 20 – 25 
per group. J, Native gel analysis of CSF samples from APP/PS1-21/ε3 mice treated with either 
cASO, PBS, or ASO. K, Similar analyses were done on CSF samples from APP/PS1-21/ε4 mice. 









Figure 2.8 Related to Figure 2.4. ASO treatment significantly alters plaque 
distribution in APP/PS1-21/ε4 mice 
A, Experimental timeline for 6-week cohort of APP/PS1-21/ε4 mice. B, Brain sections from 
APP/PS1-21/ε4 mice treated with either PBS or ASO stained with anti-Aβ antibody 82E1 are 
shown (Scale bars = 1 mm). C, Analysis of the plaque distribution was done by stratifying total 
plaque coverage based on size, and the frequency of occurrence was plotted on the Y-axis. Three 
brain sections, 300 µm apart, from each mouse are included in the analysis, and only plaques larger 
than 694 µm2 are shown for clarity. The extent of Aβ deposition was quantified from the ipsilateral 
cortex as percent coverage (D). The density of Aβ antibody-stained plaques (E) and average plaque 
size (F) was analyzed in the same cohort of mice (n = 20 – 25 per group, p < 0.0001 and p < 
0.0001, respectively). G, Experimental timeline for 6-week cohort of APP/PS1-21/ε3 mice. H, 
Brain sections from APP/PS1-21/ε3 mice treated with either ASO or controls starting at 6 weeks 
of age were stained with anti-Aβ antibody HJ3.4 and the plaque size distribution was analyzed by 
stratifying the total plaque coverage based on individual plaque size. The frequency distribution 
of only plaques larger than 694 µm2 are shown for clarity. Three sections, 300 µm apart, from each 
mouse was included in the analysis. A two-sample Kolmogorov-Smirnov test was used to compare 
the frequency of cumulative distribution of plaque sizes between the groups, and significant 
differences were found between cASO and ASO groups (p = 1.0614E-10), as well as between PBS 
and ASO groups (p = 2.1456E-05), but not between the cASO and PBS groups (p = 0.05507). I, 
Analysis of the plaque size distribution was done on brain sections from the same cohort of mice 
stained with X-34 dye using a similar approach as in (H). A two-sample Kolmogorov-Smirnov 
test was used to compare the frequency of cumulative distribution of plaque sizes between the 
groups, and a significant shift in plaque size distribution were found between the ASO and PBS 
groups (p = 0.03457), but not between the ASO and cASO groups (p = 0.94044) or between the 
cASO and PBS groups (p = 0.20289). The density of Aβ antibody-stained plaques (J) and average 
plaque size (K) were analyzed in the same cohort of mice (n = 20 – 25 per group, p = 0.6544, F = 
0.4269 and p < 0.0001, F = 11.55, respectively). The density of X-34-stained plaques (L) and 
average plaque size (M) were analyzed in the same cohort of mice (n = 20 – 25 per group, p = 
0.0866, F = 2.544 and p = 0.7580, F = 0.2783, respectively). N, Brain sections from the same 
cohort of APP/PS1-21/ε3 mice were immunostained with an antibody against activated microglial 
CD45 (Scale bars = 1 mm). Due to space constraints, only the representative images of cASO and 
ASO treatment groups were shown. There was no statistical significance between the PBS and 
cASO treatment groups. O, The percentage of areas covered by CD45 staining was quantified from 
the ipsilateral cortex of APP/PS1-21/ε3 mice (n = 20 – 25 per group, p = 0.3777, F = 0.9912).**p 







Table 2.1 Key resources 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse monoclonal anti-Aβ Antibody HJ3.4 Reference [4] N/A 
Mouse monoclonal anti-Aβ Antibody HJ5.1 Reference [5] N/A 
Mouse monoclonal anti-Aβ1-40 Antibody 
HJ2 
Reference [5] N/A 
Mouse monoclonal anti-Aβ1-42 Antibody 
HJ7.4 
Reference [5] N/A 
Mouse monoclonal anti-apoE Antibody 
(HJ15.6) 
Reference [37] N/A 
Mouse monoclonal anti-apoE Antibody 
(HJ15.7) 
Reference [37] N/A 
Mouse monoclonal anti-apoE Antibody 
(HJ15.4) 
Reference [37] N/A 
Mouse monoclonal anti-Aβ (82E1) 
Antibody  
IBL-America IBL-America Cat# 
10323; 
RRID:AB_10707424 










Rat monoclonal anti-LAMP1 Antibody  Iowa Developmental 
Studies Hybridoma 
bank 
DSHB # 1D4B 
Goat polyclonal anti-iba1 Antibody Abcam Abcam # ab5076 
GFAP Monoclonal Antibody (GA5), Alexa 









Rabbit polyclonal anti-pan-ASO Antibody Ionis Pharmaceuticals # 13545 
Donkey Anti-Mouse Donkey anti-mouse 










Peroxidase-AffiniPure Goat Anti-Mouse 






Peroxidase-AffiniPure Goat Anti-Rabbit 






Rabbit Anti-Actin Antibody, Unconjugated Sigma-Aldrich Cat# A2066 
RRID:AB_476693 
Purified anti-β-Amyloid1-16 antibody,  BioLegend Cat# 803001 
RRID:AB_2564653 
Mouse Anti-Human ApoE Monoclonal, 
Alexa Fluor 647 Conjugated, Clone WUE-4 
antibody 
Novus Biologicals Cat# NB110-60531R 
RRID:AB_1850315 
Goat anti-Rat IgG (H+L) Cross-Adsorbed 
Secondary Antibody, Alexa Fluor 488 
Thermo Fisher 
Scientific 
Cat# A-11006 also 
A11006 
RRID:AB_2534074 






Donkey Anti-Goat IgG (H+L) Antibody, 
Alexa Fluor 568 Conjugated 
Molecular Probes Cat# A-11057, 
RRID:AB_142581 
Donkey Anti-Rabbit IgG (H+L) Polyclonal 
Antibody, Alexa Fluor 647 Conjugated,  
Molecular Probes Cat# A-31573 also 
A31573 
RRID:AB_2536183 
   
Chemicals, Peptides, and Recombinant Proteins 
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Trizol Life Technologies 15596026 
Ethyl Alcohol Pharmco-Aaper 11100020S 
Sucrose Sigma-Aldrich S0389 




X-34 dye Gift from Dr. Robert 
Mach (Reference53) 
N/A 
Critical Commercial Assays 
Lumigen ECL Ultra (TMa-6) Thermo Fisher 
Scientific 
# NC024069 
Micro BCA Protein Assay Kit Thermo Fisher 
Scientific 
# 23235 
TaqMan™ Universal PCR Master Mix Thermo Fisher 
Scientific 
# 4304437 
High-Capacity RNA-to-cDNA™ Kit Thermo Fisher 
Scientific 
# 4387406 
RNeasy Mini Kit (50) Quiagen # 74104 
Experimental Models: Organisms/Strains 
B6.129P2-Apoetm3(APOE*4)Mae N8 Taconic 1549 
B6.129P2-Apoetm2(APOE*3)Mae N8 Taconic 1548 
B6-Tg(Thy1-APPswe; Thy1-PS1 L166P) Gift from Dr. Mathias 
Jucker (Reference46) 
MGI:3765351 
   
   














Taqman probe for apoE Applied Biosystems Hs00171168_m1 
Taqman probe for GAPDH Applied Biosystems Mm99999915_g1 
Gapdh 
   
Software and Algorithms 





Imaris 8 & 9 Bitplane http://www.bitplane.com
/software/imaris 





















Chapter 3:  
Differential effects of human APOE isoforms 













The pathological hallmarks of Alzheimer disease (AD) are amyloid plaques, which are cerebral 
aggregates consisting of fibrils of the amyloid β-protein (Aβ), and filamentous lesions of the 
microtubule-associated protein tau known as neurofibrillary tangles. In the early 1990s, the 
apolipoprotein E (apoE) was found to co-localize with amyloid plaques. The ε4 allele of the APOE 
gene was sequentially identified as the strongest genetic risk factor for AD. Since then, multiple 
lines of evidence suggest that the major mechanism by which apoE influences AD pathology is 
via its effects on Aβ metabolism, particularly aggregation and clearance. The aggregation of Aβ 
into higher-order species is nucleation-dependent, where the initial formation of amyloidogenic 
seeds is required to facilitate further addition of monomers. Our previous work suggests apoE to 
affect the earliest stages of plaque formation (the nucleation phase). Here we describe an isoform-
dependent effect of apoE on this process, particularly the formation and/or property of the Aβ 
seeds. 
 We analyzed the seeding patterns in two different models of amyloidosis (APP23 and APP 
NLF-KI) that had been inoculated with murine brain extracts (containing Aβ seeds) isolated from 
aged donor brains with different human apoE backgrounds (APPE2, APPE3, and APPE4). In 
APP23 hosts, APP/PS1 brain extracts from different APOE backgrounds produce plaques with 
increasing compactness and fibril content in the order of ε2 < ε3 < ε4. APP NLF-KI hosts yield 
differential seeding patterns that are driven by the donor APP strain, but not by APOE genotypes. 
These results suggest that human APOE isoforms differentially affect the properties of Aβ seeds 
in certain host environments, thus creating different strains of Aβ with distinct structural features 
and seeding capabilities. This isoform-dependent effect of apoE on Aβ may contribute to the 




Since the initial identification of the apolipoprotein E (apoE) as a component of cerebral 
amyloid plaques in 1993, the ε4 allele of APOE have emerged as the most significant genetic risk 
factor for the development of late-onset Alzheimer disease (AD). Despite intense research efforts 
over the past 25 years, it is still not completely clear how APOE confers this elevated risk for AD. 
Studies that looked at post-mortem AD patient brains found a strong correlation between APOE 
status and cerebral amyloid plaque load. These findings suggests a modulatory effect of APOE on 
the accumulation amyloid-β (Aβ) peptide, the principal component of these plaques. Indeed, 
human APOE isoforms was found to differentially regulate the clearance of soluble Aβ from the 
interstitial space (ISF) in vivo 8. Interestingly, this difference is isoform-dependent, and follows 
the same order corresponding to their respective risk for developing AD (ε4>ε3>ε2, where ε4 
impedes the clearance of soluble Aβ the most). These findings suggest that reduction of apoE 
levels might improve the clearance of soluble Aβ, thus reducing plaque pathology. We previously 
tested this hypothesis by utilizing an antisense oligonucleotide to reduce apoE expression and 
examined the effect on cerebral Aβ accumulation in vivo 21. ASO treatment starting after birth led 
to a strong and significant decrease in Aβ pathology in the cortex of APP/PS1/ε4 (APPE4) mice 
at 4 months of age. Interestingly, when ASO treatment was initiated in adulthood, no reduction of 
Aβ pathology was detected at 4 months of age in the cortex, despite achieving apoE reduction by 
>50% starting at the onset of amyloid deposition. Our colleagues complemented our findings by 
overexpressing different APOE isoforms in the brain, where overexpression of apoE4 at birth, but 
not during adulthood, led to a significant increase in Aβ accumulation 29. Collectively, these results 
suggest that apoE levels (at least the ε4 isoform) can strongly affect the initiation of Aβ pathology 
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in vivo but once Aβ plaque pathology is present, reducing apoE only has a minor effect on further 
amyloid deposition.  
 Our observations in these studies may be explained by the in vitro model of Aβ 
aggregation, a nucleation-dependent process with three distinct phases: an initial “lag phase” 
resulting in the formation of dimers, trimers, and higher-order oligomers, an exponential phase 
during which rapid fibrillization occurs, and a “plateau phase” where fibril growth reaches its 
maximum 22. ApoE has been proposed to affect the fibrillization of Aβ in vitro, and the differential 
effects of the different isoforms follow the order of apoE4>apoE3>apoE2 30,37,44. While our 
previous results support a role of apoE in the earliest stage of plaque formation (the “nucleation” 
stage), we also observed some subtle (but significant) isoform-dependent effect of apoE on Aβ. 
Specifically, postnatal (P0) reduction of apoE led to a decrease in soluble and insoluble Aβ in 
APPE4 mice, but only reduces insoluble Aβ in APPE3 mice 21. Reduction of apoE4, but not apoE3, 
in adult animals led to a paradoxical increase in Aβ area coverage, as well as plaque density. 
Consistent with our findings, overexpression of apoE4, but not apoE3, led to a significant increase 
in Aβ pathology in another model of amyloidosis 29. These results strongly suggest that apoE4 is 
more potent as a pro-amyloidogenic agent. Thus, we hypothesized that apoE can influence the 
formation and/or properties of the Aβ seeds in an isoform-dependent manner in vivo. To investigate 
this hypothesis, we performed seeding studies in APP23 and APP NLF-KI hosts using brain 
extracts from aged (20 – 22 month old) APP/PS1-21 mice that are homozygous for either murine 
apoE (APP/PS1), human ε2 (APPE2), ε3 (APPE3), or ε4 (APPE4) allele (adjusted for Aβ 
concentrations). This allows us to assess the characteristics of amyloidogenic seeds that were 
formed in the presence of different apoE isoforms, particularly their ability to facilitate the 
formation of new plaques in a neutral environment. Our results show that APP23 mice inoculated 
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with brain extracts from APPE2 mice produce diffuse amyloid deposits with a dense distribution 
pattern across the granular cell layer of the hippocampus. In contrast, amyloid deposits induced by 
APPE4 seed extracts are characterized by small, fairly compact Aβ deposits that are puncta-like in 
appearance with a sparse distribution around the granular cell layer. Amyloid deposits induced by 
APPE3 seed extracts have an intermediate phenotype. Brain extracts from non-transgenic APP 
mice failed to induce any observable seeding pattern. These results suggest that human APOE 
isoforms may differentially affect the properties of Aβ seeds, thus creating different strains of Aβ 
with distinct structural features and seeding capabilities. Interestingly, these isoform-dependent 
differences were abrogated in APP NLF-KI hosts, suggesting some degree of dependency on the 
properties of the host, such as APP expression levels or distribution pattern. 
3.3 Results 
Isolation and characterization of Aβ seed extracts from brain homogenates  
Several studies have demonstrated that SEs derived from AD patients or aged APP 
transgenic (Tg) mice can induce formation of new amyloid plaques 14,17,33. Interestingly, SEs 
derived from different APP Tg strains induced Aβ lesions that are distinct and resemble those seen 
in their respective donor strain 18,33. Thus, we hypothesized that SEs from APP Tg mice harboring 
different human APOE isoforms can induce morphologically distinct lesions in the same host 
environment. We adapted the Aβ seeding assay from those studies to design an in vivo seeding 
experiment that allowed us to test this hypothesis (Figure 3.1A). Notably, we needed to create 
donor strains that express APP alongside the various human APOE isoforms. To obtain donor 
brains with those characteristics, we crossed APP/PS1-21 Tg mice to APOE-KI mice to obtain 
APP transgenic mice on an APOE2/2, APOE3/3 or APOE4/4 background (APPE2, APPE3, and 
APPE4 mice, respectively). These mice were aged until approximately 20 – 22 months, when their 
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brains were harvested to serve as donor brains. Various control donor brains were aged and 
harvested in the same manner: APP/PS1-21 non-Tg (APPPS1-nTg), APP/PS1-21 (APPPS1), and 
APP-NLF-KI (NLF-KI), all of which carry the endogenous murine Apoe locus. 
 To obtain seeding-capable material from donor brains, snap-froze hemispheres were 
homogenized in sterile PBS, and the 3000x g supernatants were collected as crude SEs. We first 
measured the levels of Aβ in the SEs using an in-house Aβ ELISA assay that utilizes our in-house 
antibodies HJ2, HJ7.4, and HJ5.1. Since potential differences in the fibril content of the SEs might 
affect the absolute concentration detected by ELISA, we also treated crude SEs with formic acid 
(FA-SE) to dissociate larger aggregates into monomers. Aβ1-40 and Aβ1-42 levels were measured 
from both SE preparations (Figure 3.1B). As predicted, there are approximately 20x more Aβ 
detected in the FA-SE fraction relative to the crude SE fraction. However, the Aβ1-42 to Aβ1-40 
ratios remain consistent among the fractions and also the different genotypes. Similarly, the total 
Aβ concentration between the crude SE and FA-SE fractions follow the same trend (Figure 3.1C). 
To ensure accurate quantification of Aβ concentration, we subjected the FA-SE fractions to a 
second ELISA platform from Meso Scale Discovery that utilizes the 6E10 antibody (Figure 3.1D). 
When compared to values obtained from our in-house assay, the Meso Scale platform reported 
absolute values that are 1.5x higher on average. However, the general trend is very consistent 
between the two platforms.  
Seed extracts from donors with different human APOE isoforms produces distinct seeding 
patterns in APP23 hosts 
 Previous studies using a similar Aβ seeding paradigm reported that the characteristics of 
the induced Aβ lesions were also influenced by the host 18,33. Thus we utilized two different APP-
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expressing host models with distinct Aβ accumulation profiles: APP23 and APP NLF-KI (NLF-
KI). Several studies have established APP23 mice as a robust model for studying Aβ seeding 
activities, both as hosts 18,33 and donors 17. APP23 mice carry a construct that expresses the APP751 
Swedish mutation driven by the murine Thy-1 promoter 38. The transgene is overexpressed by 7 
fold in these mice with an elevated Aβ1-40 to Aβ1-42 ratio. The mice were reported to develop Aβ-
immunopositive plaques in the neocortex starting at ~ 6 months and in the hippocampus at 8 – 10 
months of age 33. APP23 mice heterozygous for the transgene were inoculated with SEs starting 
around 3 – 4 months of age, and the seeding patterns were analyzed 4 months post-injection (Figure 
3.2A) 
 Prior to being inoculated into host brains through stereotaxic injections, the total Aβ 
concentration ([Aβ1-40] + [Aβ1-42]) in SEs were adjusted through appropriate dilution with sterile 
PBS. Based on the concentration of the FA-SE fractions measured from our in-house ELISA 
platform, SEs from all donor/genotypes were diluted to contain 1.5 ng/ml of total Aβ (Figure 3.1C 
– dashed line). SEs from non-Tg APP/PS1-21 donors were not diluted. We did not attempt to 
adjust/normalize apoE levels in the SEs due to various reasons that will be discussed further in the 
discussion (section 3.4). 
 To inoculate the APP23 hosts, SEs were injected bilaterally into the hippocampus (dentate 
gyrus) of young, pre-depositing 3 – 4 month-old APP23 mice. A total of 3 ng (1.5 ng/µl x 2 µl) of 
monomer-equivalence Aβ was injected into each hemisphere. We first attempted to reproduce 
previously described findings by examining APP23 hosts inoculated with SEs from APP/PS1-nTg 
(Figure 3.2C) and APP/PS1 (Figure 3.2B) donors. Formaldehyde-fixed brain sections from the 
host were immunostained with an anti-Aβ antibody, and the seeding patterns were analyzed. 
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Consistent with previous reports, β-amyloid-containing APPPS1 extract injected in APP23 hosts 
induces punctate, coarse and compact Aβ-plaques 4 months after injections. Additionally, the 
induced Aβ deposits by the APPPS1 extract were largely confined to the subgranular layer and 
polymorphic region of the dentate gyrus. SEs from APPPS1-nTg donor failed to produce any 
detectable seeding pattern. It is important to note that the amount of induced Aβ deposits we 
observed here are significantly lower than those reported from the Jucker lab 18, despite closely 
following every applicable experimental parameter. This could be due to many reasons, but one 
explanation could be the genetic drift in either the donor or the host. Notably, our APP23 founders 
were from a colony that was re-derived from a single animal after many generations of back-
crossing to the C57Bl/6 strain. APP23 mice used in previous studies originated from the initial 
founders created on a C57Bl/6xDBA2 mixed background, though they were also back-crossed 
with C57Bl/6 strain for at least 10 generations. These inconsistent genetic background might also 
explain the lack of any significant endogenous plaque in our APP23 hosts at 7 – 8 months of age, 
while these mice were initially reported to develop neocortical plaques at 6 months and 
hippocampal plaques at 8 months. The overall lower level of Aβ concentration in the host might 
explain for the lower seeding activity compared to previous studies. 
 Next, we analyzed the seeding patterns in APP23 hosts that was seeded with SEs from 
APPE2, APPE3, and APPE4 donors (Figure 3.2D, 3.2E, and 3.2F). Qualitative analysis of brain 
sections (n = 3 per genotype) stained with the same anti-Aβ antibody revealed several induced Aβ 
deposits that are distributed in an anatomically similar manner to those seen with APPPS1 SE: the 
deposits were largely confined to the subgranular layer and polymorphic region of the dentate 
gyrus. However, there are considerable differences in the morphotype of the induced Aβ lesions. 
APPE2 SEs induce Aβ deposits that possess a very diffuse (sometimes filamentous) pattern (Figure 
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3.2D), while APPE4 SEs induce punctate, coarse, and compact Aβ plaques (Figure 3.2F). APPE3 
SEs yield an intermediate phenotype (Figure 3.2E). This pattern is consistent with our previous 
studies on APPPS1 mice expressing either of the three human APOE isoforms, where most of the 
plaques in APPE2 mice are diffuse at 3 – 4 months of age (unpublished data). For future studies, 
we are interested in performing similar analysis of the plaques in APPE2, APPE3, and APPE4 
mice at 4 months of age, and those at 20 – 22 months of age (the same animals from which the 
SEs were derived). 
 To further examine the nature of the induced Aβ lesions in APP23 hosts, we stained the 
brain sections with X-34, a fluorescent dye that binds to β-sheet structures, which are only found 
in more compact, fibrillar plaques (Figure 3.3A). Consistent with our Aβ-immunostaining 
analysis, SEs derived from APPE3 (Figure 3.3C) and APPE4 (Figure 3.3D) donors yielded mostly 
X-34-positive plaques, with an abundance of small punctate that clusters around the subgranular 
layer of the dentate gyrus. SEs from APPE2 donors produced X-34-positive deposits that are 
generally lower in intensity, and spread out in a diffuse pattern over the subgranular layer and 
polymorphic region of the dentate gyrus (Figure 3.3B).  
 Altogether, our data supports a role of human APOE in determining the characteristics of 
Aβ seeds the subsequently influence the induced plaque deposits. The three isoforms differ in their 
influence on this process, with the ε2 allele producing more diffuse plaques, whereas the ε3 and 
ε4 allele yielding plaques that are more compact and rich in β-sheet content. Of note, we 
experienced an unusually high mortality rate in APP23 hosts following the inoculation of SEs. 
There was no qualitative correlation between the source of the SEs and the mortality rate. 
108 
 
However, female mice seem to be more susceptible than male mice among the APP23 hosts (Table 
3.1). 
Seed extracts derived from different APP models produce different seeding patterns in APP 
NLF-KI hosts 
The NLF-KI line was created through a knock-in approach to express APP at wild-type 
levels with an elevated Aβ1-42 to Aβ1-40 ratio 
36. The construct contains a humanized Aβ region 
along with two pathogenic mutations, the Swedish (APP KM670/671NL), and the 
Beyreuther/Iberian (APP I716F) mutations. APP expression is controlled through the endogenous 
murine APP promoter, allowing for appropriate cell-type and temporal specificity. Initial 
description of these mice reported Aβ accumulation to begin six months of age. However, no 
substantial pathology was observed until around 12 months of age. Due to the overall lower Aβ 
levels and slower Aβ aggregation kinetics, we decided to start the SE inoculation at a later time 
point (5 – 6 months), and incubate for a longer period (6 months post-injection), compare to those 
parameters for APP23 hosts (Figure 3.4A).  
 In addition to the same donor genotypes examined in APP23 hosts, we included SE from 
an aged (~26 month-old) NLF-KI donor to detect any strain-specific phenotype. We first 
performed immunohistological analysis on fixed brain sections from 11 – 12 month-old NLF-KI 
hosts that were inoculated with either NLF-KI (Figure 3.4B), APPPS1 (Figure 3.4C), or APPPS1-
nTg (Figure 3.4D) SEs.  Qualitative analysis of the stained sections revealed striking differences 
in the amount and distribution of induced Aβ lesions from APPPS1 and NLF-KI donors. The NLF-
KI-derived SEs induced several small Aβ deposits that are punctate-like, but only with moderate 
compaction. The induced lesions are distributed sparsely along the inner and outer molecular 
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layers. The APPPS1 SEs did not yield a stereotypical seeding pattern, instead we only observed a 
single line of Aβ immunoreactive material in an anatomical fissure, just above the outer molecular 
layer (Figure 3.4C, red arrowheads). APPPS1-nTg SEs did not induced any detectable seeding 
pattern (Figure 3.4D). At this age, endogenous plaques are seen throughout the neocortex of the 
NLF-KI hosts (blue arrowheads). 
 We next examined the hosts inoculated with SEs from APPE2 (Figure 3.4E), APPE3 
(Figure 3.4F), and APPE4 (Figure 3.4G) donors. Interestingly, no isoform-dependent phenotype 
of APOE on the induced plaque deposits was observed. Additionally, the induced seeding patterns 
are qualitatively identical to that seen with APPPS1 SEs, with a single line of Aβ-immunopositive 
materials just above the outer molecular layer. For future experiments, we will further characterize 
these Aβ lesions by staining them with X-34 dye to analyze their fibrillar component. 
 Altogether, our data suggest that the exogenous induction of Aβ plaques in vivo is 
dependent on both the characteristics of the donor seeds and also the host. In the NLF-KI hosts, 
the effect of the APP donor strain (APPPS1 versus NLF-KI) is much stronger than that of the 
APOE genotypes of the donor. The post-inoculation mortality rate in NLF-KI hosts is qualitatively 
much lower than that of APP23 hosts (Table 3.2). 
Aβ seeding in APP23/EKO hosts – future direction 
Although our experimental design allows for SEs from different APOE donors to induce 
seeding in the same host, it is possible that the presence of murine apoE in the hosts can have some 
confounding effects on how the SEs induce further aggregates. This scenario is plausible, since 
murine apoE is more pro-amyloidogenic than any of the human isoforms. Replacement of the 
endogenous murine apoE locus by human APOE constructs in APP transgenic models delay the 
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appearance of amyloid plaques by several months. Thus, to rule out any potential confounding 
effects from murine apoE, we propose to perform similar seeding experiments using APP23 host 
mice that lack murine apoE (APP23/EKO) (Figure 3.5A). These hosts will be acquired through 
crossing of apoE knock-out mice (EKO) to APP23 mice for successive generations. 
Similar to our experimental construct in figure 3.1, our donor brains include frozen 
hemispheres from APPE2, APPE3, and APPE4 mice harvested at approximately 20 – 22 months. 
Various control donor brains were aged and harvested in the same manner: APPPS1-nTg, APPPS1, 
and APP23. To account for potential variations in donors’ pathology (i.e. differential transgene 
expression, litter effects, etc...), we pooled seeding-capable material from at least three donor 
brains for each genotype. Crude SEs were treated with formic acid to dissociate larger aggregates 
into monomers, and the Aβ levels were measured using a validated ELISA platform from Meso 
Scale Discovery that can detect Aβ1-38, Aβ1-40, and Aβ1-42. Consistent with the genetic construct and 
our prior data, Aβ1-42 is the major species in APPPS1, APPE2, APPE3, and APPE4 mice, whereas 
Aβ1-40 is the major species in APP23 mice (Figure 3.5C). Aβ levels in SEs from APPPS1/EKO and 
APP NLF-KI brains were shown for comparative purposes. The total concentration of soluble Aβ 
follows an isoform-dependent pattern (ε4 > ε3 > ε2) in APP/PS1-21 mice, all of which were 
significantly higher than those found in APP NLF-KI mice (Figure 3.5B). 
Data from this experimental setup is important in determining the role of sustained apoE 
production from the host in facilitating Aβ seeding. Such knowledge can carry important 




The aggregation cascade of Aβ monomers into larger aggregates have been studied 
extensively in vitro, and was proposed to follow three major phases (the term “aggregation” refers 
to all three phases in this context). In this model, monomers collide and aggregate to form 
oligomers in the initial “lag phase”, appropriately named due to its slow kinetics. Aβ oligomers 
have been proposed to act as nuclei (or seeds) that facilitate rapid fibrillization in the second phase, 
termed the exponential “growth phase”. Lastly, the growing plaques enter the “saturation phase”, 
where the growth rate slows and eventually reaches a plateau. In the context of in vitro 
experiments, this could be due to either the limitation of the technique (saturation of signals), or 
depletion of the pool of monomers. While previous in vivo studies by us 21 and our colleagues 29 
demonstrated a prominent role of apoE in the early stages of plaque pathology, it was still unclear 
whether such effect is isoform-dependent. In this study, our experimental design allowed us to 
address this question without being confounded by the well-described effect of APOE isoforms on 
the clearance of soluble Aβ from the ISF during the lifetime of the animal. Our data demonstrated 
that APOE isoforms differentially influence Aβ seeds in terms of the type of plaques that they can 
induce. However, these phenotypes are dependent on the context that they are examined, and the 
effect of the “strains” of Aβ (which can be influenced by many factors) are much stronger than the 
isoform-dependent effect of APOE.  
The effects of APOE isoforms on Aβ aggregation were investigated shortly after the initial 
discovery of APOE’s role in AD risk. It is critical to note that these early studies measured Aβ 
aggregation kinetics in vitro by adding the Thioflavin T (ThT) dye to the reaction and monitoring 
its fluorescent signal. ThT becomes fluorescently active by inserting itself in between fibril sheets, 
and the signal intensity increases as more Aβ fibrils are formed. Early experiments on the effects 
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of apoE isoforms on the aggregation of Aβ found all three isoforms of apoE to promote the 
fibrillization of Aβ in vitro, and the potency follows the order of apoE4 > apoE3> apoE2 30,37,44. 
However, technical limitations of the ThT assay prevented closer examination of the lag phase, 
when no fibrils were present and when soluble oligomeric species are being formed. Thus, it 
remained unclear for some time whether apoE exerts its effects in the nucleation, the elongation 
of plaque, or both. More recently, development of a newer, more sensitive detection method using 
Aβ conjugated to tetramethylrhodamine (TMR) offered a glimpse into what happens during the 
lag phase 16. The higher temporal resolution allowed the authors to categorize the in vitro 
aggregation of Aβ into three phases that are slightly different from those proposed earlier. First, 
an initial oligomeric phase that results in the formation of dimers, trimers, and higher-order 
oligomers. This is followed by an intermediate phase during which there is little change in 
monomer concentration but rather clustering of oligomers. Lastly, the fibrillization phase reflects 
the formation and growth of fibrils. Under this new technique, the authors found all APOE 
isoforms to interact with both oligomeric intermediates and fibrils of Aβ with high affinity, with 
apoE4 having the most dramatic effect compared to apoE2 or apoE3. Specifically, the presence of 
apoE4 dramatically increases the time that Aβ species are in the intermediate stage, presumably 
by binding and stabilizing oligomers. Our results in the APP23 hosts are consistent can further 
supplement this model, where the presence of apoE4 not only stabilizes, but also morphologically 
alter the oligomeric species being formed. On the other hand, the authors also found apoE4 to be 
most efficient at stabilizing fibrils in the final stage. Again, our results can also be explained by 
this model, since fibrils are capable of growing both by monomer addition or by fragmentation, 
followed by secondary nucleation 9,15,24,26. In this scenario, stabilization of Aβ fibrils by apoE4 
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favors the growth of fibrils over the slower conversion of oligomers to fibrils, thus resulting in 
more fibrillar species of plaques. 
 In the context of in vitro experiments, it remains unclear whether human APOE isoforms 
generally inhibit Aβ aggregation 3,11,16,45 or promote their aggregation 30,37,44. These contradictory 
findings most likely result from differences in experimental conditions, such as the preparation of 
apoE, Aβ, and/or their concentrations. Of note, the early studies 30,37,44 that reported apoE to 
accelerate Aβ fibrillization examined the interaction using the lipid-free form of apoE and prepared 
Aβ at an unusually high concentrations (~100 µM) at which almost all of the Aβ species exist as a 
mixture of oligomers 4,7,15. Thus, the observed phenotype might be an artifact produced under these 
extreme conditions. Regardless of the overall effect, all of these studies found an isoform-
dependent effect on Aβ aggregation, with apoE4 having either a stronger facilitative effect, or a 
weaker preventative effect, on Aβ aggregation. More importantly, these isoform-specific 
phenotypes were recapitulated in vivo in at least one model of amyloidosis 8. Interestingly, murine 
apoE is more amyloidogenic than all human isoforms 12,19,20, while lack of apoE reduces formation 
of fibrillar plaques 1,41. 
 Previous in vivo seeding studies found the molecular composition and conformation of the 
aggregated Aβ from different APP models to be distinct, and these characteristics are maintained 
by seeded conversion 14,18. Our results from APP23 hosts support these latter conclusions, with the 
seed characteristics being differentially influenced by APOE isoforms. Although we did not 
measure the apoE levels in the SEs after adjusting for Aβ concentration, it is conceivable that the 
concentration and/or total amount of apoE varies among the SEs. This could be due to either 
intrinsic differences between human and murine apoE, or among the human isoforms themselves 
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(i.e. differences in binding affinity to Aβ16, lipids13, and conformational stability34). These 
differences, if exist, might explain for any potential differences in the SEs’ characteristics and 
potency. From a practical perspective, normalization of both Aβ and apoE levels requires extensive 
processing and handling of the SEs beyond simple dilution, potentially risking protein degradation 
and alteration of the SEs’ biochemical composition. Nevertheless, it is of great interest to assess 
the levels of apoE (both soluble and insoluble) in our SEs in the future. Of note, while the half-life 
of soluble apoE under is relatively short (~1 day for human apoE in the CNS43 and ~7 hours for 
murine apoE2), insoluble forms of apoE are bound to to Aβ fibrils with potentially much longer 
half-life, and can potentially play a significant role in facilitating seeding activities. 
 In the seeding experiments involving NLF-KI hosts, our results corroborate the conclusions 
from another study: the exogenous induction of cerebral β-amyloidosis to be influenced by both 
the donor and the host 33. Indeed, SEs derived from APPPS1 and NLF-KI induce distinct Aβ 
deposits, both of their morphology and distribution. This strain-like behavior of Aβ was previously 
described in the context of APP23 versus APPPS1 models, where their respective Aβ morphotypes 
were presumably influenced by APP expression level and opposite Aβ1-42 to Aβ1-40 ratio 
18,33. 
However, both strains overexpress APP by several folds (3 fold for APPPS1 and 7 fold for APP23), 
whereas NLF-KI mice expresses APP under the endogenous promoter 36. This affects not only the 
Aβ levels but potentially the distribution of APP (and subsequently Aβ) throughout the brain. It is 
entirely possible that the induced seeding pattern requires more time to spread to different layers 
of the dentate gyrus due to the overall lower Aβ concentration. To test this hypothesis, a small 
cohort of NLF-KI hosts that had been seeded with various SEs is being aged until 14 – 15 months 
of age (for a total of 9 month post-inoculation). These longer incubation, if show a different seeding 
pattern, does not dismiss a strain-like transmission of Aβ in this model, as the NLF-KI SEs clearly 
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induce a more stereotypical seeding pattern over several layers of the dentate gyrus, despite having 
the lowest level of Aβ relative to all other genotypes (Figure 3.1B, 1C, and 1D). More importantly, 
this strain-dependent effect is stronger than the effects induced by the APOE isoforms, at least in 
this particular host. 
 In conclusion, we report here an investigation on the isoform-dependent effect of APOE 
on the molecular conformation and composition of Aβ seeds, where apoE2 induces Aβ plaques 
that are diffuse in nature, whereas apoE3 and apoE4 induces Aβ deposits that are punctate-like and 
more compact. Based on these results, we propose a model where the interaction between apoE 
and soluble Aβ species (monomer or oligomers) somehow modify the characteristics of the seed-
capable species that are subsequently formed (Figure 3.6A and 3.6B). We also found an Aβ strain-
dependent effect on seeding-associated phenotypes in an APP knock-in model that is much 
stronger than the effects of APOE isoforms. Since all of our findings here were done in hosts with 
endogenous apoE, it will be interesting to follow up on our ongoing seeding experiments in 
APP23/EKO hosts. Additionally, we plan to examine whether the different morphology of the 
resulting plaques lead to an altered glial response. Several studies on APOE-knock-out mice found 
an altered plaque morphology (more diffuse) that is associated with an altered microglial or 
astrocytic response. However, from those studies, it is difficult to tell whether the altered plaque 
morphology leads to the altered glial response, or vice versa. This latter point is critical to address, 
as apoE can modulate the innate immune response in the brain, where apoE4 is more pro-
inflammatory relative to the other isoforms 23,25,27,31. ApoE4-KI mice also have a greater pro-
inflammatory phenotype upon exposure to certain stimulus 42. Our experimental design, where the 
induced Aβ plaques are exposed to the same host environment can help delineate this important 
relationship between apoE and amyloid plaques. 
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3.5 Experimental procedures 
Experimental Model and Subject Details 
  Generation of human APOE isoform mice with APPswe/PS1(L166P) mutant transgenes. 
To examine any potential isoform-dependent effect of APOE on Aβ seeds, it was necessary to 
generate an amyloidogenic model that also harbors the different human APOE isoforms. These 
mice will then be utilized as “donors” in our experimental design. To accomplish this, we used 
knock-in mouse models in which the endogenous murine Apoe gene is replaced with either the 
APOE3 or APOE4 gene 40. To model the amyloidosis aspect, we utilized APPPS1-21 mice that 
overexpress a human APP cDNA with a Swedish mutation (KM670/671NL) and mutant PS1 with 
the L166P mutation. APPPS1-21 Breeding pairs were obtained from Dr. Mathias Jucker, 
University of Tübingen, Tübingen, Germany 35. To replace the murine Apoe gene with human 
APOE isoforms, APPPS1-21 mice were bred with either APOE3/3 or APOE4/4 knock-in mice. 
APPPS1-21/APOE4/Apoe mice and APOE4/Apoe mice from the first generation were bred with 
each other to generate APPPS1-21/APOE4/4 and APOE4/4 mice. APPPS1-21/APOE4/4 and 
APOE4/4 mice were then bred to generate more APPPS1-21/APOE4/4 (APPE4) mice. Similar 
breeding schemes were followed to generate APPPS1-21/APOE3/3 (APPE3) and APPPS1-
21/APOE2/2 (APPE2) mice. All mice used in this study were maintained on a C57BL/6J 
background. Based on many Aβ seeding protocols, these mice were aged to 20 – 22 months when 
their brains are harvested to generate “seed extracts”, per our experimental design. Mice were 
individually housed in AAALAC accredited facilities with temperature and humidity controls, and 
were under a 12-hours light/dark cycle (lights on at 6:00 AM) cycle with free access to food and 
water ad libitum throughout all phases of the experiments. All animal procedures were approved 
by the Institutional Animal Care and Use Committee (IACUC) at Washington University, and 
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were in agreement with the Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC, WUSM). 
Acquisition and maintenance of APP23 and APP NLF-KI mice. We needed an APP-
expressing model to serve as “hosts”, per our experimental design. The hosts need to have a 
relatively slow Aβ aggregation kinetics in order for us to differentiate between Aβ-seeded plaques 
and the endogenous plaques. We utilized two different APP mouse lines: APP23 and APP NLF-
KI. The APP23 transgenic line was a generous gift from Novartis Pharmaceuticals. This strain 
harbors a construct that expresses the APP751 Swedish mutation driven by the murine Thy-1 
promoter38. The APP23 line was initially created on the C57Bl/6xDBA2 mixed background, but 
were backcrossed to C57Bl/6 strain for many generations, and the whole line was re-established 
from a single animal that was completely black in color (which indicated that a large part of the 
DBA chromosome was now replaced by Bl6). The mice were reported to develop Aβ-
immunopositive plaques in the neocortex starting at ~ 6 months and in the hippocampus at 8 – 10 
months of age 33. The APP NLF-KI (NLF-KI) line was a generous gift from Dr. Takaomi Saido 
(RIKEN Brain Science, Japan). This line was created through a knock-in approach to express APP 
at wild-type levels with an elevated Aβ1-42 to Aβ1-40 ratio 
36. Specifically, the APP knock-in 
construct contains a humanized Aβ region along with two pathogenic mutations, the Swedish (APP 
KM670/671NL), and the Beyreuther/Iberian (APP I716F) mutations. APP expression is controlled 
through the endogenous murine APP promoter, allowing for appropriate cell-type and temporal 
specificity. Initial description of these mice reported Aβ accumulation to begin six months of age. 
However, no substantial pathology was observed until around 12 months of age. APP23 mice were 
bred to be heterozygous for the transgene and was aged to 3 months for experiments, while NLF-
KI mice were bred to be homozygous and utilized for experiments at 5 months of age.  
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Preparation of seed extracts. Fresh-frozen brain tissue was homogenized at 10% in sterile 
PBS using the Precellys Evolution super homogenizer (Bertin Instruments), 3 x 10 seconds with a 
10-second break 32. Homogenates will then be transferred into fresh 1.5 ml tube and centrifuged 
for 5 minutes at 3000 x g (4oC). The supernatant (“seed extract” - SE) will be aliquoted and stored 
at –80oC until use. Before inoculation, total Aβ concentration (Aβx-38/x-40/x-42) in each extract 
was measured through ELISA as previously shown 10. The total amount of Aβ were adjusted 
among the different donor genotypes so that the same amount of Aβ monomer-equivalence were 
injected into each brain. This was done through appropriate dilution with sterile PBS just prior to 
inoculation. The level of apoE were measured, but not adjusted. There were two independent 
rounds of SE preparation: one for APP23 and NLF-KI hosts, and one for APP23/EKO hosts. In 
the first round, SEs from a single animal from each genotype were inoculated into host brains. In 
the second round, SEs from 2 – 3 animals were mixed at equal ratios for each genotype, and the 
Aβ concentrations were adjusted accordingly prior to injections. This approach reduces the risk 
that any observable phenotype in the host is real, and not due to any unknown confounding factor 
that is unique to a donor.   
Sandwich ELISA. Brain cortices or hippocampi were sequentially homogenized with cold 
PBS (no protease inhibitor was added). The levels of Aβx-40 were measured on two different ELISA 
platforms to ensure accuracy of measurements. Prior to analysis on either platforms, the SEs were 
first treated with formic acid (final concentration: 70%) (Sigma, St. Louis, MO, USA), then 
sonicated for 30 seconds on ice and centrifuged at 25,000 × g for 1 h at 4°C. These steps ensure 
complete dissociation of plaques into monomeric Aβ species. The supernatants were equilibrated 
in neutralization buffer (1M Tris base, 0.5M Na2HPO4, 0.05% NaN3), then subjected to ELISA. 
Our in-house Aβ ELISA utilizes HJ2 (anti-Aβ35–40) as capture antibody for Aβ1-40 and HJ7.4 (anti-
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Aβ37–42) as a capture antibody for Aβ1-42. HJ5.1-biotin (anti-Aβ13–18) 
6,28 was used as the detecting 
antibody for both Aβ ELISAs. For the commercial ELISA platform, Aβ levels (Aβx–38, Aβx–40 
and Aβx–42) were measured using the MSD® 96-well MULTI-SPOT® Human (6E10) Aβ 
Triplex Assay (Meso Scale Discovery, Gaithersburg, MD, USA). Aβ detection was conducted 
according to the manufacturer’s instructions. In brief, 96-well plates pre-spotted with capture 
antibodies against Aβx–38, Aβx–40, Aβx–42 and bovine serum albumin were blocked for 1 h with 
1% Blocker A solution and then washed three times with 1× Tris buffer. In a second step, samples 
were diluted 1:100 in 1% Blocker A solution, except supernatant of ultracentrifugation, and co-
incubated with the SULFO-TAG 6E10 detection antibody solution on the plate for 2 h. After 
washing, MSD Read Buffer T was added and the plate was read immediately on a Sector® Imager 
6000. Data analysis used MSD® DISCOVERY WORKBENCH® software 2.0. For total Aβ, 
Aβx–38, Aβx–40 and Aβx–42 were combined. For apoE ELISA (in-house), HJ15.6 and HJ15.4b 
28 were used as capture and detection antibodies, respectively. All ELISA assays were performed 
in triple technical replicates with appropriate positive and negative controls. 
Surgical procedures and tissue collection. The SEs was injected bilaterally into the 
hippocampus (specifically, the dentate gyrus) of host mice using a Hamilton syringe (model #1701, 
Hamilton Company). The injection was done at a rate of 1 µl per minute for a total of 2.5 µl of 
SEs on each side, as previously described 33. The needle was held in place for 2 minutes following 
completion of injection, then withdrawn slowly. The mice were allowed to completely recover in 
a warm chamber and then returned to the home cage. The following coordinates were used, relative 
to bregma: AP -2.5 mm, L +/- 2.0 mm, DV -2.2 mm (from the surface of the skull). The surgical 
area was cleaned with sterile saline and the incision was sutured. At the end of the incubation 
period, the brains were perfused with ice-cold PBS containing 0.3% heparin, and the whole brain 
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was fixed overnight at 4oC in 4% paraformaldehyde, followed by immersion into 30% sucrose 
solution for at least 24 hours.   
Histology. Following immersion in sucrose for at least 24 hours, serial coronal sections (30 
μm thickness) were collected from frontal cortex to caudal hippocampus using a freezing sliding 
microtome (ThermoFisher). Successive coronal sections 360 μm apart were stained with 
biotinylated HJ3.4 (anti-Aβ1–13, mouse monoclonal antibody generated in-house) to visualize Aβ 
immunopositive plaques, as described previously 5. Analysis of fibrillar plaques were done by 
staining the tissues with X-34 dye 39. Quantitative analysis of immunopositive staining and X-34 
dye was performed as described previously 6. Briefly, images of Aβ-immunostained or X-34-
stained sections were acquried at 20X using a Nanozoomer 2.0-HT system (Hamamatsu, 
Bridgewater NJ)) and exported to TIFF files with NDP viewer (Hamamatsu Photonics). Using 
ImageJ software, images were converted to 8-bit grayscale, thresholded to highlight Aβ-specific 
staining and analyzed.  
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Figure 3.1 Characterization of Seed Extracts from aged donor brains 
A, Experimental design and general timeline for seeding experiments. B, PBS-soluble seed 
extracts from aged APPPS1, APPPS1-nTg, APPE2, APPE3, APPE4, and NLF-KI donors were 
subjected to in-house ELISA assays for Aβ1-40 and Aβ1-42. The absolute levels for crude and 
formic acid-treated seed extracts are reported on two independent y-axis, as indicated. C, Total 
Aβ levels (Aβ1-40 + Aβ1-42) for crude and formic acid-treated seed extracts measured from our in-
house ELISA assay. For seeding experiments, all seed extracts were diluted to 1.5 ng/ml, as 
measured from formic acid-treated fractions (dashed line). D, Formic acid-treated seed extracts 
were analyzed on the Meso Scale Discovery platform, and the absolute values were plotted on 
the left y-axis. Absolute values from our in-house assay were plotted on the right y-axis for 
comparison purposes. E, ApoE levels were measured from the same crude seed extracts using 



















Figure 3.2 Isoform-dependent effect of APOE on induced Aβ seeding pattern 
in APP23 hosts 
A, Experimental timeline for seeding studies in APP23 hosts. B, Seed extract from an aged 
APPPS1 donor was injected into the dentate gyrus of APP23 hosts at 3 months of age. The host 
brains were harvested 4 months later, and fixed brain slices were stained with an anti-Aβ 
antibody for qualitative analysis of the induced seeding pattern. C, Similar seeding experiments 
were performed using seed extracts from an aged APPPS1-nTg donor, and the Aβ-
immunostained deposits were analyzed. No induced Aβ lesions were detected. Similar seeding 
experiments were performed using seed extracts from aged APPPE2 (D), APPE3 (E), and 
APPE4 (F) donors. Right panels show higher magnification of Aβ-immunostained layers of the 
dentate gyrus from corresponding genotypes shown in (D), (E), and (F). In APP23 hosts, APPE2 
seed extract-induced Aβ-deposits appeared to be diffuse and, to a lesser extent, filamentous. On 
the contrary, the Aβ-deposits induced by APPE3 or APPE4 seed extracts are highly coarse, 
punctate and compact (sgl = subgranular cell layer; g = granular cell layer). Images are 


















Figure 3.3 Characterization of induced Aβ lesions in APP23 hosts  
A, Experimental timeline for seeding studies in APP23 hosts. Seed extracts from aged APPE2 
(B), APPE3 (C), and APPE4 (D) donors were injected into the dentate gyrus of APP23 hosts at 3 
months of age. The host brains were harvested 4 months later, and fixed brain slices were stained 
with X-34 dye for qualitative assessment of the fibrillar content of the induced lesions. Images 














Figure 3.4 Seed extracts derived from different APP models produce 
different seeding patterns in APP NLF-KI hosts 
A, Experimental timeline for seeding studies in NLF-KI hosts. Seed extracts from an aged NLF-
KI (B) or APPPS1 (C) donor was injected into the dentate gyrus of NLF-KI hosts at 5 months of 
age. The host brains were harvested 6 months later, and fixed brain slices were stained with an 
anti-Aβ antibody for qualitative analysis of the induced seeding pattern. There are significantly 
more Aβ deposits detected in NLF-KI hosts seeded with NLF-KI seed extracts compared to those 
seed with APPPS1 seed extracts. The distribution of the induced Aβ deposits throughout the 
different layers was also different between the two extracts (sgl = subgranular cell layer; g = 
granular cell layer; iml, oml = inner and outer molecular layer). D, Seed extracts derived from 
APPPS1-nTg donor failed to induce any detectable seeding pattern in NLF-KI hosts. Seed extracts 
from aged APPE2 (E), APPE3 (F), or APPE4 (G) donors were injected into the dentate gyrus of 
NLF-KI hosts at 5 months of age. The host brains were harvested 6 months later, and fixed brain 
slices were stained with an anti-Aβ antibody for qualitative analysis of the induced seeding pattern. 
No isoform-dependent effect of donors’ APOE genotype on induced lesions were detected. Images 













Figure 3.5 Aβ seeding in APP23/EKO hosts 
A, Experimental design and general timeline for seeding experiments in APP23/EKO hosts. B, 
PBS-soluble seed extracts from aged APP23, APPPS1, APPPS1/EKO, APPPS1-nTg, APPE2, 
APPE3, APPE4, and NLF-KI donors were subjected to Meso Scale ELISA assays. The total Aβ 
levels (Aβ1-38 + Aβ1-40 + Aβ1-42) for formic acid-treated seed extracts were measured. C, The 
individual contribution from each of the Aβ pools (Aβ1-38, Aβ1-40 and Aβ1-42). All values are 







Figure 3.6 Proposed model of how APOE isoforms differentially modulate 
Aβ aggregation properties 
A, A model for possible ways that Aβ and apoE interact that can alter the trajectory of plaque 
formation. Hypothetically, apoE isoforms can differentially affect the kinetic rates of Aβ 
aggregation at any step, resulting in different amounts of plaques being formed. Alternatively, 
the isoforms can exert different influences on the molecular conformation or composition of the 
seed-capable species of Aβ (oligomers) early on in the process. This, in turn, can change their 
seeding potency or morphology, both of which can affect the Aβ plaques being formed 
downstream, either in terms of number or morphotype. Our study attempted to test this latter 
hypothesis. Length of arrows are surrogate of kinetic rates for the corresponding reactions. B, A 




Table 3.1 Post-inoculation mortality rates in APP23 hosts 
 
 
Table 3.2 Post-inoculation mortality rates in APP NLF-KI hosts 
APP NLF-KI 
Hosts 
# Injected # Survive Mortality Rate 
Male 26 22 15.4 % 
Female 31 28 9.7 % 













APP23 Hosts # Injected # Survive Mortality Rate 
Male 33 6 81.8 % 
Female 27 13 51.8 % 










Chapter 4  
Lack of hepatic apoE does not influence early 
Aβ deposition: Observations from a new 
APOE knock-in model 
 
This chapter is adapted from a manuscript published in Molecular Neurodegeneration: 
Huynh, T.V.*, Wang*, C., Tran, A.S., Mahan T.E., Tabor, G.T., Francis, C.M., Finn, M.B., 
Spellman, R., Manis, M., Rudolph E. Tanzi, Ulrich, J.D., & Holtzman, D.M. Lack of 
hepatic apoE does not influence early Aβ deposition: Observations from a new APOE 
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 Background: The apolipoprotein E (APOE) gene is the strongest genetic risk factor for 
late-onset Alzheimer disease (AD). ApoE is produced by both astrocytes and microglia in the 
brain, whereas hepatocytes produce the majority of apoE found in the periphery. Studies using 
APOE knock-in and transgenic mice have demonstrated a strong isoform-dependent effect of apoE 
on the accumulation of amyloid-β (Aβ) deposition in the brain in the form of both Aβ-containing 
amyloid plaques and cerebral amyloid angiopathy. However, the specific contributions of different 
apoE pools to AD pathogenesis remain unknown.  
 Methods: We have begun to address these questions by generating new lines of APOE 
knock-in (APOE-KI) mice (ε2/ε2, ε3/ε3, and ε4/ε4) where the exons in the coding region of APOE 
are flanked by loxP sites, allowing for cell type-specific manipulation of gene expression.  We 
assessed these mice both alone as well as after crossing them with mice with and without amyloid 
deposition in the brain as well as after removing apoE expression from hepatocytes using 
biochemical and histological methods. 
 Results: As in other APOE knock-in mice, apoE protein was present predominantly in 
astrocytes in the brain under basal conditions and was also detected in reactive microglia 
surrounding amyloid plaques.  Primary cultured astrocytes and microglia from the APOE KI mice 
secreted apoE in lipoprotein particles of distinct size distribution upon native gel analysis with 
microglia particles being substantially smaller than the HDL-like particles secreted by astrocytes.  
Crossing of APP/PS1 transgenic mice to the different APOE-KI mice recapitulated the previously 
described isoform-specific effect (ε4 > ε3) on amyloid plaque and Aβ accumulation. Deletion of 
APOE in hepatocytes did not alter brain apoE levels but did lead to a marked decrease in plasma 
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apoE levels and changes in plasma lipid profile.  Despite these changes in peripheral apoE and on 
plasma lipids, cerebral accumulation of amyloid plaques in APP/PS1 mice was not affected. 
 Conclusions: Altogether, these new knock-in strains offer a novel and dynamic tool to 





Over the past 20 years, studies on apolipoprotein E (apoE) and its roles in various 
physiologic processes (atherosclerosis, Alzheimer disease – AD, etc..) have relied heavily on 
murine models that express the three main human isoforms (ε2, ε3, and ε4) under the control of 
the endogenous murine apoE regulatory sequences 30,33,78. These APOE knock-in mice were 
generated through targeted replacement strategies (referred to as APOE-TR mice from here 
onward) and have played instrumental roles in elucidating the isoform-specific differences in lipid 
metabolism and receptor binding affinity. In the context of AD, APOE modifies the risk for 
development of late-onset AD in an isoform-dependent manner (ε2 < ε3 < ε4, where the ε4 allele 
carries the highest risk) 39. One mechanism through which APOE influences AD risk is through 
its effects on the metabolism of the amyloid-β peptide (Aβ), the main constituent of amyloid 
plaques found in AD patients. Indeed, crossing of transgenic mice that develop Aβ deposition in 
the brain (e.g. APP/PS1 or PDAPP mice that develop human-like Aβ plaques) to APOE-TR mice 
led to an isoform-dependent effect on cerebral amyloid plaque accumulation 2,14, which is 
consistent with observations in humans 58. Intriguingly, the effects of APOE on amyloidosis appear 
to be both isoform- and quantity-dependent, as reduction of apoE3 and apoE4 levels through 
genetic 8,43 or pharmacologic 38 manipulations results in reduction of cerebral amyloid plaque load. 
While these studies shed important insights on one aspect of apoE’s role in AD pathogenesis, it 
remains unclear whether the effects resulted from a cell-independent or cell-autonomous 
mechanism.  
Emerging data indicate that APOE not only affects AD risk, but also severity of pathology 
in dementia with Lewy bodies and neurodegeneration in tauopathies 19,46,75,81. In particular, 
microglia-derived apoE appears to regulate the inflammatory response 42,47,62,75, suggesting that 
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the cellular source of apoE in both the brain and periphery has distinct functions in different 
diseases. In the brain, both astrocytes 63 and microglia 76 contribute to the pool of apoE. 
Additionally, apoE cannot cross the blood-brain barrier (BBB) 9, thus the pools of apoE in the 
central nervous system (CNS) and the periphery exist predominantly independently from one 
another. Some early studies in Apoe-deficient mice found age-dependent synaptic loss and learning 
deficits 56.  These deficits reflect the potential role of apoE in multiple physiologic processes 
responsible for maintaining brain homeostasis, including protection from oxidative damage 74,84, 
maintenance of the BBB 5,26, and cholesterol transport in the setting of synapse development 57 or 
neuronal injury 66. Intriguingly, rescue of peripheral Apoe expression in an Apoe knock-out mice 
rescues the learning and memory deficit found in Apoe-deficient mice, despite exhibiting a similar 
degree of synaptic loss 49. These findings suggest that both CNS and peripheral apoE (together 
with plasma lipids) are independent parameters that can affect neuronal function.  
These and many other outstanding gaps in knowledge regarding apoE biology necessitate 
an experimental model where APOE expression can be specifically manipulated in different tissues 
and cell types. Here, we report the generation of an APOE knock-in mouse model where the 
various human APOE variants (ε2, ε3, and ε4) replace the endogenous murine Apoe locus (termed 
E2F, E3F, E4F mice individually, and APOE-KI mice collectively). Importantly, the human locus 
(specifically exons 2 to 4) is flanked by loxP sites that allow for the tissue-specific manipulation 
of APOE expression.  We characterized the expression of apoE in the brain and brain cell types as 
well as the effects of APOE isoforms on Aβ deposition in this new model. We also investigated 
the effects of peripheral APOE knock-out (via hepatocyte-specific deletion of APOE expression 





Design and generation of APOE-KI mice 
 In order to investigate the effects of tissue-specific APOE deletion, we set out to create a 
knock-in model that can allow for promoter-specific deletion of the APOE coding region under 
the Cre-loxP system. Three separate vector constructs with human sequences corresponding to the 
ε2, ε3, and ε4 alleles of APOE were generated with loxP sites flanking exons 2 through 4 (Figure 
4.1A – 4.1E). The targeting strategy allows for the humanization of the coding region within the 
murine Apoe gene (Figure 4.1A) with the various human isoforms (APOE-ε2, APOE-ε3, and 
APOE-ε4), as well as the opportunity to conditionally knock-out the coding region of the gene. 
Mouse genomic sequence from the translation initiation codon in exon 2 to the termination codon 
in exon 4 was replaced with its human counterparts: [Cys130, Cys176] for APOE-ε2, [Cys130, 
Arg176] for APOE-ε3, and [Arg130, Arg176] for APOE-ε4 (Figures 4.10B, 4.10C, and S1D). 
Exons 2 to 4 (~3.9 kb) are flanked by LoxP sites to allow for conditional deletion by Cre-
recombinase. Homologous recombinant clones were isolated using double positive (NeoR and 
PuroR) and negative (Thymidine kinase - TK) selections, and the respective resistance genes were 
included in the targeting vector (Figures 4.1B, 4.1C). The constitutive humanized/conditional 
knock-out alleles were achieved after in vivo Flp-mediated removal of the selection markers 
(Figure 4.1D). In the presence of Cre-recombinase (either through directed genetic crossing with 
a Cre line or viral vector), constitutive knock-out of the APOE gene is achieved when the loxP-
flanked region is removed (Figure 4.1E). Of note, the chimeric locus retains all normal mouse 
regulatory sequences in addition to the non-coding exon one. Exon 2 contains the translation 
initiation codon (Figure 4.10A). The cleavable signal peptide is encoded within exons 2 and 3 
(amino acids 1-18 – Figure 4.10A). Due to the non-conserved cleavage sites of mouse and human 
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signal peptides (please see alignment – Figure 4.10A), the humanized allele expresses the full-
length human APOE protein, including its signal peptide, rather than a fusion protein between the 
mouse signal peptide and the human mature protein. To verify accuracy and successful creation of 
the model, brain samples from all 3 lines were submitted for sequencing of exon 4 of the APOE 
locus by GENEWIZ, which confirmed the presence of human sequence and appropriate single 
nucleotide polymorphisms (SNPs) specific for each isoform. Further details on the specific design 
of the vector can be found in the methods section.  
 We first characterized the newly created APOE-KI strains by confirming the presence of 
human APOE mRNA expression in the mice with qPCR analysis (Figures 4.10E and 4.10F). At 3 
months of age, there was a slight, but statistically significant, elevation in APOE mRNA level in 
the hippocampus of E4F mice compared to E2F or E3F mice (Figure 4.10E). We also assessed 
APOE mRNA levels in whole brain hemispheres. Again, APOE mRNA levels were similar 
between genotypes, although APOE mRNA levels were slightly lower in E2F mice compared to 
either E3F or E4F mice, both of which were statistically significant (Figure 4.10F). Next, we 
biochemically assessed the apoE protein levels in the brains of APOE-KI mice at 21 days and 3 
months after birth. At 21 days of age, apoE protein levels in the cortex were significantly higher 
in E2F mice relative to those found in E3F or E4F mice (Figure 4.1F). At 3 months of age, there 
was no difference in PBS-soluble apoE protein concentration between E2F and E3F mice, while 
E4F mice had significantly lower levels relative to E2F mice (Figure 4.1G). We also measured 
guanidine-soluble apoE and found E3F mice to have significantly higher levels than E2F mice 
(Figure 4.1H). Lower apoE protein levels in 3-month-old E4F mice were also seen via Western 
blot analysis of the same brain lysates utilizing HJ15.7 as the detecting antibody (Figure 4.1I). 
This latter finding was replicated using another anti-apoE antibody (Figure 4.10H). These data 
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demonstrated that the newly generated APOE-KI mice expressing different apoE isoforms have 
similar levels of human APOE mRNA in the brain. Some differences in protein levels (higher 
apoE2, lower apoE4) are likely secondary to differences in protein stability, half-life, and 
metabolism, as has been seen in previous APOE knock-in mice 2,16,27,32,41,48,87,91,96. 
Human APOE is expressed in astrocytes and microglia in APOE-KI mice 
 The majority of apoE molecules in the CNS are synthesized by astrocytes 63, with a small 
portion coming from microglia 76. We further characterized the expression pattern of apoE in the 
brain of APOE-KI mice by co-staining for apoE and traditional markers for astrocytes as well as 
microglia. We confirmed the presence of apoE protein in astrocytes by co-staining for apoE and 
the astrocytic marker GFAP (Figure 4.2A). We also assessed microglia for the presence of apoE 
protein by co-staining for the microglial marker IBA1, however, we did not observe significant 
overlap of apoE and IBA1 signal (Figure 4.2B). For simplicity, only representative images from 
E4F mice are shown, as similar findings were found in E2F and E3F mice. 
 ApoE’s role in AD pathogenesis was first recognized when apoE was found to co-localize 
with amyloid plaques, specifically at the center (i.e. the “core”) of mature, fibrillar amyloid plaques 
59,89. ApoE expression is low in microglia under basal, homeostatic conditions, but is strongly up-
regulated in the setting of various neurodegenerative insults 12,13,62,95. Thus, we investigated 
whether apoE can be found in microglia in the setting of amyloidosis, specifically in the APP/PS1-
21 model which develops Aβ deposition in amyloid plaques beginning at 6-8 weeks of age 67. 
APP/PS1-21 mice were crossed with APOE-KI mice for two successive generations and the brain 
sections from 4-month-old APP/PS1-21 mice homozygous for human APOE alleles (ε2/ε2, ε3/ε3, 
or ε4/ε4) were subjected to immunohistochemical analysis. Qualitative assessment of the staining 
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pattern showed co-localization of apoE in the center of plaques, and significant co-localization 
with IBA1 in surrounding microglia, suggesting microglial expression of apoE (Figures 4.3A, 
4.3B). We made similar observations in APP/PS1-21 mice expressing APOE-ε2 and APOE-ε3 
(data not shown). These histological observations confirm the presence of apoE in astrocytes and 
microglia, which is consistent with previous studies, and highlight the validity of our model 
system. 
Qualitative assessment of microglia and astrocyte-derived apoE particles 
 Most of the biologically active apoE exists in the brain in lipidated HDL-like particles and 
alterations in the lipidation state of apoE have been shown to drastically affect Aβ accumulation 
in models of Aβ amyloidosis 34,35,45,85,86. Thus, we investigated whether apoE particles from 
astrocytes and microglia are comparable in size, which is associated with the amount of lipidation.  
 To assess how apoE lipoprotein particles derived from microglia compare to those derived 
from astrocytes, conditioned media samples from primary microglial and astrocyte cultures 
derived from post-natal day 1-3 E2F, E3F, and E4F pups were subjected to non-denaturing 
gradient gel electrophoresis (NDGGE) followed by Western blotting.  ApoE-containing 
lipoprotein particles from astrocyte-conditioned media for all three APOE isoforms were > 12 nm 
in diameter, consistent with what has been reported previously (Figure 4.4) 17,21.  While the E2F 
and E3F astrocyte-derived particles showed little to no particles that were < 12 nm in size, E4F 
astrocytes did appear to produce a small, but notable, amount of approximately 8 nm-sized 
particles (Figure 4.4). Microglia-conditioned media contained apoE particles that were overall 
much smaller than the astrocyte-derived particles.  For E3F and E4F microglia, the majority of 
particles produced were about 8 nm in size with a small amount of particles 10 – 17 nm in size 
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(Figure 4.4). However, for E2F microglia there did appear to be a shift in the relative amount of 
10-15 nm-sized particles versus 8-nm-sized particles.  While E2F microglia did produce a 
considerable amount of ~8 nm-sized particles, more 10 – 15-nm-sized particles were present than 
what was seen for E3F and E4F microglia. As larger particles contain greater amounts of 
cholesterol and phospholipid, these findings suggest that microglia secrete poorly lipidated apoE 
relative to the larger HDL-like lipoproteins secreted by astrocytes. These results highlight the need 
for future studies to more closely examine the properties of these apoE-containing particles and 
whether they also differ in their normal function as well as in pathological states. 
APOE isoform-dependent effect on Aβ accumulation in APP/PS1/EKI mice 
 While APOE may influence AD pathogenesis in several ways, one of the major 
mechanisms is via its effect on Aβ accumulation in the brain, specifically on Aβ seeding and 
clearance.  As previous APOE knock-in mice have been shown to influence Aβ deposition in an 
isoform-dependent fashion 2,8,14,24,43,61,91, we wanted to assess the effects of the major human 
APOE isoforms in the new APOE-KI model. Specifically, we investigated the effect of different 
human APOE alleles on Aβ accumulation in APP/PS1-21 transgenic mice. In this model, 
overexpression of the amyloid precursor protein (APP) in neurons leads to cerebral accumulation 
of Aβ-containing plaques that resemble those found in AD brains 67. We crossed APP/PS1-21 mice 
on a C57BL/6 background with either E2F, E3F, or E4F mice on a C57BL/6 background to obtain 
APP/PS1-21 transgenic mice on an APOE-ε2, ε3, or ε4 background (APP/PS1/E2F, APP/PS1/E3F, 
and APP/PS1/E4F mice, respectively) that do not express murine Apoe (collectively referred to as 
APP/PS1/EKI mice). We first measured the amount of PBS-soluble apoE in the cortex of 
APP/PS1/EKI mice via ELISA (Figure 4.6A) and found overall apoE protein levels to be similar 
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to those seen in APOE-KI mice. ApoE protein concentration in the cortex of APP/PS1/E4F mice 
was slightly, albeit statistically significantly, higher than those found in APP/PS1/E3F mice. 
 Since the APP/PS1-21 mice have visible neocortical plaque deposits beginning around 2 
months of age 67, we assessed plaque accumulation in APP/PS1/EKI mice at 4 months of age, 
when sufficient plaques are present in the neocortex to allow for quantitative assessments. We first 
examined cerebral plaque load histologically by staining brain sections with an anti-Aβ antibody 
HJ3.4b (Figure 4.5A). Quantitative analysis of the area covered by HJ3.4b staining in the cortex 
showed independent, but significant, effects of sex and APOE isoform. Post hoc analysis 
comparing APOE genotype within each sex found a significant increase in Aβ deposition in female 
apoE4-expressing mice compared to apoE3. There were no significant difference in Aβ burden 
between APP/PS1/E2F mice (males or females) and either of the other APOE genotypes. We next 
quantified the area covered by X-34 staining, which detects fibrillar amyloid plaques (Figure 
4.5B). Again, there were significant and independent effects of sex and APOE genotype. Post hoc 
analysis comparing apoE isoform within each sex did not find a statistically significant difference, 
although there was a trend towards elevated X-34 staining in apoE4-expressing female mice 
compared to apoE2 and apoE3. The relative differences in cortical burden of Aβ and X-34 
pathology between different isoforms are very similar to what we observed when APP/PS1-21 
mice were crossed to APOE-TR mice (Figure 4.11A and 4.11C) and in our published data 43. 
Interestingly, there was no effect of sex on Aβ pathology in this latter model (Figure 4.11B and 
4.11D). 
 To characterize the factors that account for the differences in Aβ pathology, we assessed 
the plaque density and average plaque size in APP/PS1/EKI mice. For Aβ staining, there was a 
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significant effect of sex and APOE genotype, but no interaction. Post hoc analysis showed an 
increase in plaque density in female APP/PS1/E4F compared to APP/PS1/E3F mice (Figure 4.5C). 
There was a significant effect of sex, but not of APOE genotype, on average plaque size (Figure 
4.5D). For X-34 staining, there was a significant effect of sex and APOE genotype (but no 
interaction) on plaque density. Post hoc analysis comparing APOE genotype within each sex found 
a significant increase in plaque density in female APP/PS1/E4F mice compared to APP/PS1/E3F 
or APP/PS1/E2F mice (Figure 4.5E). There was a significant effect of sex, but not APOE genotype 
on average X-34 plaque size. No differences were detected on post hoc analysis between any 
subgroup (Figure 4.5F). 
 To further assess the total amount of Aβ accumulation, we measured the amount of PBS-
soluble and PBS-insoluble (guanidine fraction) Aβ40 and Aβ42 in the cortex of APP/PS1/EKI mice. 
We observed a significant increase in PBS-soluble Aβ40 and Aβ42 in APP/PS1/E2F mice compared 
to APP/PS1/E3F mice (Figures 4.6B and 4.6C) and significantly higher levels of Aβ42 in 
APP/PS1/E4F compared to APP/PS1/E3F mice (Figure 4.6C). In the guanidine fraction (PBS-
insoluble fraction) where the majority of Aβ accumulates, we detected a significant increase (~ 2-
fold) in insoluble Aβ42 in APP/PS1/E4F mice relative to APP/PS1/E3F mice (Figure 4.6D and 
4.6E). There were no statistically significant differences between the other groups. 
 Our findings are consistent with previous studies where APOE-TR mice were crossed to 
various models of amyloidosis 80 and recapitulate (at least in part) the allele-dependent effect of 
APOE on amyloid deposition found in humans.  
Plasma lipid alterations in mice lacking liver-derived apoE 
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  Previous studies from our lab and others showed that complete ablation 3,4,25,36,83 or 
reduction 8,38,43 of apoE levels results in a decrease of Aβ pathology, particularly a marked 
reduction of fibrillar Aβ in the brain. However, it was difficult to assess the contribution of 
peripheral apoE ablation to phenotypes found in the brain in complete knock-out models. Thus, it 
remains unclear whether peripherally-derived apoE (or lack thereof) exerts any effect on cerebral 
amyloid pathology when apoE is still present in the brain. To this end, we took advantage of the 
newly created APOE-KI lines and investigated whether a lack of the main source of peripheral 
apoE in the blood, (i.e. the liver), can influence Aβ pathology in the brain.  
 While apoE is synthesized by a number of different organs outside of the CNS, the liver 
accounts for most circulating apoE 53. Thus, we set out to ablate APOE expression in the liver 
through Cre-lox technology, targeted through the hepatocyte-specific Alb promoter (that normally 
controls albumin expression). Specifically, mice expressing Cre-recombinase under the Alb 
promoter (Alb-Cre mice) 90 were crossed with APOE-KI mice for two successive generations to 
obtain Alb-Cre mice on all three human APOE backgrounds (AlbCre-EKI). The AlbCre-EKI mice 
were subsequently crossed with APP/PS1/EKI mice to achieve hepatocyte-specific knock-out of 
APOE in APP/PS1/EKI mice (APP/PS1/E2FCre, APP/PS1/E3FCre, APP/PS1/E4FCre mice, and 
APP/PS1/EKICre mice collectively). Littermates lacking Cre-recombinase expression (Cre-/-) serve 
as controls, which are effectively APP/PS1/EKI mice. We first confirmed successful deletion of 
APOE from hepatocytes by performing qPCR analysis from liver tissue, which showed 
undetectable levels of APOE mRNA in Cre-expressing mice (Figure 4.7A). We next measured 
apoE protein from liver tissue and also found the levels to be markedly decreased in Cre-expressing 
mice, regardless of APOE genotype (Figure 4.7B). APP/PS1/E2F mice also had significantly more 
148 
 
apoE protein in the liver relative to APP/PS1/E3F or APP/PS1/E4F mice, despite similar hepatic 
expression of APOE mRNA. 
 We also collected the plasma from APP/PS1/EKICre mice and investigated the effect of 
Alb-Cre expression on the levels of apoE protein as well as the major lipid species. Due to the 
observed effect of sex on Aβ pathology in APP/PS1/EKI mice (Figures 4.5 and 4.6), the males and 
females from this cohort were analyzed independently. Assessment of apoE levels in the plasma 
of male APP/PS1/EKICre mice through an ELISA assay showed a significant effect of APOE 
genotype and Cre expression, with a significant interaction (Figure 4.7C). Plasma apoE levels in 
female mice were also influenced by APOE genotype and Cre expression, with a significant 
interaction between the latter two parameters (Figure 4.7D). We performed post hoc pair-wise 
comparisons between male Cre+/- and Cre-/- groups, and found Cre expression significantly 
decreased plasma apoE levels across apoE isoforms regardless of sex (Figures 4.7C and 4.7D). 
Notably, residual amounts of apoE protein were detected in both male (Figure 4.7C) and female 
(Figure 4.7D) APP/PS1/E2FCre mice, likely because apoE2 has a low affinity for the LDL receptor.  
 As apoE plays an essential physiologic role in peripheral lipid homeostasis, we next 
examined the levels of total cholesterol (TC), triglycerides, and HDL in the plasma of 
APP/PS1/EKICre mice. For these analyses, male and female were analyzed separately, and plasma 
samples from mice with global deletion of murine Apoe (EKO mice) were included for 
comparative purposes (n = 5 males, 3 females). Our analyses of male mice showed a significant 
effect of both APOE and Cre genotype on plasma TC, with a significant interaction between these 
two parameters. Post hoc pair-wise comparisons between Cre+/- and Cre-/- groups found Cre 
expression to significantly increase plasma TC levels in mice expressing apoE2 or apoE3, but not 
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apoE4 (Figure 4.7E). Similarly, significant effects of APOE and Cre genotype on plasma TC were 
found in female mice, with significant interaction between APOE and Cre genotype. Post hoc pair-
wise comparisons between Cre+/- and Cre-/- groups found Cre expression to significantly increase 
plasma TC levels in apoE2-expressing mice, but not apoE3 or apoE4-expressing mice (Figure 
4.7F). In both male and female mice, the TC level in APP/PS1/E2FCre mice is of greatest 
magnitude, and appeared to be comparable to those found in EKO mice (though the EKO mice 
were not included in the direct statistical analysis). Plasma triglyceride concentrations in male mice 
follow a similar trend with a significant effect of APOE genotype and Cre expression, with a 
significant interaction. Post hoc pairwise comparisons between Cre+/- and Cre-/- groups found Cre 
expression significantly increased triglyceride levels in mice expressing apoE2 and apoE3, but not 
apoE4 (Figure 4.7G). In female mice, there was a significant effect of APOE and Cre genotype, 
but no significant interaction. Post hoc pair-wise comparisons did not identify significant 
differences in triglyceride levels in that are dependent on Cre expression (Figure 4.7H). In male 
mice, there was a significant effect of APOE genotype, but not Cre expression, on plasma HDL 
levels, with a significant interaction between APOE and Cre genotypes (Figure 4.7I). Similarly, 
there was a significant effect of APOE genotype, but not Cre expression in female mice (Figure 
4.7J). There were no significant interactions between APOE and Cre genotypes in female mice. 
 The changes in plasma lipid composition found in APP/PS1/EKICre mice have some 
similarities and some differences compared to what was found in EKO mice. Though no direct 
statistical comparison was performed, the incongruence in some of the dataset relative to the EKO 
control could reflect the effect of residual extrahepatic APOE expression (e.g. in macrophages) 
that is below the detection limit of our ELISA assay.  
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Liver-derived apoE does not influence Aβ accumulation in the brain 
 We next examined the effects of hepatocyte-specific APOE deletion on cerebral Aβ 
accumulation. Again, due to the observed effect of sex on Aβ pathology in APP/PS1/EKI mice 
(Figures 4.5 and 4.6), the males and females from this cohort were analyzed independently. Brain 
sections from 4-month-old APP/PS1/EKICre mice and littermate controls were assessed for Aβ 
immunostaining with HJ3.4b antibody (Figures 4.8A, 4.8B, and 4.8C). Quantitative analyses in 
both male (Figure 4.8G) and female (Figure 4.8H) mice found a significant effect of APOE 
genotype, but not Cre expression on the cortical area covered by Aβ staining. To further 
characterize the nature of the deposited Aβ plaques, brain sections were stained with X-34 dye 
which only stains fibrillar plaques (Figures 4.8D, 4.8E, and 4.8F). Quantitative analyses of the area 
covered by X-34 staining showed similar trends to those found in HJ3.4b staining, with a 
significant effect of APOE genotype, but not Cre expression, in both male (Figure 4.8I) and female 
(Figure 4.8J) mice.  
 To examine whether Alb-Cre expression alter apoE protein levels in the brain of 
APP/PS1/EKICre mice, we performed ELISA assays on cortical brain homogenates. In PBS-
soluble fraction from male mice, there was a trend towards a significant effect of APOE genotype, 
but no significant effect of Cre genotype, on apoE protein levels (Figure 4.9A). In female mice, 
there was no significant effect of APOE or Cre genotype (Figure 4.9B). No differences between 
any subgroups were detected on post hoc analyses of male or female mice. In the guanidine-soluble 
fraction from male mice, there was a trend towards a significant effect of APOE genotype, but not 
Cre genotype, on apoE protein level (Figure 4.9G). In female mice, there was a significant effect 
of APOE genotype, but not Cre genotype, on apoE protein level (Figure 4.9H). Post hoc analysis 
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found no significant effect of Alb-Cre on guanidine-soluble apoE in either male (Figure 4.9G) or 
female (Figure 4.9H) mice. 
 Next, we analyzed total Aβ levels in APP/PS1/EKICre mice and their respective Cre-/- 
littermates. For these analyses, cortical samples from APP/PS1-21 mice with global deletion of 
murine Apoe (APP/PS1/EKO mice) were included for comparative purposes, and were not 
included in statistical analyses due to low n (n = 4, 3 males, 1 female). The cortices were 
sequentially homogenized in PBS and 5M guanidine and the amounts of Aβ40 and Aβ42 were 
measured in each fraction via ELISA. In the PBS-soluble fraction from both male (Figure 4.9C) 
and female (Figure 4.9D) mice, we detected a significant effect of APOE genotype on the levels 
of Aβ40. Similarly, there was significant effect of APOE genotype on Aβ42 levels in male mice 
(Figure 4.9E). In female mice, there was a trend towards a significant effect of APOE genotype on 
the levels of Aβ42 (Figure 4.9F). In our analyses of PBS-soluble Aβ40 or Aβ42, there were no 
significant effects of Cre expression or an interaction between APOE genotype and Cre expression 
in male or female mice. In the guanidine-soluble fraction, we also observed a significant effect of 
APOE genotype on Aβ40 (Figure 4.9I) and Aβ42 (Figure 4.9K) in male mice. In female mice, there 
was a significant effect of APOE genotype on Aβ40 (Figure 4.9J) and Aβ42 (Figure 4.9L) levels. In 
our analyses of guanidine-soluble Aβ40 or Aβ42, there were no significant effects of Cre expression 
or an interaction between APOE genotype and Cre expression in male or female mice. Of note, 
the APP/PS1/EKO mice had lower levels of Aβ40 or Aβ42 than most other genotypes, but direct 
comparison was not performed due to low n value. 
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 Together, these results suggest that, while depletion of human APOE expression in 
hepatocytes led to a marked lowering of plasma apoE with some changes in plasma lipid 
composition, there were no significant effects on cerebral Aβ accumulation.  
4.4 Discussion 
 APOE is the strongest genetic risk factor for late-onset AD and intensive research efforts 
have led to several important insights regarding apoE and its role in AD. Nevertheless, cell-type 
specific roles for APOE isoform expression, secretion, and lipidation in neurodegenerative disease 
remain poorly understood. In an effort to help to begin to answer these and other questions, we 
created a new generation of human APOE-expressing mice to study cell-specific processes. 
Specifically, we generated three separate lines of APOE-KI mice, each carrying one of the three 
most common variants of the human APOE gene. The presence of loxP site on either side of the 
human gene sequence allow for cell-type-specific manipulation of APOE expression through the 
Cre-loxP system. Here, we characterized the newly created mice in terms of CNS as well as 
peripheral expression. We also qualitatively compared apoE particles isolated from astrocytes and 
microglia, and found the latter to produce significantly smaller lipid-containing particles. We took 
a step further to validate the functionality of the loxP sites by specifically ablating hepatocyte 
expression of APOE, effectively eliminating the majority of apoE protein in the plasma. We found 
this virtual absence of apoE in the plasma to cause significant alterations in the plasma lipid profile 
without significantly altering cerebral amyloid plaque accumulation in a model of Aβ-driven 
amyloidosis. 
 Our targeting construct retained the natural genetic context surrounding the human exon 
sequence, including endogenous regulatory elements such as enhancers. Thus, we expected the 
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tissue-specific expression of the human APOE gene to closely parallel that of the endogenous 
mouse Apoe gene. Our APOE gene expression and protein analysis in the brain and plasma showed 
a similar expression level to wild type C57/BL6 mice and other APOE knock-in mice 2,28,78,91. 
Interestingly, we detected a subtle but statistically significant isoform-dependent difference in 
APOE mRNA levels in APOE-KI mice, where higher mRNA levels were detected in E4F mice 
relative to E2F or E3F mice in the hippocampus and lower levels of mRNA were detected in the 
brain hemisphere of E2F mice compared to E3F or E4F mice. These different mRNA levels could 
arise from compensatory changes in APOE transcription in response to isoform-dependent 
differences in protein stability or subtle differences in mRNA stability. Other than our new model, 
one other APOE knock-in model with floxed APOE alleles has been described 8. In one 
experiment, apoE4 reduction in adult hippocampal astrocytes using an AAV-Cre vector resulted 
in a 50% decrease in insoluble Aβ42 in PDAPP mice 
8. Future studies using floxed allele APOE KI 
mice can test the temporal and cell-type specific effects of disrupting APOE expression on Aβ and 
tau pathology using a variety of inducible Cre mouse strains.   
 At 3 months of age, there was significantly less PBS-soluble apoE in the cortex of E4F 
mice compared to those from E2F or E3F mice at the same age, consistent with previously 
described findings in human and other APOE transgenic and knock-in mouse models 
2,16,27,32,41,48,87,91,96. Concordantly, the level of apoE2 protein is the highest compared with other 
apoE isoforms in the CSF 2,70, interstitial fluid (ISF) 82, brain parenchyma 77, and plasma 52,65,68.  
The reason apoE2 is generally higher both in brain and plasma is likely due to decreased strongly 
reduced binding affinity to the LDL receptor 73. Some studies report apoE4 is more susceptible to 
proteolysis compared to the other major isoforms of APOE 31,37, and other studies have 
demonstrated the presence of apoE4 fragments (14–20 kDa) in AD brains 15,71. Structural 
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differences between apoE3 and apoE4, particularly at the hinge region between the N- and C-
terminal domains, may explain their different susceptibility to proteolytic degradation as well as 
lipid binding affinity 23. In spite of these numerous observations, the exact nature of the protease 
responsible for apoE4 cleavage is unknown, although several candidates have been reported 
including cathepsin D 97, aspartic proteases 55, and a chymotrypsin-like protease 31. A prior study 
using APOE-TR mice reported differences in apoE protein levels only in the hippocampus and 
cortex, regions that are susceptible to neurodegeneration in AD brains 91. Significant differences 
in protein levels among apoE isoforms (apoE4 < apoE3 < apoE2) were also observed in the CSF 
and brain homogenates of APOE-TR mice when crossed to PDAPP mice 2. It will be important in 
future studies to assess both CSF and brain levels of apoE in our new model in multiple brain 
regions as well as in all relevant cell types. Importantly, these results should be complemented 
with similar studies in human. 
 In regards to the effects of apoE isoforms in our new model on Aβ aggregation and 
accumulation in the brain, we found very similar findings that we described previously in 
APP/PS1-21 mice crossed to another APOE knock-in model 38,43.  Namely, the presence of apoE4 
in the brain resulted in significantly greater Aβ deposition than apoE3, similar to what is seen in 
humans 58,69.  However, when different APP transgenic mouse strains were crossed with other 
APOE knock-in mice, apoE2-expressing mice generally exhibited less Aβ deposition than those 
expressing apoE3 or apoE4 2,8,14, also similar to what is seen in humans. Crossing of APP/PS1-21 
mice to our new APOE-KI model results in similar levels of Aβ accumulation in those expressing 
apoE2 and apoE4. Interestingly, crossing of another APOE knock-in model (APOE-TR mice) with 
APP/PS1-21 mice also resulted in similar levels of Aβ deposition in apoE2- and apoE4-expressing 
mice (Figures 4.11A and 4.11C). The effect of sex on Aβ pathology in our new EKI models are 
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intriguing, as we did not detect an effect of sex on Aβ pathology when the APOE-TR mice were 
crossed to the same strain of APP/PS1-21 mice (Figures 4.11B and 4.11D). In another APP/PS1 
transgenic model, 5XFAD mice, apoE2-expressing mice were also found to have similar Aβ 
deposition to those expressing apoE3 or apoE4 in the subiculum 91.  In aggressive amyloidogenic 
models such as APP/PS1-21 and 5XFAD, due to the particular APP and PS1 mutations present, 
there is a much higher ratio of Aβ42 to other Aβ species than in many less aggressive APP 
transgenic mice 67.  Since Aβ42 is more aggregation-prone than other Aβ species 
72, this difference 
might abrogate the effect of apoE2 on lowering Aβ pathology compared to other models and in 
humans.  Further studies with our new model can test this hypothesis in other APP models such as 
APP knock-in mice or APP transgenic mice.  
 Outside of the brain, apoE is synthesized in multiple other sites, including the liver, spleen, 
adrenal gland, lung, testis, and ovary 20,88,92. Total knock-out of Apoe results in severe 
hypercholesterolemia with accelerated atherosclerosis in the periphery 64,94, accompanied in some 
56 but not all studies 22 by synaptic loss and cognitive dysfunction. Due to the nature of a global 
knock-out, it was difficult to assess in the latter finding whether lack of apoE in the brain, in the 
periphery, or both, was responsible for the aforementioned phenotype. Given these outstanding 
questions, we tested whether specific ablation of a large source of peripheral apoE could modulate 
cerebral Aβ pathology. Indeed, virtual ablation of plasma apoE using an Alb-Cre line did not result 
in any change in cerebral apoE levels, which is consistent with previous reports on the inability of 
peripheral apoE to cross the BBB 9 or the blood-CSF barrier 51. It is worth noting that hepatocytes 
are not the sole source of apoE in the periphery, as peripheral macrophages 92 and adipocytes 93 
are known to contribute to the pool of apoE in the plasma. Accordingly, we did detect a non-
negligible amount of apoE protein in plasma from APP/PS1/E2FCre mice, likely due to apoE2’s 
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low affinity for the LDL receptor 10,44 that results in slower clearance from the plasma. The lack 
of detection in APP/PS1/E3FCre and APP/PS1/E4FCre mice was perhaps due to a combination of 
lower protein levels and over-dilution that put the concentration outside of the assay’s detection 
limits. Our histological and biochemical analyses of cerebral Aβ pathology did not reveal a 
significant effect of knocking out liver-derived apoE at 4 months of age. Additionally, we failed 
to detect any changes in the degree of astrogliosis or microgliosis immediately surrounding the 
plaques between APP/PS1/EKICre mice and their Cre-/- littermates (data not shown). Altogether, 
our data suggest CNS- and peripherally-derived apoE exist in distinct pools that are independent 
from one another, as has been suggested in human studies 1. However, we cannot rule out other 
hypotheses that would otherwise explain for a lack of any appreciable effect on Aβ in 
APP/PS1/EKICre mice, such as an unknown adaptive response that masked the contribution of 
hepatic apoE to brain Aβ pathology.  
 Alternatively, it is possible that apoE from one pool can indirectly exert an effect on the 
other side of the BBB. For example, a recent study showed that restoration of peripheral Apoe 
expression led to a partial rescue of cognitive phenotypes in mice lacking apoE in the brain 49. 
These findings suggest a dual mechanism by which apoE deficiency causes behavioral deficits, 
and that peripherally derived apoE may influence neuronal function through an indirect 
mechanism, such as vascular dysfunction secondary to dyslipidemia or via effects on brain 
endothelial cells that make up the BBB. In support of this latter hypothesis, prior studies found the 
BBB in EKO mice to be severely compromised 26,29, and the severity (or permeability of the BBB) 
also increased with age 29. Thus, it is conceivable that an effect of hepatocyte-derived apoE on 
brain Aβ pathology may be observed in aged APP/PS1/EKICre mice, or if conditional knock-out 
of hepatic apoE occurs at a later stage of Aβ pathology. Such an effect may be modulated by 
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apoE’s effects on cerebrovascular function and/or through its ability to cross the leaky BBB. Some 
researchers have proposed a two-hit vascular hypothesis of AD cerebrovascular damage, where hit 
1 is an initial insult on the BBB itself that is sufficient to initiate neuronal injury and 
neurodegeneration, but can also promote the accumulation of Aβ in the brain through defects in 
clearance of Aβ through the BBB (reviewed extensively in 60 and 79).  
 BBB dysfunction is a common co-occurrence and may directly contribute to 
neurodegeneration and cognitive decline in AD 60,79. In support of this latter hypothesis, data 
obtained from an older APOE knock-in model also supports an isoform-dependent effect of apoE 
on BBB integrity, where EKO and apoE4-expressing mice developed vascular defects before 
neuronal and synaptic changes occur 5. A more recent study showed apoE4-expressing mice to 
have impaired spontaneous BBB repair following traumatic brain injury (TBI) compared to apoE2- 
or apoE3-expressing mice 54. Both studies explored various mechanisms that could explain for the 
negative influence of apoE4 on the BBB integrity, all of which involved changes in astrocytes and 
pericytes located in the neurovascular unit. However, it is theoretically possible that peripherally 
derived apoE species can somehow contribute to this process, especially with the leakiness of the 
BBB in early stages of TBI and later stages of AD. As there are several sources of apoE in the 
periphery, they could differentially affect BBB homeostasis. Intriguingly, a prior study utilized 
bone marrow transplant to show that BBB homeostasis depends on equal contributions from tissue 
and blood cell derived apoE, but lack of Apoe expression in bone marrow-derived cells alone was 
enough to significantly increase the BBB permeability 29. These findings underscore the putative 
role for leukocytes (i.e. macrophages) in BBB maintenance. It remains elusive how apoE from 
bone marrow-derived cells may contribute to the integrity of the BBB, the dysfunction of which 
had been proposed to contribute to neurodegeneration in AD 79. In this context, it would be 
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interesting to investigate whether restoration of APOE-ε4 expression in peripheral macrophages 
could rescue BBB defects in EKO mice, and how that compares to restoration of APOE-ε2 or 
APOE-ε3 expression. 
 It is our hope that these new APOE-KI mice will facilitate studies into apoE physiology 
and AD pathogenesis. It is also important, however, to acknowledge their limitations. While the 
APOE-KI mice harbor the human gene sequence, they retain the regulatory elements found in 
mice. Considerable species differences between rodents and humans exist and might challenge our 
ability to generate findings that are all relevant and directly translatable to humans from studies in 
mice and rats. Apparent differences in physiological function and metabolism, such as lipid 
metabolism and immune response between humans and rodents might preclude some discoveries 
that are relevant to disease mechanism. For example, apoB is a ligand for the LDLR along with 
apoE in humans, albeit with a lower affinity than apoE. Hepatic-derived apoB is secreted as 
apoB100 (a full length protein) and contains the LDLR binding domain. However, a large portion 
of hepatically derived apoB in mice is truncated (apoB48) and does not contain the LDLR domain. 
Wild-type mouse VLDL and IDL contain roughly equal portions of apoB48 and apoB100, and this 
leads to a compromised compensatory mechanism in the absence of apoE, leading to severe 
hypercholesterolemia in Apoe knock-out mice 11,94. This latter example highlights the need to 
address these and other caveats when interpreting rodent studies, especially in those where such 
physiologic differences might confound some findings.  
Conclusions 
 We employed a targeted gene replacement strategy to generate mouse lines that express 
the three most common alleles of the human APOE gene at physiological levels. We fully 
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characterized all three lines with respect to their apoE levels in the CNS as well as the plasma, 
from early life to adulthood. We partially recapitulated the isoform-dependent effect of APOE on 
Aβ accumulation in a model of amyloidosis. Furthermore, we also validated the functionality of 
the loxP sites in facilitating constitutive, tissue-specific, knock-out of APOE through liver-specific 
expression of Cre-recombinase. Lastly, we also investigated the effects of knocking out liver-
derived apoE on plasma lipid profiles and Aβ deposition in the brain. Moving forward, these mice 
should prove an invaluable asset for further studies on the physiological and pathophysiological 
roles of APOE, especially the role of apoE isoforms in specific cell types and different organs in 
the context of AD and other neurodegenerative diseases.   
4.5 Experimental Procedures 
Experimental Model and Subject Details 
 Targeting construct. The targeting strategy allows the generation of a constitutive 
humanization of the Apoe gene with the various human isoforms (APOE-ε2, APOE-ε3, and APOE-
ε4), as well as a conditional knock-out and a constitutive knock-out of the gene. The targeting 
strategy is based on Ensembl transcripts ENSMUST00000174064 (mouse, corresponding to NCBI 
transcript NM_009696.3) and ENST00000252486 (human, corresponding to NCBI transcript 
NM_000041.3). The humanized alleles express the full length human proteins, including its signal 
peptide. Mouse genomic sequence from the translation initiation codon in exon 2 to the termination 
codon in exon 4 was replaced with its human counterparts: [Cys130, Cys176] for APOE-ε2, 
[Cys130, Arg176] for APOE-ε3, and [Arg130, Arg176] for APOE-ε4. Exons 2 to 4 (~3.9 kb) have 
been flanked by LoxP sites. A polyadenylation signal (hGHpA: human Growth Hormone 
polyadenylation signal) has been inserted to the 3’ of the genes (downstream of the distal loxP 
sites) in order to prevent transcriptional read-through. Positive selection markers were flanked by 
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FRT (Neomycin resistance – NeoR) and F3 (Puromycin resistance – PuroR) sites and inserted 
downstream of the proximal loxP site and upstream of the distal loxP site, respectively. The 
targeting vectors were generated using BAC clones from the mouse C57BL/6J RPCI-23 and 
human RPCI-11 BAC libraries.  
Generation of knock-in mice homozygous for human APOE isoforms (APOE-KI mice). 
Targeting vectors for the various human APOE isoforms were individually transfected into the 
Taconic Biosciences C57BL/6N Tac ES cell line. Homologous recombinant clones were isolated 
using double positive (NeoR and PuroR) and negative (Thymidine kinase – Tk) selections. The 
constitutive humanized/conditional knock-out alleles were obtained after in vivo Flp-mediated 
removal of the selection markers. The newly introduced human APOE gene is expressed under 
control of the endogenous Apoe promoter. The resulting strains are referred to by their specific 
isoform expression (E2F, E3F, and E4F), or collectively as APOE-KI mice. The specific DNA 
sequence corresponding to each isoform (see figure 4.10) were verified through sequencing of 
exon 4 by GENEWIZ. DNA was isolated from fresh-frozen brain tissues, and exon 4 were 
amplified using specific primers (Forward: AACAACTGACCCCGGTGG; and reverse: 
GCTCGAACCAGCTCTTGAGG). 
Conditional knock-out of human APOE alleles. To achieve tissue-specific knock-out of the 
human APOE alleles, APOE-KI mice were crossed to the appropriate strain with tissue-specific 
expression of Cre-recombinase. Specifically, peripheral knock-out of apoE was achieved by 
crossing Albumin-Cre (Alb-Cre) mice 90 (purchased from Jackson laboratory, strain # 003574, also 
known as B6.Cg-Speer6-ps1Tg(Alb-cre)21Mgn/J) to APOE-KI mice for two successive generations to 
obtain Alb-Cre mice homozygous for various APOE isoforms. All mice used in this study were 
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maintained on a C57BL/6J background. Mice were subjected to experiments at either P7, P21, 1.5 
months, or 3 months of age, per the various experimental designs. Mice were individually housed 
in AAALAC accredited facilities with temperature and humidity controls, and were under a 12-
hours light/dark cycle (lights on at 6:00 AM) cycle with free access to food and water ad libitum 
throughout all phases of the experiments. All animal procedures were approved by the Institutional 
Animal Care and Use Committee (IACUC) at Washington University, and were in agreement with 
the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC, 
WUSM). 
Method Details 
 Brain extraction and preparation. At the predetermined date of brain harvesting, the 
appropriate mice were anesthetized with intraperitoneal pentobarbital (200 mg kg−1), and 
subsequently perfused with 3 U ml−1 heparin in cold Dulbecco’s PBS for 3 minutes. The brains 
were then extracted carefully from the skull. The right hemisphere were fixed in 4% 
paraformaldehyde for at least 48 hours before being transferred to 30% sucrose and stored at 4 °C 
until they were sectioned. The left hemi-brain was dissected on an ice-cold stage into various parts 
(cortex, hippocampus, etc...), all of which were flash-frozen on dry ice and subsequently stored at 
-80 °C until needed for biochemical analyses.  
Histology. Following immersion in sucrose for at least 24 hours, serial coronal sections (50 
μm thickness) were collected from frontal cortex to caudal hippocampus (right hemisphere) using 
a freezing sliding microtome (ThermoFisher). Three hippocampal-containing sections (separated 
by 300 μm) from the right hemisphere of each brain were stained with biotinylated HJ3.4 (anti-
Aβ1–13, mouse monoclonal antibody generated in-house, 1:500 dilution) 




18,40 to visualize Aβ immunopositive plaques, as described previously. 
Microglia were immunostained using goat anti- IBA1 antibody (Abcam ab5076, 1:500 dilution). 
Astrocytes were immunostained using mouse anti-GFAP antibody (MAB3402, 1:1000 dilution). 
ApoE was immunostained with rabbit anti-apoE antibody (Cell signaling D719N, 1:500 dilution. 
All secondary antibodies were used in appropriate combinations depending on the primary 
antibody host, including: donkey anti-goat AF-488 (Invitrogen catalog # A-32814), donkey anti-
rabbit AF-647 (Invitrogen catalog  # A-31573), donkey anti-mouse AF-488 (Invitrogen catalog # 
A-21202), donkey anti-rabbit AF-568 (Invitrogen catalog # A-10042). All secondary antibodies 
were incubated at 1:500 dilution. Quantitative analysis of immunopositive staining was performed 
as described previously 7. Briefly, images of immunostained sections were exported with NDP 
viewer (Hamamatsu Photonics). Using ImageJ software, images were converted to 8-bit grayscale, 
thresholded to highlight Aβ-specific staining and the percent area of a given brain region covered 
by thresholded staining calculated. For analyses of immunofluorescent staining (including GFAP, 
IBA1, apoE, X-34, and Aβ), 20X – 40X images were acquired on Nikon A1Rsi confocal 
microscope. Random z-stacks containing clusters of plaques were imaged, spanning 
approximately 30 µm of tissue in the z-plane with steps of 1.5 µm. Representative images are 
generated by projecting maximal intensity of each voxel on the same z-plane (using ImageJ 
software). All analyses were done blinded to treatment and genotype.  
Real-time qPCR analysis. RNA was extracted from frozen cortical tissue using Trizol (Life 
Technologies # 15596026) and purified using the RNeasy mini kit (Qiagen # 71404). Reverse 
transcription was performed using a High-Capacity cDNA Reverse Transcription Kit (Life 
Technologies). Real-time qPCR was conducted with TaqMan primers (Life Technologies) and the 
TaqMan Universal PCR Master Mix (Thermo Fisher Scientific # 4304437) using the StepOnePlus 
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machine (Applied Biosystems). Relative gene expression levels were compared using the ΔΔCt 
method with Taqman probe for human apoE (Hs00171168_m1). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) mRNA level was used as a reference (Mm99999915_g1 Gapdh)  
Brain homogenization. Brain cortices or hippocampi were sequentially homogenized with 
cold PBS and then the PBS insoluble material with 5M guanidine buffer in the presence of 1X 
protease inhibitor (PI) mixture (Roche). Specifically, the frozen brain tissue were weighed on a 
microscale, and the ice-chilled PBS/PI buffer solution were added at a ratio of 1 ml of buffer per 
100 mg tissue. The mixture were then manually homogenized with a double-ended pestle 
(ThermoFisher Scientific catalog # 50-256-12), until no visible chunks were seen. The samples 
were subsequently centrifuged at 12,000 g (4 °C ) for 30 minutes, and the supernatant were 
collected as PBS-soluble homogenates. To the remaining pellet, 5M guanidine/PI buffer were 
added at the same ratio (1 ml buffer per 100 mg tissue) and homogenized by sonication. The 
homogenates were rotated at room temperature for 1 hour and subsequently centrifuged at 12,000 
g (4 °C) for 30 minutes. The supernatant was collected at guanidine-soluble fraction. All 
procedures were done on ice as much as possible unless noted otherwise. 
Sandwich ELISA. The levels of Aβx-40, Aβx-42 and apoE in PBS- and guanidine-soluble 
brain homogenates were measured by sandwich ELISA. For apoE ELISA, HJ15.3 and HJ15.7b 
were used as capture and detection antibodies, respectively. For Aβx-40 ELISA, HJ2 (anti-Aβ35–40) 
was used as a capture antibody and for Aβx-42 ELISA, HJ7.4 (anti-Aβ37–42) was used as a capture 
antibody. HJ5.1-biotin (anti-Aβ13–18) 
7,50 was used as the detecting antibody for both Aβ ELISAs.  
Primary Astrocyte and Microglia Cultures. Mixed glial cultures were prepared from the 
cortex of E2F, E3F, and E4F neonatal mice (1 – 3 days old), similar to as previously described 
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17,21.  Cortices were dissected in calcium- and magnesium-free Hanks’ Balanced Salt solution 
(HBSS) with careful removal of meninges. Tissue was digested in HBSS containing 0.25% trypsin 
and 0.2 mg/ml DNase at 37°C for 10 minutes, and was dissociated by trituration in HBSS 
containing 0.4 mg/ml DNase.   Material was filtered through a 70-μm nylon mesh, pelleted at 1000 
g for 5 min, and re-suspended in glia media (DMEM + 10% FBS+ 1X Glutamax + 1X 
Penicillin/Streptomyicin).  Cells were then plated on a poly-L-lysine (PLL)-coated 10 cm dish and 
then switched to glia media containing 10% L929-conditioned media (10% L929 glia media) the 
next day.  10% L929 glia media changes were performed every 3-4 days until cells were grown to 
confluence (14 – 16 days).  The top layer of loosely attached microglia were then harvested by 
pipetting media over the dish ~10 – 15 times to flush off the microglia. The media containing the 
suspended microglia was then collected and spun down at 1000x G for 5 minutes at 4°C.  Microglia 
were then re-suspended in 10% L929 glia media and re-plated onto a 12-well plate coated with 
PLL.  Astrocytes remaining in the 10 cm dish were detached by treating with 3 ml of 0.25% 
Trypsin-EDTA for 10 minutes at 37°C.  7 ml of glia media was added to suspend the astrocytes 
and material was then collected and spun down at 1000 g for 5 minutes at 4°C.  Cells were re-
suspended in glia media and re-plated onto a T75 flask coated with Geltrex.  Microglia were 
allowed to grow for 3 days in 10% L929 glia media before being washed 2-times with sterile PBS 
and then switched to serum-free glia media (DMEM + 1X Glutamax + 1X 
Penicillin/Streptomyicin) containing 25 ng/ml mCSF.  Astrocytes were allowed to grow for 4 days 
in glia media before being shaken overnight at 250 RPM at 37°C to remove loosely attached cells 
from astrocyte layer. The glia media was removed and astrocytes were then washed 2-times with 
sterile PBS and switched to serum-free glia media. Serum-free glia media from microglia and 
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astrocyte cultures was collected after 48 hours and stored at 4°C for non-denaturing gel 
electrophoresis. 
Non-Denaturing Gradient Gel Electrophoresis. Microglia-conditioned serum-free media 
and astrocyte-conditioned serum-free media samples were run on a 4-20% Tris-Glycine native 
non-denaturing gel at 100 V for 18hours at 4°C.  Gels were transferred to PVDF membrane at 25V 
for 90 minutes at 4°C and probed with an anti-ApoE antibody (HJ15.7, 1:1000; in house).  ApoE 
immunoreactivity was detected by chemiluminescent development with ECL ultra reagents. 
Western blot analysis. PBS-soluble brain lysates from the sequential homogenization step 
were analyzed for total protein concentration with a micro BCA kit (Thermo Scientific). 30 µg of 
proteins from each sample were loaded onto a NU-PAGE 4-12% Bis-Tris 15 well gel (Thermo 
Fisher Scientific # NP0336BOX) and the gel was run at 150 V for 1.5 hours. The proteins were 
subsequently dry-transferred onto a PVDF membrane using the iblot2 system (Life Technologies) 
and blocked with 5% milk in TBS-Tween (0.05%). The membrane was incubated with anti-apoE 
antibody HJ15.7 50 (or HJ15.3) and anti-β-tubulin antibodies to probe for apoE and a loading 
control, respectively. Donkey-anti-mouse IgG-HRP was used as secondary antibody (Santa Cruz 
Biotechnology # sc-2096). All blots were developed for ~10 seconds using an enhanced 
chemiluminescence (ECL) Ultra kit (Lumigen TMA-6) and imaged on the SynGene Imager 
(BioRad) at the appropriate exposure.  
Lipid Measurements. Plasma Triglyceride (Wako Diagnostics catalog # 290-63701), HDL 
(HDL-Cholesterol E, Wako Diagnostics catalog # 997-01301), and Total Cholesterol (Total 
Cholesterol-E, Wako Diagnostics catalog # 999-02601) concentrations were measured using kits 
from Wako Diagnostics adapted to half-area 96-well dishes (Corning, catalog # 3690). The 
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protocols were performed according to the manufacturer’s specifications with the following 
adjustments. For the triglyceride and cholesterol measurements: half volumes of the samples and 
standards described in the provided microplate/microtiter methods were used. For the cholesterol 
measurements: a standard curve with levels of 0, 25, 100, 200, 397.4, 592.2 mg/dL was used. For 
the HDL measurements: 20 µL sample were mixed with an equal amount of Precipitating Reagent. 
Due to low sample HDL concentrations, samples were loaded at twice the volume of the standard 
curve. As a result, the derived sample concentrations were halved to reach the true value. After 
adding color reagent to the wells (150 µL/well), the dishes were gently mixed and incubated at 
37oC for ~5 minutes before reading. Absorbance at 600 nm and 700 nm were measured using a 
Cytation 5 Imaging Reader. Analysis was performed using Gen5 software and Microsoft Excel. 
Absorbance at 700 nm was subtracted from that at 600 nm to correct for contaminants. Samples 
and standards were measured in duplicate and triplicate, respectively. Sample concentrations were 
derived from a linear regression fit to the standard curve. For analysis, the blank absorbance was 
counted as the 0 mg/dL level (it was not subtracted). Samples were subjected to ~1-3 freeze-thaw 
cycles. 
Quantification and Statistical Analysis 
Statistics. All values are reported as mean ± SEM. A one-way ANOVA was used to assess 
significance between more than two groups (Figures 4.1 and 4.10), and Bonferroni’s post-hoc test 
was used to test for differences between each of the groups. A two-way ANOVA was used to 
assess significance between more than two groups in the presence of additional variables (Figures 
4.5, 4.6, 4.7, 4.8, and 4.9), and Tukey’s post-hoc test was used to test for differences between each 
of the groups (Figures 4.5, 4.6, 4.7, 4.8, 4.9), with the exception of figures 4.7C – 4.7H, where 
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Holm-Sidak multiple comparisons testing was used due to non-normal distribution of data in some 
groups. All statistical analyses were performed using Prism software (Graphpad). p < 0.05 is 
considered significant for all tests. No statistical analysis was used to determine sample size a 
priori. The sample sizes chosen are based on those used in previous studies from our laboratory. 
The number of samples indicates biological replicates as indicated in each of the figure legends. 
At most one outlier was removed per genotype via the Grubb’s test (alpha = 0.05, GraphPad 
QuickCalcs1). 
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Figure 4.1 Replacement of the mouse Apoe gene with the human APOE gene 
in APOE-KI mice 
A, Genomic organization of the mouse Apoe gene containing exons 1 – 4. B, The APOE-ε3 
targeting construct containing the 5’ and 3’ arms of mouse homology interrupted by the human 
APOE-ε3 gene sequence. Exons 2 to 4 of the human sequence were flanked with loxP sites. 
Positive selection markers were flanked by FRT (Neomycin resistance – NeoR) and F3 
(Puromycin resistance – PuroR) sites and inserted downstream of the proximal loxP site and 
upstream of the distal loxP site, respectively. C, Homologous recombinant clones were isolated 
using double positive (NeoR and PuroR) and negative (Thymidine kinase - TK) selections. D, 
The constitutive humanized/conditional knock-out alleles were achieved after in vivo Flp-
mediated removal of the selection markers. The newly introduced human APOE gene is 
expressed under control of the endogenous Apoe promoter. E, Constitutive knock-out allele is 
achieved when the loxP-flanked region is removed by Cre-recombinase. F, PBS-soluble apoE 
protein concentration was measured in cortical brain homogenates from APOE-KI mice at 21 
days (p = 0.0004, F = 15.77). G, PBS-soluble apoE protein concentration was measured in 
cortical brain homogenates from APOE-KI mice at 3 months of age (p = 0.0043, F = 8.880). H, 
Guanidine-soluble apoE protein concentration was also measured in cortical brain homogenates 
from APOE-KI mice at 3 months of age (p = 0.0144, F = 6.169). I, The same brain homogenates 
were subjected to Western blot analysis for apoE using antibody HJ15.7. White arrowhead = 
sialylated apoE (MW ~ 35.3 kDa). Black arrow = non-sialylated apoE (MW ~ 33.6 kDa). N = 2 
males, 2 females per genotype. *p < 0.05, ***p < 0.001. A one-way ANOVA was used to assess 
significance between more than two groups, and Bonferroni’s post-hoc test was used to test for 
differences between each of the groups. All values are reported as mean ± SEM. N = 5 per 








Figure 4.2 Human APOE is expressed in astrocytes in APOE-KI mice 
A, Brain sections from APOE-KI mice were co-stained for nuclei (DAPI), apoE, and GFAP. 
Multiple foci of ApoE/GFAP co-localization can be seen at high magnification (bottom panels). 
B, Brain sections from APOE-KI mice were co-stained for nuclei (DAPI), apoE, and IBA1. No 
overlap of apoE and IBA1 staining was observed. Scale bars = 200 µm (top panels) and 50 µm 
(bottom panels). Images are from E4F mice, and are representative of at least 3 random cortical 
areas from 3 biological replicates. There were no appreciable qualitative differences between 





Figure 4.3 Microglial APOE expression in APP/PS1/EKI mice 
A, Brain sections from APP/PS1/E4F mice were co-stained for nuclei (DAPI), apoE, and IBA1. 
Multiple foci of apoE/ IBA1 co-localization can be seen (arrows). Scale bars = 20 µm B, Brain 
sections from APP/PS1/E4F mice were co-stained with DAPI, apoE, Aβ, and IBA1. ApoE is co-
localized with IBA1 (arrowhead). Scale bars = 25 µm. Images are representative of at least 3 
random cortical areas from 3 biological replicates. There were no appreciable qualitative 






Figure 4.4 Qualitative assessment of microglia and astrocyte-derived apoE 
particles 
Conditioned media samples from E2F, E3F, and E4F-derived primary cultures enriched for 
microglia and astrocyte were subjected to non-denaturing 4-20% Tris-glycine gradient gel 
electrophoresis followed by Western blotting. Approximate hydrated radius of marker proteins, 
run on the same gel, are shown for comparative purposes. Data shown are representative of 3 




























Figure 4.5 ApoE isoforms differentially influence Aβ plaque deposition in 
APP/PS1/EKI mice 
A, Brain sections from 4-month-old APP/PS1/EKI mice were immunostained with anti-
Aβ antibody (HJ3.4-biotin) and the extent of Aβ deposition in the cortex quantified. There was a 
significant effect of sex (F1,57 = 5.792, p = 0.0194) and apoE isoform (F2,57 = 4.356, p = 0.0174) 
but no interaction (F2,57 = 0.3269, p = 0.7225). Post hoc analysis comparing apoE isoform within 
each sex found a statistically significant increase in Aβ deposition in female apoE4-
expressing mice compared to apoE3 (p = 0.0466), APP/PS1/E2F = 8 males, 10 female; 
APP/PS1/E3F = 9 males, 10 females; APP/PS1/E4F = 13 males, 13 females. Scale bar = 1 mm. 
B, Brain sections from 4-month-old APP/PS1/EKI mice were stained with X-34 dye that 
recognizes only fibrillar plaques and the cortical area stained by X-34 was quantified. There was 
a significant effect of sex (F1,59 = 9.008, p = 0.0039) and apoE isoform (F2,59 = 4.838, p = 0.0113) 
but no interaction (F2,59 = 0.1898, p = 0.8276). Post hoc analysis comparing apoE isoform within 
each sex did not find a statistically significant difference, although there was a trend towards 
elevated X-34 staining in apoE4-expressing female mice compared to apoE2 (p = 0.0602) and 
apoE3 (0.0830), APP/PS1/E2F = 8 males, 9 females; APP/PS1/E3F = 11 males, 10 females; 
APP/PS1/E4F = 12 males, 15 females. Scale bar = 1 mm. C, The density of plaques from 4-
month old APP/PS1/EKI mice was calculated. There was a significant effect of sex (F1,57 = 
5.101, p = 0.0278) and apoE isoform (F2,57 = 8.8085, p = 0.0008) but no interaction (F2,57 = 
0.7514, p = 0.4763). Post hoc analysis comparing apoE isoform within each sex found a 
statistically significant increase in Aβ plaque density in female apoE4-expressing mice compared 
to apoE3 (p = 0.0032) or apoE2 (p = 0.0484), APP/ PS1/E2F = 8 males, 10 females; 
APP/PS1/E3F = 9 males, 10 females; APP/PS1/E4F = 13 males, 13 females. D, The average 
plaque size was quantified. There was a significant effect of sex (F1,57 = 5.410, p = 0.0236), but 
not of apoE isoform (F2,57 = 2.202, p = 0.1420) with no interaction (F2,57 = 0.05053, p = 0.9508), 
APP/PS1/E2F = 8 males, 10 females; APP/PS1/E3F = 9 males, 10 females; APP/PS1/E4F = 13 
males, 13 females. E, The density of X-34+ plaques was quantified. There was a significant 
effect of sex (F1,61 = 9.527, p = 0.0030) and apoE isoform (F2,61 = 9.941, p = 0.0002) but no 
interaction (F2,61 = 0.8835, p = 0.4186). Post hoc analysis comparing apoE isoforms within each 
sex found a statistically significant increase in plaque density in female apoE4-expressing mice 
compared to apoE3 (p = 0.0053), or apoE2 (p = 0.0016), APP/PS1/E2F = 8 males, 9 females; 
APP/ PS1/E3F = 11 males, 10 females; APP/PS1/E4F = 14 males, 15 females. F, The 
average X-34+ plaque size was quantified. There was a significant effect of sex (F1,61 = 11.97, p 
= 0.0010), but not apoE isoform (F2,61 = 2.094, p =0.1320) with no interaction (F2,61 = 0.9353, p 
= 0.3980). All statistics were performed using a 2-way ANOVA followed by Tukey post-
































Figure 4.6 APOE isoforms differentially influence Aβ accumulation in 
APP/PS1/EKI mice 
Cortical tissues from 4-month-old APP/PS1-EKI mice were sequentially homogenized in PBS 
and 5 M guanidine-HCl buffer. A, The amount of PBS-soluble apoE was quantified by ELISA. 
There was a significant effect of sex (F1,66 = 8.373, p = 0.0052) and apoE isoform (F2,66 = 3.911, 
p = 0.0248) but no interaction (F2,66 = 0.8546, p = 0.4301). Post hoc analysis comparing apoE 
isoform within each sex identified a statistically significant increase in apoE levels in 
female apoE4-expressing compared to apoE3 (p = 0.0293). B, The amount of PBS-
soluble Aβ40 was quantified by ELISA. There was a significant effect of apoE genotype (F2,66 = 
3.204, p = 0.0470), and a trend towards a significant effect of sex (F1,66 = 3.203, p = 0.0781), 
with no interaction (F2,66 = 0.06043, p = 0.9414). Post hoc analysis comparing apoE isoforms 
within each sex did not identify statistically significant pair-wise differences. C, The amount 
of PBS-soluble Aβ42 was quantified by ELISA. There was a significant effect of sex (F1, 66 = 
4.246, p = 0.0433) and apoE isoform (F2,66 = 4.943, p = 0.0100) without interaction (F2,66 = 
0.5411, p = 0.5847). Post hoc analysis comparing apoE isoform within each sex identified a 
statistically significant increase in Aβ42 levels in male apoE2-expressing mice compared to 
apoE3 (p = 0.0338). D, The amount of guanidine-soluble Aβ40 was quantified by ELISA. There 
was a significant effect of sex (F1, 66 = 5.240, p = 0.0253) and apoE isoform (F2,66 = 3.953, p = 
0.0239) without interaction (F2,66 = 1.211, p = 0.3044). Post hoc analysis comparing apoE 
isoforms within each sex identified a statistically significant increase of Aβ40 in female apoE4- 
expressing mice compared to apoE3 (p = 0.0086). E, The amount of guanidine-soluble Aβ42 was 
quantified by ELISA. There was a trend towards a significant effect of sex (F1, 66 = 3.915, p = 
0.0520) and a significant effect of apoE isoform (F2,66 = 5.476, p = 0.0063) without interaction 
(F2,66 = 1.384, p = 0.2578). Post hoc analysis comparing apoE isoform within each sex identified 
a statistically significant increase in Aβ42 levels in female apoE4-expressing mice compared to 
apoE3 (p = 0.0030). 2-way ANOVA, Tukey’s post-hoc test, APP/PS1/E2F = 9 males, 10 
females; APP/PS1/E3F = 12 males, 12 females; APP/PS1/E4F = 14 males, 15 females. Data 







Figure 4.7 Plasma lipid alterations in APP/PS1/EKI mice lacking liver-
derived apoE 
A, APOE mRNA levels in liver tissues from 4-month-old APP/ PS1-EKI mice were analyzed by 
qPCR (p < 0.0001, F = 31.60). Post hoc analysis showed a significant difference between Cre+/- 
and Cre-/- mice in all APOE genotypes (p < 0.0001 for all). B, PBS-soluble apoE protein 
concentration was measured in liver homogenates from the same cohort of mice (p < 0.0001, F = 
23.03) Post hoc analysis showed a significant difference between Cre+/- and Cre-/- mice in all 
APOE genotypes (p < 0.0001 for all). Data for (A) and (B) were analyzed by one-way ANOVA, 
followed by Bonferroni’s post-hoc test for differences between each of the groups. N = 3 males, 
2 females in each group. C, Plasma apoE levels in male mice were measured by ELISA. There 
was a significant effect of apoE isoform (F2,49 = 70.97, p<0.0001) and Cre expression (F1,49 = 
51.79, p < 0.0001) with a significant interaction (F2,49 = 7.748, p = 0.0012). Post hoc pair-
wise comparisons between Cre+/- and Cre-/- groups found Cre expression significantly decreased 
plasma apoE levels across apoE isoforms. (apoE2, p <0.0001; apoE3, p = 0.0112; apoE4, p = 
0.0232). (n; E2F:  8 Cre-/-, 12 Cre+/-; E3F: 11 Cre-/-, 12 Cre+/-; E4F: 5 Cre-/-, 8 Cre+/-). D, Plasma 
apoE levels in female mice were measured by ELISA. There was a significant effect of apoE 
isoform (F1,41 = 43.03, p<0.0001) and Cre expression (F1,41 = 61.81, p<0.0001) with a significant 
interaction (F2,41 = 9.954, p = 0.0003). Post hoc pair-wise comparisons between Cre
+/− and 
Cre−/− groups found Cre expression significantly decreased plasma apoE levels across apoE 
isoforms. (apoE2, p < 0.0001; apoE3, p = 0.0372; apoE4, p = 0.0025). (n; E2F: 5 Cre−/−, 8 Cre+/−; 
E3F: 11 Cre−/−, 6 Cre+/−; E4F: 11 Cre−/−, 7 Cre+/−). E, Total cholesterol in male mice was 
quantified. There was a significant effect of apoE isoform (F2,49 = 31.14, p < 0.0001) and Cre 
expression (F1,49 = 86.12, p < 0.0001) and a significant interaction (F2,49 = 24.10, p < 0.0001). 
Post hoc pair-wise comparisons between Cre+/− and Cre−/− groups found Cre expression 
significantly increased plasma cholesterol levels in mice expressing apoE2 (p < 0.0001) or apoE3 
(p = 0.0001), but not apoE4 (p = 0.1971). (n; E2F: 8 Cre−/−, 12 Cre+/−; E3F: 11 Cre−/−, 12 Cre+/−; 
E4F: 4 Cre−/−, 9 Cre+/−). F, Total plasma cholesterol in female mice was quantified. There was a 
significant effect of apoE isoform (F2,41 = 46.39, p < 0.0001) and Cre genotype (F1,41 = 24.31, p 
< 0.0001) with a significant interaction (F2,41 = 12.59, p < 0.0001). Post hoc pair-
wise comparisons between Cre+/− and Cre−/− groups found Cre expression significantly increased 
plasma cholesterol levels in apoE2-expressing mice (p < 0.0001), but not apoE3 or apoE4-
expressing mice. (n; E2F: 5 Cre−/−, 8 Cre+/−; E3F: 10 Cre−/−, 6 Cre+/−; E4F: 11 Cre−/−, 7 Cre+/−). 
G, Total plasma triglycerides in male mice were quantified. There was a significant effect of 
apoE isoform (F2,48 = 13.31, p < 0.0001) and Cre expression (F1,48 = 36.70, p < 0.0001), with a 
significant interaction (F2,48 = 3.755, p = 0.0306). Post hoc pairwise comparisons between 
Cre+/− and Cre−/− groups found Cre expression significantly increased triglyceride levels in mice 
expressing apoE2 (p < 0.0001) or apoE3 (p = 0.0001), but not apoE4. (n; E2F: 8 Cre−/−, 11 
Cre+/−; E3F: 11 Cre−/−, 12 Cre+/−; E4F: 4 Cre−/−, 9 Cre+/−). H, Total plasma triglycerides in female 
mice were quantified. There was a significant effect of apoE isoform (F2,40 = 10.68, p = 0.0002) 
and Cre expression (F1,40 = 4.168, p = 0.0478), but no significant interaction (F2,40 = 0.1031, p = 
0.9023). Post hoc pair-wise comparisons did not identify significant differences in triglyceride 
levels in mice dependent on Cre expression. (n; E2F: 4 Cre−/−, 8 Cre+/−; E3F: 10 Cre−/−, 6 Cre+/−; 
E4F: 11 Cre−/−, 7 Cre+/−). I, Total plasma HDL in male mice was quantified. There was a 
significant effect of apoE isoform (F2,49 = 8.239, p = 0.0008), but not Cre expression (F1,49 = 




12 Cre+/−; E3F: 11 Cre−/−, 12 Cre+/−; E4F: 4 Cre−/−, 9 Cre+/−). J, Total plasma HDL in female 
mice was quantified. There was a significant effect of apoE isoform (F2,42 = 9.9098, p = 0.0005), 
but not Cre expression (F1,42 = 0.9699, p = 0.3304), with no interaction (F2,42 = 1.668, p = 
0.2010). (n; E2F: 5 Cre−/−, 8 Cre+/−; E3F: 11 Cre−/−, 6 Cre+/−; E4F: 11 Cre−/−, 7 Cre+/−). Data 
analyzed by 2-way ANOVA followed by Holm-Sidak multiple comparisons testing. Values from 
EKO mice are also plotted according to sex (n = 5 males, 3 females), but were not included in 






































Figure 4.8 Liver-derived apoE does not influence Aβ accumulation in the 
brain 
A, B, C, Brain sections from 4-month-old APP/PS1/EKICre mice and littermates were 
immunostained with an anti-Aβ antibody. Scale bars = 1 mm. G, The extent of cortical 
Aβ deposition in male mice was quantified. There was a significant effect of apoE isoform 
(F2,49 = 10.63, p = 0.0001), but not Cre expression (F1,49 = 2.693, p = 0.1072) with no interaction 
(F2,49 = 0.1845). (n; E2F: 8 Cre
−/−, 12 Cre+/−; E3F: 10 Cre−/−, 12 Cre+/−; E4F: 5 Cre−/−, 8 Cre+/−). 
H, The extent of cortical Aβ deposition in female mice was quantified. There was a significant 
effect of apoE isoform (F2,41 = 12.00, p < 0.0001), but not Cre expression (F1,41 = 0.2520, p = 
0.6183) with no interaction (F2,41 = 0.09684, p = 0.9079). (n; E2F: 5 Cre
−/−, 8 Cre+/−; E3F: 11 
Cre−/−, 6 Cre+/−; E4F: 10 Cre−/−, 7 Cre+/−). D, E, F, Brain sections from the same cohort were 
stained with X-34 dye. I, The cortical fibrillar plaque load in male mice was quantified. There 
was a significant effect of apoE isoform (F2,50 = 11.34, p < 0.0001), but not Cre expression 
(F1,50 = 0.3027, p = 0.5846) with no interaction (F2,50 = 1.607, p = 0.2106). (n; E2F: 8 Cre
−/−, 12 
Cre+/−; E3F: 11 Cre−/−, 12 Cre+/−; E4F: 4 Cre−/−, 9 Cre+/−). J, The cortical fibrillary plaque load in 
female mice was quantified. There was a significant effect of apoE isoform (F2,42 = 10.53, p = 
0.0002), but not Cre expression (F1,42 = 0.5502, p = 0.4624) with no interaction (F2,42 = 0.2734, p 
= 0.7622). (n; E2F: 5 Cre−/−; 8 Cre+/−; E3F: 11 Cre−/−, 6 Cre+/−; E4F: 11 Cre−/−, 7 Cre+/−). Data 







Figure 4.9 Replacement of the mouse Apoe gene with the human APOE gene 
in APOE-KI mice 
Cortical tissues were sequentially homogenized in PBS and 5M guanidine HCl buffer. Aβ and 
apoE levels were quantified by ELISA. A, Levels of PBS-soluble apoE in cortex of male mice. 
There was a trend towards a significant effect of apoE isoform (F2,50 = 3.040, p = 0.568), and no 
significant effect of Cre (F1,50 = 0.3673, p = 0.5472) or interaction (F2,50 = 0.1696, p = 0.8445). 
(n; APP/PS1/E2F: 8 Cre-/-,12 Cre+/-; APP/PS1/E3F: Cre-/-,12 Cre+/-; APP/PS1/E4F: 5 Cre-/-, 8 
Cre+/-). B, Levels of PBS-soluble apoE in cortex of female mice. There was no significant effect 
of apoE isoform (F2,42 = 0.1669, p = 0.8468), Cre expression (F1,42 = 0.02187, p = 0.8831) or 
interaction (F2,42 = 2.277, p = 0.1151). (n; APP/PS1/E2F: 5 Cre
-/-, 8 Cre+/-; APP/PS1/E3F: 11 
Cre-/-, 6 Cre+/-; APP/PS1/E4F: 11 Cre-/-, 7 Cre+/-). C, Levels of PBS-soluble Aβ40 in the cortex of 
male mice. There was a significant effect of apoE isoform (F2,49 = 10.12, p = 0.0002), but not 
Cre expression (F1,49 = 0.002707, p = 0.9587) or interaction (F2,49 = 0.4113, p = 0.6650). (n; 
APP/PS1/E2F: 8 Cre-/-, 12 Cre+/-; APP/PS1/E3F: 10 Cre-/-, 12 Cre+/-; APP/PS1/E4F: 5 Cre-/-, 8 
Cre+/-). D, Levels of PBS-soluble Aβ40 in the cortex of female mice. There was a significant 
effect of apoE isoform (F2,42 = 3.495, p = 0.0394), but not Cre expression (F1,42 = 0.4314, p = 
0.5149) or interaction (F2,42 = 1.217, p = 0.3065). (n; APP/PS1/E2F: 8 Cre
-/-, 12 Cre+/-; 
APP/PS1/E3F: 11 Cre-/-, 12 Cre+/-; APP/PS1/E4F: 5 Cre-/-, 8 Cre+/-). E, Levels of PBS-soluble 
Aβ42 in cortex of male mice. There was a significant effect of apoE isoform (F2,50 = 5.328, p = 
0.0080), but not Cre expression (F1,50 = 0.07241, p = 0.7890), or interaction (F2,50 = 0.1759, p = 
0.8392). (n; APP/PS1/E2F: 8 Cre-/-, 12 Cre+/-; APP/PS1/E3F: 11 Cre-/-, 12 Cre+/-; APP/PS1/E4F: 
5 Cre-/-, 8 Cre+/-).  F, Levels of PBS-soluble Aβ42 in the cortex of female mice. There was a trend 
towards a significant effect of apoE isoform (F2,42 = 2.597, p = 0.0864), and no significant effect 
of Cre expression (F1,42 = 0.1586, p = 0.6925) or interaction (F2,42 = 0.2245, p = 0.7999). (n; 
APP/PS1/E2F: 5 Cre-/-, 8 Cre+/-; APP/PS1/E3F: 11 Cre-/-, 6 Cre+/-; APP/PS1/E4F: 11 Cre-/-, 7 
Cre+/-). G, Levels of guanidine-soluble apoE in the cortex of male mice. There was a trend 
towards a significant effect of apoE isoform (F2,50 = 2.513, p = 0.0912), and no effect of Cre 
expression (F1,50 = 0.8026, p = 0.3746) or interaction (F2,50 = 0.9035, p = 0.4116). (n; 
APP/PS1/E2F: 8 Cre-/-, 12 Cre+/-; APP/PS1/E3F: 11 Cre-/-, 12 Cre+/-; APP/PS1/E4F: 5 Cre-/-, 8 
Cre+/-). H, Levels of guanidine soluble apoE in the cortex of female mice. There was a 
significant effect of apoE isoform (F2,42 = 3.669, p = 0.0340), but no significant effect of Cre 
expression (F1,42 = 0.0003, p =0.9857) or interaction (F2,42 = 0.2874, p = 0.7517). (n; 
APP/PS1/E2F: 5 Cre-/-, 8 Cre+/-; APP/PS1/E3F: 11 Cre-/-, 6 Cre+/-; APP/PS1/E4F: 11 Cre-/-, 7 
Cre+/-). I, Levels of guanidine-soluble Aβ40 in the cortex of male mice. There was a significant 
effect of apoE isoform (F2,48 = 7.273, p = 0.0017), but not Cre expression (F1,48 = 0.1102, p = 
0.7414) or interaction (F2,48 = 2.333, p = 0.1079). (n; APP/PS1/E2F: 7 Cre
-/-, 12 Cre+/-; 
APP/PS1/E3F: 11 Cre-/-, 12 Cre+/-; APP/PS1/E4F: 5 Cre-/-, 7 Cre+/-). J, Levels of guanidine-
soluble Aβ40 in the cortex of female mice. There was a significant effect of apoE isoform (F2,41 = 
9.575, p =0.0004), but no significant effect of Cre expression (F1,41 = 0.1030, p = 0.7499) and no 
interaction (F2,41 = 2.354, p = 0.1077). (n; APP/PS1/E2F: 4 Cre
-/-, 8 Cre+/-; APP/PS1/E3F: 11 
Cre-/-, 6 Cre+/-; APP/PS1/E4F: 11 Cre-/-, 7 Cre+/-). K, Levels of guanidine-soluble Aβ42 in the 
cortex of male mice. There was a significant effect of apoE isoform (F2,49 = 10.88, p = 0.0001), 
but no significant effect of Cre expression (F1,49 = 0.05731, p = 0.8118), and a trend towards a 
significant interaction (F2,49 = 2.925, p = 0.0631). (n; APP/PS1/E2F: 7 Cre
-/-, 12 Cre+/-; 
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APP/PS1/E3F: 11 Cre-/-, 12 Cre+/-; APP/PS1/E4F: 5 Cre-/-, 8 Cre+/-). L, Levels of guanidine-
soluble Aβ42 in the cortex of female mice. There was a significant effect of apoE isoform (F2,41 = 
16.32, p<0.0001), but not Cre expression (F1,41 = 0.4266, p = 0.5173) and no interaction (F2,41 = 
1.722, p = 0.1914). (n; APP/PS1/E2F: 4 Cre-/-, 8 Cre+/-; APP/PS1/E3F: 11 Cre-/-, 6 Cre+/-; 
APP/PS1/E4F: 11 Cre-/-, 7 Cre+/-). Data analyzed by 2 way ANOVA. Data from APP/PS1/EKO 










Figure 4.10 Replacement of the mouse Apoe gene with the human APOE gene 
in APOE-KI mice 
A, The specific sequence of the genomic region surrounding the translation initiation codon of 
the human and mouse APOE gene, located on exon 2, is shown. The mouse and human 
sequences are aligned for comparative purposes. The cleavable signal peptide is encoded within 
exons 2 and 3 (amino acids 1-18). B, C, D, Targeting vectors for the ε2 and ε4 alleles have 
identical sequence other than their respective SNPs at positions 130 and 176, both located on 
exon 4 ([Cys130, Cys176] for APOE-ε2 (B), [Cys130, Arg176] for APOE-ε3 (C), and [Arg130, 
Arg176] for APOE-ε4) (D). The red arrowheads identify the SNPs at positions 130 and 176 in 
each of the allele sequences. E, F, APOE mRNA levels in the hippocampus (E), and hemisphere 
(F) of APOE-KI mice were analyzed at 3 months of age (p = 0.0169, F = 5.843 and p = 0.0025, 
F = 10.88, respectively). G, Cortex-derived brain homogenates from 3-month-old APOE-KI mice 
were subjected to western blot analysis for apoE using antibody HJ15.3. White arrowhead = 
sialylated apoE (MW ~ 35.3 kDa). Black arrow = non-sialylated apoE (MW ~ 33.6 kDa). *p < 
0.05, **p < 0.01, ***p < 0.001. A one-way ANOVA was used to assess significance between 
more than two groups, and Bonferroni’s post-hoc test was used to test for differences between 
each of the groups. All values are reported as mean ± SEM. N = 5 per genotype for ELISA 

















Figure 4.11 ApoE isoforms differentially influence Aβ plaque deposition in 
APP/PS1/APOE-TR mice 
A, Brain sections from 3- month-old APP/PS1/APOE-TR mice were immunostained with anti-
Aβ antibody 3D6 and the extent of Aβ deposition in the cortex quantified. Two-way ANOVA 
analysis found a significant effect of apoE isoform (F2,38 = 10.13, p = 0.0003) but no significant 
effect of sex (F1,38 = 0.001177, p = 0.9728), and no interaction (F2,38 = 0.06101, p = 0.9409). Post 
hoc analysis comparing apoE isoform within each sex found a statistically significant increase in 
Aβ deposition in male apoE2- (p = 0.0010) and apoE4- expressing (p = 0.0430) mice compared 
to apoE3, APP/PS1/E2 = 8 males, 9 female; APP/PS1/E3 = 11 males, 4 females; APP/PS1/E4 = 
7 males, 5 females. B, Since there was no effect of sex on Aβ staining, data for both males and 
females were pooled together. A one-way ANOVA was performed (F = 11.92, p < 0.0001), 
followed by Tukey’s post hoc test for multiple comparisons. C, Brain sections from 4-month-
old APP/PS1/APOE-TR mice were stained with X-34 dye that recognizes only fibrillar plaques 
and the cortical area stained by X-34 was quantified. There was a significant effect of genotype 
(F2,37 = 8.701, p = 0.0008) but no significant effect of sex (F1,37 = 0.6014, p = 0.4430), and no 
interaction (F2,37 = 0.2230, p = 0.8012). Post hoc analysis comparing apoE isoform within each 
sex found a statistically significant increase in X-34 staining in male apoE2-expressing mice 
compared to apoE3 (p = 0.0011), APP/PS1/E2 = 8 males, 9 female; APP/ PS1/E3 = 10 males, 4 
females; APP/PS1/E4 = 7 males, 5 females. D, Since there was no effect of sex on X-34 staining, 
data for both males and females were pooled together. A one-way ANOVA was performed (F = 
11.69, p = 0.0001), followed by Tukey’s post hoc test for multiple comparisons. * p < 0.05, ** p 





























Chapter 5  













5.1 Delineating the effects of apoE on amyloid plaques 
versus the innate immune response 
 We discussed in chapter 1 the many ways that APOE can influence Aβ, one of the key 
players in the pathogenesis of Alzheimer disease (AD). We initiated the ASO studies (discussed 
in chapter 2) with some understanding of how APOE isoforms can influence the clearance of 
soluble Aβ from the ISF 3,13. Additionally, genetically lower apoE levels lead to an impressive 
reduction of cerebral Aβ accumulation in at least one model of amyloidosis9. During the process, 
however, we learned more about how apoE influences the earliest stages of Aβ aggregation, an 
unexpected finding. Though this aspect of the APOE-Aβ interaction was described 
previously2,11,14, our study6 and that of our colleagues10 were the first ones to demonstrate the 
consequences of such interaction in an in vivo context. More importantly, our study carries 
important therapeutic indications: simply lowering apoE levels in symptomatic AD patients may 
not lead to reduction of cerebral plaque load. Based on our data, apoE reduction must be initiated 
before any Aβ aggregates can be detected in order to slow the overall progression of amyloidosis. 
These results, if translated to humans, mean that one must be treated in their 20s or 30s (depending 
on their APOE genotype), based on some estimates7. Though biomarker studies are hitting great 
strides towards finding an early diagnostic marker of AD, we currently have no proven method to 
predict late-onset AD risk reliably that early in the disease process.  
 However, another finding from our ASO studies offers a glimpse of hope for APOE-
targeted therapy for late-onset AD: the reduction of dystrophic neurites. Cerebral Aβ accumulation 
does not correlate well with clinical symptoms of AD1,8, and most models of amyloidosis do not 
develop significant neurodegeneration. However, most APP transgenic models, including the 
APPPS1 strain we utilized, do develop neuritic dystrophy. Neuritic dystrophy is a phenomenon 
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where damaged neuronal processes become dysmorphic, and are often referred to as dystrophic 
neurites. This phenotype is used as a surrogate read-out for plaque toxicity, as they are often found 
immediately around the plaques. We found a reduction in the amount of dystrophic neurites in the 
mice treated with the ASO, whether or not there was a reduction in plaques. Interestingly, we also 
found a small, but significant, reduction of the complement protein C1q in the same mice 
(unpublished data). This is consistent with a previous study that found elevated C1q levels in 
APOE4-knock-in mice that subsequently affected astrocytic functions in those mice4. Thus, future 
studies on the role of apoE in modulating neurotoxicity and the immune system might open up 
therapeutic options bypassing the need to reduce plaque pathology (Figure 5.1).  
 In the context of our Aβ seeding studies (discussed in chapter 3), future analysis on the 
glial response to the induced Aβ species will shed more insight on the role of apoE on the innate 
immune response. Specifically, we will be able to examine whether the glial response leads to 
alterations in plaque morphology or dystrophic neurites, or the other way around. Having been 
demonstrated to influence both of these events, APOE remains an attractive therapeutic target for 
AD. This goal must be approached cautiously in a step-wise manner, where one scientific question 
is addressed at a time. Along with the lessons learned during the early trials that target Aβ, a 
systematic approach to developing AD therapeutics can increase the likelihood of success for 
future trials. 
5.2 Current and future challenges to Alzheimer disease 
research 
 The increasing prevalence of Alzheimer disease (AD) and other neurodegenerative 
diseases is not only due to the aging population, but also the severe lack of effective treatment 
options. Over 200 compounds were tested in over 400 clinical trials for AD between 2002 and 
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2012, with only one single compound approved. That’s a 99.6 % failure rate (compared to 81% 
failure rate for trials on cancer drugs)5.  
Why is our knowledge gained from the bench not translating to the bed side? This lack of 
translatability is one of the biggest challenges of current neurodegeneration research. In addition 
to technical limitations of the clinical trials (flawed study design, lack of definitive endpoint 
measures, etc...), a key challenge lies in the lack of an ideal disease model. Many rodent models 
used to study neurodegenerative diseases retain the native regulatory elements, despite harboring 
the human sequence. This precludes rigorous studies on the upstream components of the novel 
gene. Most transgenic mice used to study amyloidosis in the context of AD overexpress the human 
gene by several folds. Flooding the system with such high concentration of the transgene might 
overwhelm the brain’s homeostatic capacity, and potentially create phenotypes that are artifacts. 
The artificially strong phenotype might also mask beneficial effects of potentially effective drugs. 
Additionally, considerable species differences between rodents and humans exist and challenge 
our ability to generate findings that are relevant and directly translatable to humans from studies 
in mice and rats. Apparent differences in physiological function and metabolism, such as lipid 
metabolism and immune response between humans and rodents might preclude important 
discoveries that are relevant to disease mechanism. 
Our effort to address some of the limitations of the existing APOE knock-in (APOE-TR) 
mice resulted in the generation of the novel APOE-KI mice, whose genetic construct and general 
characterization was discussed in chapter 4. The engineered loxP sites around the APOE locus 
have allowed us to specifically suppress APOE expression in hepatocytes, and investigate the 
physiologic response both in the periphery and the CNS. In addition to the ability to target a 
specific tissue, the Cre-loxP system also allows researchers to manipulate APOE expression in a 
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temporally controlled manner. It is important to acknowledge that, while our newly created mouse 
lines (and the previous generation of APOE knock-in mice) harbor the human gene sequence, they 
retain the regulatory elements found in mice. It is critical to address this caveat in past, current, 
and future rodent studies, in lieu of a recent studies including one showing evidence that apoE can 
act as a transcription factor and influence a wide variety of signaling pathways12. To circumvent 
the limitation of existing animal models, new experimental paradigms, particularly those derived 
from humans (such as iPSCs and brain organoids), need to be developed and characterized. An 
alternative approach is to engineer human Aβ and/or Tau into species with more human-like 
physiology than rodents. These new experimental platforms will undoubtedly complement the 
current animal models and fuel a new wave of discovery that is necessary to fully understand AD 
pathology, explore its relationship with apoE, and design new therapies. Another motivation for 
developing better model systems is the high incidence of unexpected side effects in human trials, 
particularly with antibody-based therapy, despite not being observed in preclinical studies.  
 More than 20 years have passed since the landmark discovery linking APOE with AD, and 
APOE remains the strongest known genetic risk factor for LOAD. Intensive research efforts have 
undoubtedly unveiled several important insights regarding apoE and its role in AD. Nevertheless, 
no APOE-based (or any) disease-modifying therapy has been approved for AD treatment within 
that period. That means many questions remain unanswered, including the most important 
question: how does APOE gene polymorphism confer AD risk? While the evidence that APOE 
influences AD risk substantially via effects on Aβ is strong, it should be noted that a relatively 
large body of literature also exists to support APOE’s roles in AD pathogenesis that are Aβ-
independent. This area needs further exploration. It is possible that apoE participates in an 
unknown fundamental mechanistic event (such as a general signaling cascade) that influences 
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brain homeostasis. If true, the single amino acid change among the different isoforms (particularly 
apoE4) somehow alters the behavior/function of apoE in this process that ultimately lowers the 
brain’s ability to tolerate neurotoxic insults (such as Aβ or tau accumulations). This increased 
vulnerability, in turn, could affect AD risk. Similarly, apoE’s potential role in facilitating the 
immune response to AD pathology needs further investigation. Considering TREM2’s newly 
described role as a lipid-sensing receptor, it is necessary to definitively determine whether there’s 
a true, meaningful connection between APOE and TREM2. 
Along with the affordability and availability of big data science, there needs to be more 
studies that look at apoE isoforms’ differential effects on specific cell populations in the brain in 
an unbiased fashion. Such studies might identify novel targets that will allow us to gain a deeper 
understand as to why AD occurs when it does (old age) and where it does (susceptibility regions 
within the brain). Standing on the shoulder of giants, and aided by the advancement of technology, 
researchers are empowered more than ever to push the field towards a meaningful understanding 
of APOE and AD pathogenesis. From that insight, we hope to develop new and effective therapies 
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5.4 Figures and tables 
 
Figure 5.1 Delineating the effects of apoE on amyloid plaques versus the 
innate immune response 
Our work suggests an active role of apoE in the initial stages of Aβ aggregation (red arrow). 
However, apoE’s role in modulating the immune response in the context of amyloid plaques or 
neurodegeneration is not as well understood (blue arrows). A deeper understanding of how apoE 
might influence the microglial response or complement activation might yield new opportunities 
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University of California, Los Angeles, CA 
Abstract: Stabilization of Aβ42 oligomers through PICUP and Tyr 
“scanning” mutagenesis. 
 
Nov 2010 Presenter – Annual Biomedical Research Conference for Minority Students 
(ABRCMS), Charlotte, North Carolina.  
Abstract: Understanding the Formation of Neurotoxic Aβ 
Oligomers Responsible for Alzheimer’s Disease. 
 
Aug 2010 Presenter –  Poster Sessions, Summer Program for Undergraduate 
Research (SPUR), University of California, Los Angeles, CA 
Abstract: Understanding the Formation of Neurotoxic Aβ 
Oligomers Responsible for Alzheimer’s Disease. 
 
May 2010 Presenter – 2010 UCLA Science Poster Day Undergraduate Symposium, 
University of California, Los Angeles, CA 
Abstract: Understanding the Formation of Neurotoxic Aβ 
Oligomers Responsible for Alzheimer’s Disease. 
 
May 2010  Presenter – 6th Annual Undergraduate Research Symposium, Department of 
Molecular, Cell, and Developmental Biology, University of California, Los 
Angeles, CA 
Abstract: Understanding the Formation of Neurotoxic Aβ 





Sep 2015 – Present  Certified CPR Instructor – Washington University School of Medicine 




Sep 2014 – Aug 2018  Head of Teaching Team – Anatomy and Physiology teaching team, Young 
Scientist Program (YSP), Washington University School of Medicine 
YSP is a community outreach organization designed to attract high school students 
from disadvantaged backgrounds into scientific careers through hands-on 
learning/research activities and mentorship between young people and active 
scientists. I organized teams of graduate and medical students to hold scientific 
demonstrations at local public schools with topics ranging from human anatomy 
(heart, lung, and gastrointestinal), physiology, to neuroscience. Our 
demonstrations with preserved human organs in small-group format fosters an 
atmosphere where the students feel comfortable posing their own questions and 
discussion. I also held open discussions about the different paths to pursue a 
scientific career and presented available opportunities for the students to get 
involved in the STEM field at different ages/levels. Our team reaches hundreds of 
students in the Saint Louis City public schools each year, ranging from elementary 
to high school. 
Aug 2014 – Dec 2014 Teaching assistant – Human Body: Anatomy, Embryology, Imaging, first year 
medical school curriculum, Washington University School of Medicine. 
 Served as teaching assistant in anatomy course for first year medical students. 
Responsibilities included lecture attendance, cadaver dissection, hands-on 
teaching in the anatomy lab, preparation and presentation of review sessions, and 




Sep 2013 – Present Coordinator – Acute stroke action program (ASAP), Washington University 
School of Medicine. 
 ASAP provides an opportunity for first year medical students to carry the acute 
stroke pager for 2 weeks and come to the emergency department along with the 
stroke team to observe the hyperacute management of patients experiencing a 
stroke, including the administration of tPA or mechanical thrombectomy 
procedures. I organize the training sessions, compose the schedule and facilitate 
communication between student participants and faculty to ensure the program 
provides a great learning experience. In addition to education on acute stroke 
management, ASAP also aims to attract students to a career in neurology through 
exposure and networking opportunities. 
Jun 2016 – Jun 2018 MSTP Representative – Medical Student Government (MSG), Washington 
University School of Medicine 
  
 MSG is the main communication pathway between the student body and the 
administration. MSG takes an active role in addressing student concerns and is 
responsible for advancing student interests and welfare to achieve excellence in 
academic pursuits and professional interactions. I served on the student life 
subcommittee of MSG and advocated for improvement of student well-being, 




insurance coverage. I also participated in other common MSG activities, such as 
organizing social events, award ceremonies, and voted on various proposals. 
Jun 2015 – Jun 2017 MSTP Representative – Neuroscience Steering Committee, Division of Biology 
and Biomedical Sciences, Washington University School of Medicine 
 Served as a liaison between the neuroscience graduate students and faculty, 
offered students advice and expectations for qualifying exam. I also participated 
in faculty steering committee meetings and addressed student needs by making 
recommendation for curriculum changes. I organized school-wide social events 
at scientific meetings and participated in editing/re-writing of the neuroscience 
program guidelines. 
Sep 2012 – Sep 2014 Founder and President – Radiology Interest Group (RIG), Washington 
University School of Medicine, Saint Louis, MO 
 RIG is committed to fostering interest in radiology among all medical students. 
Through various activities and resources, we aim to bring students an educational 
experience that not only broadens their understanding of radiology, but also 
contribute to their professional development. As RIG founder, I organized 
educational sessions about the nature of the specialty, career paths, and residency 
applications.  We also encourage networking between students and 
residents/faculty and announce opportunities to establish these relationships by 
getting involved with shadowing, electives, or research at the Mallinckrodt 
Institute of Radiology (MIR). RIG enables students to gain early exposure and 
involvement in preparation for a career in radiology. 
Sep 2012 – Sep 2014  IT Liaison – Washington University School of Medicine Class of 2016 
Represent the students to the information technology (IT) department of the 
medical school. Solicit to student concerns regarding IT. Communicate with the 
IT department to address issues and discuss/propose solutions to improve the 
student’s educational experience. I helped implementing a new scheduling system, 
as well as improving the quality of lecture recordings. 
Summer 2013, 2014 Counselor – Camp Neuro. Washington University School of Medicine 
Served as lecturer and camp counselor in a one-week, non-profit summer day camp 
for high school students who are interested in medicine with a primary focus on 
neurology/neurosurgery/psychiatry. Tasks include coordinating camp activities, 
giving lecture on basic neuron physiology, and work with faculty to organize 
lectures. 
2012 – 2013  Coordinator – Washington University Medical Plunge (WUMP) 
   Served as leader on a subcommittee responsible for coordinating site visits 
   for incoming medical students participating in WUMP. WUMP is week- 
   long program that exposes new students to public health in St. Louis.  
   WUMP consists of presentations on public health topics relevant to St.  
   Louis, visits to different sites around the city that serve the St. Louis  
   community, and community service projects.  
Sep 2012 – Jun 2013 Participant – Dementia understanding opportunity (DUO) program, 
Washington University School of Medicine. 
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 Community outreach program that pairs a medical student with a “mentor”, who 
has a dementia diagnosis. I developed a meaningful relationship with my mentor 
and his caregiver through various interpersonal activities. I also learned about the 
challenges they face while developing an appreciation for their positivity and 
resilience that will meaningfully influence my clinical practice. 
2012 – 2013 Sectional Editor – Dis-orientation Guide, Washington University School of 
Medicine 
Served as editor and writer for a subsection of Dis-orientation Guide, a detailed 
and personal guide to the school and the city for the next incoming class. The Dis-
orientation Guide is conceived, written, edited and published entirely by first year 
medical students. 
Feb 2010 – Sep 2011 Volunteer – Care Extender Program, Ronald Reagan UCLA Medical Center. 
Volunteer site: Clinical Research Unit, Department of Hematology and oncology, 
UCLA Jonsson Comprehensive Cancer Center. 
  Principal Investigator:  Dr. Antoni Ribas, M.D. 
     Department of hematology and oncology,  
     Ronald Reagan UCLA Medical Center 
Assist clinical investigators in clinical trials for melanoma patients. Tasks include 
preparing lab kits, processing data, drugs delivery, sample preparation and 
shipment, and handling administrative paperwork. I also observe procedures, and 
shadow doctors in clinical settings. 
May 2011 – Sep 2011 Volunteer – No One Dies Alone (NODA) Program, Hoag memorial hospital 
Presbyterian, Newport Beach, CA 
Participate in a program that provides the reassuring presence of a volunteer 
companion to dying patients who would otherwise be alone. As a NODA 
volunteer, I act as a family member and stay alongside the patients who are in the 
process of passing away naturally, where the family either cannot be or choose not 
to be there. Tasks include holding the hand of the patient, play music, read to the 
patient, fluff pillows, and assist in comfort care measures as requested by the 
patient or directed by the nurse. 
Mar 2011 - Jun 2011 Undergraduate Teaching Assistant - Life Sciences Core Curriculum, 
University of California, Los Angeles, CA 
  Course assigned:  Life Sciences 3 – Introduction to Molecular Biology 
 Assist in the teaching of a Life Sciences Lab Course. Prepare laboratory reagents 
and equipment for the class, instruct students on lab techniques as well as 
procedures. Prepare presentations on the background information and present them 
to the class, and assist the Teaching assistant to run the lab smoothly. 
Dec 2010 - Jun 2011 Reviewer – Review Board, Undergraduate Science Journal (USJ), University 
of California, Los Angeles, CA 
 Serve as reviewer of undergraduate scientific research submitted to the journal 
for publication. Evaluate articles for completeness and logic and provide 
feedback to the author prior to recommending for publication. 
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Sep 2010 – Jun 2011 Special Events Coordinator – Community and Public Health committee, 
American Medical Student Association (AMSA), UCLA pre-medical chapter 
Organize community outreach events to raise AMSA members’ awareness about 
the local community and urge them to give back by taking the initiatives and 
participate in various volunteer projects. Frequent trips are made to the Ronald 
McDonald House of Los Angeles, where food and entertainment are provided to 
the children as well as their families 
Sep 2010 – Jun 2011 Director of Scholarships – Golden Key International Honour Society, UCLA 
Chapter. 
Responsible for organizing and direct the selection process for scholarship 
applications quarterly. I am also in the finance committee to coordinate the 
available funds and organize fundraising events for the chapter 
Jul 2010 – Sep 2010 Special Projects Coordinator – Leadership Team, Clinical Care Extender 
Pipeline, Hoag Memorial Hospital Presbyterian, Newport Beach, CA 
Organize and monitor special projects that promote volunteerism and help clinical 
care extenders to reach out and give back to the community. Ongoing Special 
Projects: Patient Ambassadors Program, Adopt-A-Family Campaign, March of 
Dimes for babies, etc. I also interview prospective interns and assist in a rigorous 
3-day training process 
Oct 2008 – Sep 2010  Clinical Care Extender – Hoag Memorial Hospital Presbyterian, Newport 
Beach, CA 
Hands-on Clinical Experience, tasks include, but are not limited to, shadow 
doctors, transport and assist patients, and help the nurses 
Floors Rotated:  Gynecology/Urology 
    Stroke Unit 
    Emergency Department 
    Orthopedics 





2019 – present  Member – American Neurological Association (ANA) 
2018 – present  Member – American Physician Scientists Association (APSA) 
2012 – present  Member – Radiological Society of North America (RSNA) 
2012 – present Member – Phi Beta Kappa National Honor Society 
2010 – 2012 Member – American Medical Student Association (AMSA) UCLA Pre-Medical 
Chapter 
2010 – 2012 Member – Golden Key International Honour Society, UCLA Chapter 
Membership/Associations 
